Antibodies targeting Epstein-Barr virus proteins and their application methods

By developing antibodies or fragments that specifically bind to the extracellular domain of the EBV membrane protein BILF-1 and altering its conformational structure, the lack of targeting in existing EBV infection treatments has been addressed, enabling effective treatment of EBV infection and related diseases.

CN123124996APending Publication Date: 2026-11-17FULAI TAILAN BIOLOGICAL CO LTD
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
CN202580029655.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-02-23
Filing Date
2025-02-24
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Current treatments for EBV infection and related diseases lack specificity and are insufficient to effectively address various EBV-related symptoms.

Method used

An antibody or its antigen-binding fragment that specifically binds to the extracellular domain of the EBV membrane protein BILF-1 was developed. By contacting specific amino acid residues, it alters the conformational structure of BILF-1 and changes its function.

Benefits of technology

It provides more targeted treatment strategies that are effective against EBV infection and related diseases, particularly lymphoproliferative disorders and cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123124996A_ABST
    Figure CN123124996A_ABST
Patent Text Reader

Abstract

This disclosure provides antibodies and antigen-binding fragments that bind to the extracellular domains of Epstein-Barr virus (EBV) membrane proteins, as well as related nucleic acids, vectors, pharmaceutical compositions, cells, and methods of use. The antibodies and antigen-binding fragments described herein can be used as therapeutic and diagnostic agents for EBV infection and EBV-mediated diseases, or as investigational agents.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 557,416, filed February 23, 2024, which is incorporated herein by reference in its entirety.

[0003] sequence list

[0004] This application contains a sequence list of electronically filed documents in XML format, the contents of which are incorporated herein by reference in their entirety. The XML file containing the sequence list is named FLAT_002_01WO_SeqList_ST26.xml. This XML file is 302,465 bytes in size, was created on February 23, 2024, and was filed electronically through the USPTO Patent Centre. Technical Field

[0005] This disclosure relates in general to antibodies targeting the extracellular domain (ECD) region of Epstein-Barr virus (EBV) membrane proteins, as well as related pharmaceutical compositions and methods of use for treating EBV infection and EBV-mediated diseases such as lymphoproliferative disorders, cancer, and autoimmune diseases. Background Technology

[0006] Epstein-Barr virus (EBV), also known as human gamma herpesvirus 4, is one of the most common viruses in humans, infecting more than 90% of adults worldwide. It belongs to the genus Lymphocyvirus within the subfamily Gammaherpesviruses (Cohen, 2000; Knerr et al., 2021; Wang et al., 2001). It is a major cause of infectious mononucleosis and is associated with various non-malignant, precancerous, and malignant EBV-mediated lymphoproliferative disorders, certain non-lymphoid cancers, and autoimmune diseases. EBV was the first identified oncogenic virus and is associated with B-cell, T-cell, or NK-cell cancers (Burkitt lymphoma (BL), Hodgkin lymphoma (HL), post-transplant lymphoproliferative disorder (PTLD), and mature T-cell and NK-cell tumors (MTNKL) / peripheral T-cell lymphoma (PTCL)) (Ambinder and Cesarman, 2007; Hjalgrim et al., 2011; Siaghani et al., 2019). Some EBV-associated cancers are of epithelial origin (nasopharyngeal carcinoma (NPC), EBV-associated gastric cancer (EBVaGC), lymphoepithelioma-like carcinoma), and very rarely of mesenchymal (leiomyosarcoma) origin (Ambinder and Cesarman, 2007; Hjalgrim et al., 2011). Furthermore, causal relationships between EBV and multiple sclerosis (MS) (Bjornevik et al., 2022; Guan et al., 2019; Hassani et al., 2018; Houen et al., 2020; Lanz et al., 2022), systemic lupus erythematosus (SLE) (Aygun et al., 2020; Draborg et al., 2012; ZX Li et al., 2019), and breast cancer (Farahmand et al., 2019; Hu et al., 2016; Jin et al., 2020; Sinclair et al., 2021) have been established. The global incidence of EBV-related cancers is approximately 200,000 cases per year, with EBV-related gastric and nasopharyngeal cancers affecting more than 100,000 people annually (Knerr et al., 2021). Current attempts to treat EBV-mediated diseases include the use of anti-EBV T cells, small-molecule antiviral agents active against EBV, pan-B-cell scavengers such as anti-CD20 antibodies, and chemotherapy agents. However, improved treatment strategies, particularly more targeted therapies, are still needed in the field to address the diverse symptoms associated with EBV infection. Summary of the Invention

[0007] This disclosure provides an isolated antibody or antigen-binding fragment thereof that specifically binds to the extracellular domain (ECD) of the Epstein-Barr virus (EBV) membrane protein BILF-1.

[0008] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof specifically binds to one or more BILF-1 extracellular domains selected from the group consisting of: ECD1, ECD2, ECD3, ECD4, and combinations thereof.

[0009] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof specifically binds to ECD1 of BILF-1 by contacting one or more amino acid residues within the epitope comprising SEQ ID NO: 2.

[0010] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof specifically binds to BILF-1 ECD2 by contacting one or more amino acid residues within the epitope comprising SEQ ID NO: 3.

[0011] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof specifically binds to ECD3 of BILF-1 by contacting one or more amino acid residues within the epitope comprising SEQ ID NO: 4.

[0012] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof specifically binds to ECD4 of BILF-1 by contacting one or more amino acid residues within the epitope comprising SEQ ID NO: 5.

[0013] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof specifically binds to the ECD of BILF-1 by contacting one or more amino acid residues selected from the group consisting of SEQ ID NO: 1: L2, S3, T4, P7, S9, T10, L14, V15, N17, M18, T19, S20, V21, N22, A23, T24, T29, K30, S31, Y32, E90, F91, S92, G95, T160, M161, G162, M173, E176, G177, P178, H183, T184, A191, T259, L262, V263, A264, R265, and G269.

[0014] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof specifically binds to the ECD of BILF-1 by contacting three or more amino acid residues selected from the group consisting of SEQ ID NO: 1: L2, S3, T4, P7, S9, T10, L14, V15, N17, M18, T19, S20, V21, N22, A23, T24, T29, K30, S31, Y32, E90, F91, S92, G95, T160, M161, G162, M173, E176, G177, P178, H183, T184, A191, T259, L262, V263, A264, R265, and G269.

[0015] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof specifically binds to the ECD of BILF-1 by contacting one or more amino acid residues selected from the group consisting of SEQ ID NO: 1: M39, D164, A165, N166, L167, N168, R169, G170, P171, N172, R175, T179, K180, G181, M182, A185, V186, Q187, G188, L189, K190, A251, S253, L254, G255, F256, D257, C258, E260, S261, Y266, Y267, and P268.

[0016] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof specifically binds to the ECD of BILF-1 by contacting three or more amino acid residues selected from the group consisting of SEQ ID NO: 1: M39, D164, A165, N166, L167, N168, R169, G170, P171, N172, R175, T179, K180, G181, M182, A185, V186, Q187, G188, L189, K190, A251, S253, L254, G255, F256, D257, C258, E260, S261, Y266, Y267, and P268.

[0017] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof specifically binds to amino acids in the transmembrane region of a neighboring EBV membrane protein, and this specific binding alters the conformational structure of BILF-1 and changes the function of BILF-1.

[0018] In some embodiments of the isolated antibodies or fragments thereof disclosed herein, the antibody or fragment thereof is a monoclonal antibody and / or a humanized antibody, or an antigen-binding fragment thereof.

[0019] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the antibody or fragment thereof is an intact antibody, a fragment antigen-binding domain (Fab), an F(ab')2 domain, a single-chain variable fragment (scFv), a dimer single-chain variable fragment (di-scFv), or a single-domain antibody (sdAb).

[0020] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof comprises an Fc region selected from the group consisting of IgA, IgD, IgE, IgG, and IgM Fc regions, and optionally, the Fc region is a human Fc region. In some embodiments, the Fc region is selected from the group consisting of IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4.

[0021] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof contains an IgG Fc region that has high effector function in humans. In some embodiments, the Fc region is IgG1 or IgG3.

[0022] In some embodiments of the isolated antibodies or fragments thereof disclosed herein, the antibody or fragment comprises a modified Fc region having at least one altered effector function and / or pharmacokinetic (PK) property relative to the wild-type Fc region. In some embodiments, the at least one altered effector function includes increased binding to natural killer (NK) cells, macrophages, neutrophils, and / or dendritic cells. In some embodiments, the modified Fc region has increased affinity for CD16a (FcγRIIIa). In some embodiments, the modified Fc region is unfucosylated.

[0023] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof comprises:

[0024] a) Heavy chain (HC) complementarity-determining region (CDR) 1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16;

[0025] HC CDR1 sequence SEQ ID NO: 290, HC CDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292;

[0026] HC CDR1 sequence SEQ ID NO: 297, HC CDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299;

[0027] HC CDR1 sequence SEQ ID NO: 304, HC CDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306; or

[0028] HC CDR1 sequence SEQ ID NO: 311, HC CDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313; and

[0029] b) Light chain (LC) complementarity-determining region (CDR) 1 sequence SEQ ID NO: 17, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 19;

[0030] LC CDR1 sequence SEQ ID NO: 234, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 236;

[0031] LC CDR1 sequence SEQ ID NO: 241, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 243;

[0032] LC CDR1 sequence SEQ ID NO: 248, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 250;

[0033] LC CDR1 sequence SEQ ID NO: 255, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 257;

[0034] LC CDR1 sequence SEQ ID NO: 262, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 264;

[0035] LC CDR1 sequence SEQ ID NO: 269, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 271;

[0036] LC CDR1 sequence SEQ ID NO: 276, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 278; or

[0037] LC CDR1 sequence SEQ ID NO: 283, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 285.

[0038] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof comprises:

[0039] a) Heavy chain (HC) complementarity-determining region (CDR) 1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, light chain (LC) CDR1 sequence SEQ ID NO: 17, LC CDR2 sequence GTS and LCCDR3 sequence SEQ ID NO: 19;

[0040] b) HC CDR1 sequence SEQ ID NO: 28, HC CDR2 sequence SEQ ID NO: 29, HC CDR3 sequence SEQ ID NO: 30, LC CDR1 sequence SEQ ID NO: 31, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 33;

[0041] c) HC CDR1 sequence SEQ ID NO: 42, HC CDR2 sequence SEQ ID NO: 43, HC CDR3 sequence SEQ ID NO: 44, LC CDR1 sequence SEQ ID NO: 45, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 47;

[0042] d) HC CDR1 sequence SEQ ID NO: 56, HC CDR2 sequence SEQ ID NO: 57, HC CDR3 sequence SEQ ID NO: 58, LC CDR1 sequence SEQ ID NO: 59, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 61;

[0043] e) HC CDR1 sequence SEQ ID NO: 70, HC CDR2 sequence SEQ ID NO: 71, HC CDR3 sequence SEQ ID NO: 72, LC CDR1 sequence SEQ ID NO: 73, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 75;

[0044] f) HC CDR1 sequence SEQ ID NO: 84, HC CDR2 sequence SEQ ID NO: 85, HC CDR3 sequence SEQ ID NO: 86, LC CDR1 sequence SEQ ID NO: 87, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 89;

[0045] g) HC CDR1 sequence SEQ ID NO: 98, HC CDR2 sequence SEQ ID NO: 99, HC CDR3 sequence SEQ ID NO: 100, LC CDR1 sequence SEQ ID NO: 101, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 103;

[0046] h) HC CDR1 sequence SEQ ID NO: 112, HC CDR2 sequence SEQ ID NO: 113, HC CDR3 sequence SEQ ID NO: 114, LC CDR1 sequence SEQ ID NO: 115, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 117;

[0047] i) HC CDR1 sequence SEQ ID NO: 126, HC CDR2 sequence SEQ ID NO: 127, HC CDR3 sequence SEQ ID NO: 128, LC CDR1 sequence SEQ ID NO: 129, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 131;

[0048] j) HC CDR1 sequence SEQ ID NO: 140, HC CDR2 sequence SEQ ID NO: 141, HC CDR3 sequence SEQ ID NO: 142, LC CDR1 sequence SEQ ID NO: 143, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 145;

[0049] k) HC CDR1 sequence SEQ ID NO: 154, HC CDR2 sequence SEQ ID NO: 155, HC CDR3 sequence SEQ ID NO: 156, LC CDR1 sequence SEQ ID NO: 157, LC CDR2 sequence WAS and LC CDR3 sequence SEQ ID NO: 159;

[0050] l) HC CDR1 sequence SEQ ID NO: 168, HC CDR2 sequence SEQ ID NO: 169, HC CDR3 sequence SEQ ID NO: 170, LC CDR1 sequence SEQ ID NO: 171, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 173;

[0051] m) HC CDR1 sequence SEQ ID NO: 182, HC CDR2 sequence SEQ ID NO: 183, HC CDR3 sequence SEQ ID NO: 184, LC CDR1 sequence SEQ ID NO: 185, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 187;

[0052] n) HC CDR1 sequence SEQ ID NO: 196, HC CDR2 sequence SEQ ID NO: 197, HC CDR3 sequence SEQ ID NO: 198, LC CDR1 sequence SEQ ID NO: 199, LC CDR2 sequence AAS and LC CDR3 sequence SEQ ID NO: 201;

[0053] o) HC CDR1 sequence SEQ ID NO: 210, HC CDR2 sequence SEQ ID NO: 211, HC CDR3 sequence SEQ ID NO: 212, LC CDR1 sequence SEQ ID NO: 213, LC CDR2 sequence GTN and LC CDR3 sequence SEQ ID NO: 215;

[0054] p) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 234, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 236;

[0055] q) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 241, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 243;

[0056] r) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 248, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 250;

[0057] s) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 255, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 257;

[0058] t) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 262, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 264;

[0059] u) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 269, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 271;

[0060] v) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 276, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 278; or

[0061] w)HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 283, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 285.

[0062] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof comprises:

[0063] a) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9;

[0064] HC CDR1 sequence SEQ ID NO: 290, HC CDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289;

[0065] HC CDR1 sequence SEQ ID NO: 297, HC CDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296;

[0066] HC CDR1 sequence SEQ ID NO: 304, HC CDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303; or

[0067] HC CDR1 sequence SEQ ID NO: 311, HC CDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310; and

[0068] b) LC CDR1 sequence SEQ ID NO: 17, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 19, LCFR1 sequence SEQ ID NO: 10, LC FR2 sequence SEQ ID NO: 11, LC FR3 sequence SEQ ID NO: 12 and LC FR4 sequence SEQ ID NO: 13;

[0069] LC CDR1 sequence SEQ ID NO: 234, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 236, LC FR1 sequence SEQ ID NO: 230, LC FR2 sequence SEQ ID NO: 231, LC FR3 sequence SEQ ID NO: 232 and LC FR4 sequence SEQ ID NO: 233;

[0070] LC CDR1 sequence SEQ ID NO: 241, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 243, LC FR1 sequence SEQ ID NO: 237, LC FR2 sequence SEQ ID NO: 238, LC FR3 sequence SEQ ID NO: 239 and LC FR4 sequence SEQ ID NO: 240;

[0071] LC CDR1 sequence SEQ ID NO: 248, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 250, LC FR1 sequence SEQ ID NO: 244, LC FR2 sequence SEQ ID NO: 245, LC FR3 sequence SEQ ID NO: 246 and LC FR4 sequence SEQ ID NO: 247;

[0072] LC CDR1 sequence SEQ ID NO: 255, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 257, LC FR1 sequence SEQ ID NO: 251, LC FR2 sequence SEQ ID NO: 252, LC FR3 sequence SEQ ID NO: 253 and LC FR4 sequence SEQ ID NO: 254;

[0073] LC CDR1 sequence SEQ ID NO: 262, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 264, LC FR1 sequence SEQ ID NO: 258, LC FR2 sequence SEQ ID NO: 259, LC FR3 sequence SEQ ID NO: 260 and LC FR4 sequence SEQ ID NO: 261;

[0074] LC CDR1 sequence SEQ ID NO: 269, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 271, LC FR1 sequence SEQ ID NO: 265, LC FR2 sequence SEQ ID NO: 266, LC FR3 sequence SEQ ID NO: 267 and LC FR4 sequence SEQ ID NO: 268;

[0075] LC CDR1 sequence SEQ ID NO: 276, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 278, LC FR1 sequence SEQ ID NO: 272, LC FR2 sequence SEQ ID NO: 273, LC FR3 sequence SEQ ID NO: 274 and LC FR4 sequence SEQ ID NO: 275; or

[0076] LC CDR1 sequence SEQ ID NO: 283, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 285, LC FR1 sequence SEQ ID NO: 279, LC FR2 sequence SEQ ID NO: 280, LC FR3 sequence SEQ ID NO: 281 and LC FR4 sequence SEQ ID NO: 282.

[0077] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof comprises:

[0078] a) Heavy chain (HC) complementarity-determining region (CDR) 1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, Light chain (LC) CDR1 sequence SEQ ID NO: 17, LC CDR2 sequence GTS, LCCDR3 sequence SEQ ID NO: 19, HC frame region (FR) 1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 10, LC FR2 sequence SEQ ID NO: 11, LC FR3 sequence SEQ ID NO: 12 and LC FR4 sequence SEQ ID NO: 13;

[0079] b) HC CDR1 sequence SEQ ID NO: 28, HC CDR2 sequence SEQ ID NO: 29, HC CDR3 sequence SEQ ID NO: 30, LC CDR1 sequence SEQ ID NO: 31, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 33, HCFR1 sequence SEQ ID NO: 20, HC FR2 sequence SEQ ID NO: 21, HC FR3 sequence SEQ ID NO: 22, HC FR4 sequence SEQ ID NO: 23, LC FR1 sequence SEQ ID NO: 24, LC FR2 sequence SEQ ID NO: 25, LC FR3 sequence SEQ ID NO: 26 and LC FR4 sequence SEQ ID NO: 27;

[0080] c) HC CDR1 sequence SEQ ID NO: 42, HC CDR2 sequence SEQ ID NO: 43, HC CDR3 sequence SEQ ID NO: 44, LC CDR1 sequence SEQ ID NO: 45, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 47, HCFR1 sequence SEQ ID NO: 34, HC FR2 sequence SEQ ID NO: 35, HC FR3 sequence SEQ ID NO: 36, HC FR4 sequence SEQ ID NO: 37, LC FR1 sequence SEQ ID NO: 38, LC FR2 sequence SEQ ID NO: 39, LC FR3 sequence SEQ ID NO: 40 and LC FR4 sequence SEQ ID NO: 41;

[0081] d) HC CDR1 sequence SEQ ID NO: 56, HC CDR2 sequence SEQ ID NO: 57, HC CDR3 sequence SEQ ID NO: 58, LC CDR1 sequence SEQ ID NO: 59, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 61, HCFR1 sequence SEQ ID NO: 48, HC FR2 sequence SEQ ID NO: 49, HC FR3 sequence SEQ ID NO: 50, HC FR4 sequence SEQ ID NO: 51, LC FR1 sequence SEQ ID NO: 52, LC FR2 sequence SEQ ID NO: 53, LC FR3 sequence SEQ ID NO: 54 and LC FR4 sequence SEQ ID NO: 55;

[0082] e) HC CDR1 sequence SEQ ID NO: 70, HC CDR2 sequence SEQ ID NO: 71, HC CDR3 sequence SEQ ID NO: 72, LC CDR1 sequence SEQ ID NO: 73, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 75, HCFR1 sequence SEQ ID NO: 62, HC FR2 sequence SEQ ID NO: 63, HC FR3 sequence SEQ ID NO: 64, HC FR4 sequence SEQ ID NO: 65, LC FR1 sequence SEQ ID NO: 66, LC FR2 sequence SEQ ID NO: 67, LC FR3 sequence SEQ ID NO: 68 and LC FR4 sequence SEQ ID NO: 69;

[0083] f) HC CDR1 sequence SEQ ID NO: 84, HC CDR2 sequence SEQ ID NO: 85, HC CDR3 sequence SEQ ID NO: 86, LC CDR1 sequence SEQ ID NO: 87, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 89, HCFR1 sequence SEQ ID NO: 76, HC FR2 sequence SEQ ID NO: 77, HC FR3 sequence SEQ ID NO: 78, HC FR4 sequence SEQ ID NO: 79, LC FR1 sequence SEQ ID NO: 80, LC FR2 sequence SEQ ID NO: 81, LC FR3 sequence SEQ ID NO: 82 and LC FR4 sequence SEQ ID NO: 83;

[0084] g) HC CDR1 sequence SEQ ID NO: 98, HC CDR2 sequence SEQ ID NO: 99, HC CDR3 sequence SEQ ID NO: 100, LC CDR1 sequence SEQ ID NO: 101, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 103, HC FR1 sequence SEQ ID NO: 90, HC FR2 sequence SEQ ID NO: 91, HC FR3 sequence SEQ ID NO: 92, HC FR4 sequence SEQ ID NO: 93, LC FR1 sequence SEQ ID NO: 94, LC FR2 sequence SEQ ID NO: 95, LC FR3 sequence SEQ ID NO: 96 and LC FR4 sequence SEQ ID NO: 97;

[0085] h) HC CDR1 sequence SEQ ID NO: 112, HC CDR2 sequence SEQ ID NO: 113, HC CDR3 sequence SEQ ID NO: 114, LC CDR1 sequence SEQ ID NO: 115, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 117, HC FR1 sequence SEQ ID NO: 104, HC FR2 sequence SEQ ID NO: 105, HC FR3 sequence SEQ ID NO: 106, HC FR4 sequence SEQ ID NO: 107, LC FR1 sequence SEQ ID NO: 108, LC FR2 sequence SEQ ID NO: 109, LC FR3 sequence SEQ ID NO: 110 and LC FR4 sequence SEQ ID NO: 111;

[0086] i) HC CDR1 sequence SEQ ID NO: 126, HC CDR2 sequence SEQ ID NO: 127, HC CDR3 sequence SEQ ID NO: 128, LC CDR1 sequence SEQ ID NO: 129, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 131, HC FR1 sequence SEQ ID NO: 118, HC FR2 sequence SEQ ID NO: 119, HC FR3 sequence SEQ ID NO: 120, HC FR4 sequence SEQ ID NO: 121, LC FR1 sequence SEQ ID NO: 122, LC FR2 sequence SEQ ID NO: 123, LC FR3 sequence SEQ ID NO: 124 and LC FR4 sequence SEQ ID NO: 125;

[0087] j) HC CDR1 sequence SEQ ID NO: 140, HC CDR2 sequence SEQ ID NO: 141, HC CDR3 sequence SEQ ID NO: 142, LC CDR1 sequence SEQ ID NO: 143, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 145, HC FR1 sequence SEQ ID NO: 132, HC FR2 sequence SEQ ID NO: 133, HC FR3 sequence SEQ ID NO: 134, HC FR4 sequence SEQ ID NO: 135, LC FR1 sequence SEQ ID NO: 136, LC FR2 sequence SEQ ID NO: 137, LC FR3 sequence SEQ ID NO: 138 and LC FR4 sequence SEQ ID NO: 139;

[0088] k) HC CDR1 sequence SEQ ID NO: 154, HC CDR2 sequence SEQ ID NO: 155, HC CDR3 sequence SEQ ID NO: 156, LC CDR1 sequence SEQ ID NO: 157, LC CDR2 sequence WAS and LC CDR3 sequence SEQ ID NO: 159, HC FR1 sequence SEQ ID NO: 146, HC FR2 sequence SEQ ID NO: 147, HC FR3 sequence SEQ ID NO: 148, HC FR4 sequence SEQ ID NO: 149, LC FR1 sequence SEQ ID NO: 150, LC FR2 sequence SEQ ID NO: 151, LC FR3 sequence SEQ ID NO: 152 and LC FR4 sequence SEQ ID NO: 153;

[0089] l) HC CDR1 sequence SEQ ID NO: 168, HC CDR2 sequence SEQ ID NO: 169, HC CDR3 sequence SEQ ID NO: 170, LC CDR1 sequence SEQ ID NO: 171, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 173, HC FR1 sequence SEQ ID NO: 160, HC FR2 sequence SEQ ID NO: 161, HC FR3 sequence SEQ ID NO: 162, HC FR4 sequence SEQ ID NO: 163, LC FR1 sequence SEQ ID NO: 164, LC FR2 sequence SEQ ID NO: 165, LC FR3 sequence SEQ ID NO: 166 and LC FR4 sequence SEQ ID NO: 167;

[0090] m) HC CDR1 sequence SEQ ID NO: 182, HC CDR2 sequence SEQ ID NO: 183, HC CDR3 sequence SEQ ID NO: 184, LC CDR1 sequence SEQ ID NO: 185, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 187, HC FR1 sequence SEQ ID NO: 174, HC FR2 sequence SEQ ID NO: 175, HC FR3 sequence SEQ ID NO: 176, HC FR4 sequence SEQ ID NO: 177, LC FR1 sequence SEQ ID NO: 178, LC FR2 sequence SEQ ID NO: 179, LC FR3 sequence SEQ ID NO: 180 and LC FR4 sequence SEQ ID NO: 181;

[0091] n) HC CDR1 sequence SEQ ID NO: 196, HC CDR2 sequence SEQ ID NO: 197, HC CDR3 sequence SEQ ID NO: 198, LC CDR1 sequence SEQ ID NO: 199, LC CDR2 sequence AAS and LC CDR3 sequence SEQ ID NO: 201, HC FR1 sequence SEQ ID NO: 188, HC FR2 sequence SEQ ID NO: 189, HC FR3 sequence SEQ ID NO: 190, HC FR4 sequence SEQ ID NO: 191, LC FR1 sequence SEQ ID NO: 192, LC FR2 sequence SEQ ID NO: 193, LC FR3 sequence SEQ ID NO: 194 and LC FR4 sequence SEQ ID NO: 195;

[0092] o) HC CDR1 sequence SEQ ID NO: 210, HC CDR2 sequence SEQ ID NO: 211, HC CDR3 sequence SEQ ID NO: 212, LC CDR1 sequence SEQ ID NO: 213, LC CDR2 sequence GTN and LC CDR3 sequence SEQ ID NO: 215, HC FR1 sequence SEQ ID NO: 202, HC FR2 sequence SEQ ID NO: 203, HC FR3 sequence SEQ ID NO: 204, HC FR4 sequence SEQ ID NO: 205, LC FR1 sequence SEQ ID NO: 206, LC FR2 sequence SEQ ID NO: 207, LC FR3 sequence SEQ ID NO: 208 and LC FR4 sequence SEQ ID NO: 209;

[0093] p) HC CDR1 sequence SEQ ID NO: 224, HC CDR2 sequence SEQ ID NO: 225, HC CDR3 sequence SEQ ID NO: 226, LC CDR1 sequence SEQ ID NO: 227, LC CDR2 sequence GAS and LC CDR3 sequence SEQ ID NO: 229, HC FR1 sequence SEQ ID NO: 216, HC FR2 sequence SEQ ID NO: 217, HC FR3 sequence SEQ ID NO: 218, HC FR4 sequence SEQ ID NO: 219, LC FR1 sequence SEQ ID NO: 220, LC FR2 sequence SEQ ID NO: 221, LC FR3 sequence SEQ ID NO: 222 and LC FR4 sequence SEQ ID NO: 223;

[0094] q) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 234, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 236, HCFR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 230, LC FR2 sequence SEQ ID NO: 231, LC FR3 sequence SEQ ID NO: 232 and LC FR4 sequence SEQ ID NO: 233;

[0095] r) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 241, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 243, HCFR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 237, LC FR2 sequence SEQ ID NO: 238, LC FR3 sequence SEQ ID NO: 239 and LC FR4 sequence SEQ ID NO: 240;

[0096] s) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 248, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 250, HCFR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 244, LC FR2 sequence SEQ ID NO: 245, LC FR3 sequence SEQ ID NO: 246 and LC FR4 sequence SEQ ID NO: 247;

[0097] t) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 255, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 257, HCFR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 251, LC FR2 sequence SEQ ID NO: 252, LC FR3 sequence SEQ ID NO: 253 and LC FR4 sequence SEQ ID NO: 254;

[0098] u) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 262, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 264, HCFR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 258, LC FR2 sequence SEQ ID NO: 259, LC FR3 sequence SEQ ID NO: 260, and LC FR4 sequence SEQ ID NO: 261;

[0099] v) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 269, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 271, HCFR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 265, LC FR2 sequence SEQ ID NO: 266, LC FR3 sequence SEQ ID NO: 267, and LC FR4 sequence SEQ ID NO: 268;

[0100] w) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 276, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 278, HCFR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 272, LC FR2 sequence SEQ ID NO: 273, LC FR3 sequence SEQ ID NO: 274 and LC FR4 sequence SEQ ID NO: 275; or

[0101] x) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 283, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 285, HCFR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 279, LC FR2 sequence SEQ ID NO: 280, LC FR3 sequence SEQ ID NO: 281 and LC FR4 sequence SEQ ID NO: 282.

[0102] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL).

[0103] The VH contains an amino acid sequence represented by any one of SEQ ID NO: 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 354, 355, 356, 357, or an amino acid sequence that is at least 80% identical to the amino acid sequence represented by any one of SEQ ID NO: 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 354, 355, 356, 357; and

[0104] The VL contains an amino acid sequence that is at least 80% identical to the amino acid sequence shown in any one of SEQ ID NO: 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 346, 347, 348, 349, 350, 351, 352, 353, or any one of SEQ ID NO: 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 346, 347, 348, 349, 350, 351, 352, 353.

[0105] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof is a bispecific antibody comprising: (a) a first antigen-binding domain (ABD) that specifically binds to BILF-1; and (b) a second ABD domain that specifically binds to a cell surface receptor, wherein the cell surface receptor is expressed on immune cells, can form a heterodimer with BILF-1, and / or is co-expressed with BILF-1.

[0106] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof enhances the binding of BILF-1-expressing cells to immune cells. In some embodiments, the immune cells are T cells or natural killer (NK) cells.

[0107] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof binds to a cell surface receptor, wherein the cell surface receptor is CD3, CD16, IL-8 receptor, CD19, BCMA, CD38, vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), EBV latent membrane protein 1 (LMP1) or EBV latent membrane protein 2 (LMP2). In some embodiments, the cell surface receptor is CD3 or CD16. In some embodiments, the cell surface receptor is IL-8 receptor, CD19, BCMA, CD38, vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), EBV latent membrane protein 1 (LMP1) or EBV latent membrane protein 2 (LMP2).

[0108] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof is conjugated with a cytotoxic agent. In some embodiments, the cytotoxic agent is monomethylolpropionate F (MMAF), monomethylolpropionate E (MMAE), or pyruvic DM.

[0109] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof is conjugated or fused with an immune activator. In some embodiments, the immune activator is a Toll-like receptor (TLR) agonist, an interferon gene-stimulating factor (STING) agonist, or a cytokine. In some embodiments, the cytokine is interleukin-2 (IL-2), interleukin-15 (IL-15), or a TNF superfamily ligand. In some embodiments, the TNF superfamily ligand is TRAIL, 4-1BBL, interleukin-21 (IL-21), IFN-α, IFN-β, CD40, GITR-L, OX40L, or CD70.

[0110] In some embodiments of the isolated antibody or fragment thereof disclosed herein, the isolated antibody or fragment thereof is a single-chain variable fragment (scFv), wherein the scFv is fused with a transmembrane domain and an intracellular T cell signaling domain via a spacer region (hinge region) to form a chimeric antigen receptor (CAR).

[0111] In some embodiments of the isolated antibodies or fragments thereof disclosed herein, the amino acid sequence of the antibody or fragment contains one or more mutations, wherein the one or more mutations improve the binding affinity, stability, and / or pharmacokinetics of the antibody or fragment. In some embodiments, the one or more mutations are located in the light chain of the antibody or fragment. In some embodiments, the one or more mutations comprise amino acid substitutions. In some embodiments, the one or more mutations are located in an amino acid selected from asparagine, cysteine, and leucine. In some embodiments, the one or more mutations comprise asparagine to histidine substitution, cysteine ​​to alanine substitution, asparagine to arginine substitution, leucine to isoleucine substitution, cysteine ​​to valine substitution, asparagine to serine substitution, or asparagine to alanine substitution. In some embodiments, unpaired cysteine ​​residues in the amino acid sequence of the antibody or fragment are eliminated by the one or more mutations.

[0112] In some embodiments, this disclosure provides isolated nucleic acid molecules comprising nucleic acid sequences encoding isolated antibodies or fragments thereof described herein.

[0113] In some embodiments, this disclosure provides a vector comprising the isolated nucleic acid molecule described herein. In some embodiments, the vector further comprises a heterologous promoter. In some embodiments, the heterologous promoter is an inducible promoter or a constitutive promoter. In some embodiments, the expression of the isolated antibody or a fragment thereof is driven by the promoter.

[0114] In some embodiments, this disclosure provides an isolated cell containing the isolated nucleic acid molecules or vectors described herein.

[0115] In some embodiments, this disclosure provides a method for producing the isolated antibody or fragment thereof described herein. In some embodiments, the method includes culturing the isolated cells described herein under culture conditions suitable for expression of the antibody or fragment thereof, and isolating the antibody or fragment thereof from the culture.

[0116] In some embodiments, this disclosure provides a pharmaceutical composition comprising an antibody or fragment thereof as described herein and a physiologically acceptable carrier. In some embodiments, the pharmaceutical composition comprises two or more antibodies or fragments thereof as described herein. In some embodiments, the pharmaceutical composition further comprises a second antibody or antigen-binding fragment thereof that specifically binds to LMP-1 and / or LMP-2. In some embodiments, the second antibody or antigen-binding fragment thereof specifically binds to LMP-2.

[0117] In some embodiments, the pharmaceutical composition further comprises one or more therapeutic agents that increase the expression of EBV membrane proteins in EBV-infected cells. In some embodiments, the EBV-infected cells comprise B cells. In some embodiments, the one or more therapeutic agents are selected from the group consisting of: valproic acid, trichostatin A (TSA), 5-azacytidine (5-AZA), romidesin, pabistal, vorinostat, decitabine, netenostat, deraxixix, rituximab, and combinations thereof.

[0118] In some embodiments, this disclosure provides a method for treating a subject who has or is at risk of having one or more of Epstein-Barr virus (EBV) infection or EBV-mediated diseases, the method comprising administering the pharmaceutical composition described herein to the subject.

[0119] In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases, the subject is EBV positive and has latent EBV infection. In some embodiments, the EBV infection is characterized as latent type O, latent type I, latent type II, or latent type III. In some embodiments, the EBV infection is chronic active EBV infection or acute active EBV infection.

[0120] In some embodiments of the method for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases, wherein the EBV-mediated disease is one or more diseases selected from the group consisting of EBV-mediated lymphoproliferative disorders (LPD), EBV-mediated cancer, EBV-mediated autoimmune diseases, infectious mononucleosis, and combinations thereof.

[0121] In some embodiments, the EBV-mediated disease is hemophagocytic lymphohistiocytosis (HLH), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL). In some embodiments, the NHL is Burkitt lymphoma, diffuse large B-cell lymphoma, B-cell NHL, T-cell NHL, or NK-cell NHL. In some embodiments, the T-cell or NK-cell NHL includes peripheral T-cell lymphoma (PTCL), optionally angioimmunoblastic T-cell lymphoma (AILT). In some embodiments, the EBV-mediated LPD is post-transplant lymphoproliferative disorder (PTLD) or HIV-related LPD.

[0122] In some embodiments, the EBV-mediated cancer is a non-lymphoid malignancy selected from the group consisting of nasopharyngeal carcinoma (NPC), gastric cancer (GC), gastric adenocarcinoma, and leiomyosarcoma.

[0123] In some embodiments, the EBV-mediated autoimmune disease is one or more diseases selected from the group consisting of multiple sclerosis (MS), systemic lupus erythematosus (SLE), Sjögren's syndrome, type 1 diabetes mellitus (T1D), rheumatoid arthritis (RA), dermatomyositis, and combinations thereof.

[0124] In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases, the subject is immunocompromised.

[0125] In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases, the subject is about to receive, is receiving, or has received an organ transplant including therapeutic immunosuppression. In some embodiments, the organ transplant is a bone marrow transplant.

[0126] In some embodiments of a method for treating a subject who has or is at risk of having one or more of EBV infection or EBV-mediated diseases, the method includes administering an additional therapeutic agent to the subject. In some embodiments, the additional therapeutic agent increases the expression of EBV membrane proteins in EBV-infected cells. In some embodiments, the EBV-infected cells comprise B cells. In some embodiments, the additional therapeutic agent is selected from the group consisting of romidesin, pabistal, vorinostat, decitabine, netenostat, rituximab, and combinations thereof.

[0127] In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated disease, the antibodies or fragments thereof described herein increase the killing of EBV-infected cells in the subject by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, or more compared to an untreated control. In some embodiments, the antibody or fragment thereof described herein reduces the cell-free EBV DNA load in the subject by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, or more compared to an untreated control. In some embodiments, the antibody or fragment thereof described herein reduces the EBV-positive cell count and optionally the EBV-positive cancer cell count by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, or more compared to an untreated control.

[0128] In some embodiments of methods for treating subjects who have or are at risk of having one or more EBV infection or EBV-mediated diseases, the antibodies or fragments thereof or pharmaceutical compositions described herein improve the subject's overall survival, progression-free survival, time to progression, or any combination thereof. In some embodiments, the antibodies or fragments thereof or pharmaceutical compositions described herein reduce the number and / or severity of one or more adverse events in the subject.

[0129] In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases, wherein the subject has an EBV-mediated autoimmune disease, the antibody or fragment thereof or pharmaceutical composition described herein reduces the subject’s disability progression, optionally measured by the Kurtzke Extended Disability Status Scale (EDSS) or the SLE Disease Activity Index (SLEDAI).

[0130] In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases, wherein the subject has EBV-mediated multiple sclerosis, the antibody or fragment thereof or pharmaceutical composition described herein reduces the subject’s relapse rate and / or central nervous system (CNS) lesion burden.

[0131] In some embodiments of a method for treating a subject who has or is at risk of having one or more of EBV infection or EBV-mediated diseases, the method includes administering the pharmaceutical composition to the subject via parenteral administration. In some embodiments, the parenteral administration is intravenous administration.

[0132] In some embodiments of a method for treating a subject who has or is at risk of having one or more of EBV infection or EBV-mediated disease, the method includes genotyping the EBV in the subject and administering the pharmaceutical composition described herein to the subject if the EBV genotype is associated with a high risk of EBV-mediated disease.

[0133] In some embodiments of a method for treating a subject who has or is at risk of having one or more EBV infections or EBV-mediated diseases, wherein the subject has an autoimmune disease, the method includes measuring the expression of EBV proteins in activated B cells in the subject, and administering the pharmaceutical composition described herein to the subject if the activated B cells express one or more EBV proteins. In some embodiments, the one or more EBV proteins are selected from the group consisting of EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-LP, LMP-1, LMP-2A, LMP-2B, and combinations thereof. Attached Figure Description

[0134] Figure 1A A schematic diagram of the amino acid sequence of BILF-1 is shown, with the intracellular domain, transmembrane domain and extracellular domain labeled. Figure 1B A schematic diagram illustrating the interaction between BILF-1 and cell signaling pathways is shown.

[0135] Figure 2A Tissue microarray (TMA) images of nasopharyngeal carcinoma (NPC), lymphoma, post-transplant lymphoproliferative disorder (PTLD), and gastric adenocarcinoma (STAD) tissues stained with EBER1 and BILF1 in situ hybridization (ISH) are shown. Figure 2B A statistical evaluation plot of TMA ISH staining is provided.

[0136] Figure 3ABar graphs of BILF1 RNA expression are provided for untreated P3HR1 cells and P3HR1 cells treated with phorbol 12-myristate 13-acetate (PMA) with and without sodium butyrate (SB), 5-azacytidine (5-AZA) and decitabine in combination with and without tenosat, derarosi, trichostatin A or romidasin. Figure 3B The bar charts show BILF1 expression in P3HR1 cells after treatment with DMSO, 5-AZA and decitabine with or without romidesin, romidesin, and PMA and SB. Figure 3C A bar chart showing BILF1 expression in P3HR1 cells after treatment with different concentrations of romidesin is provided. Figure 3D A bar chart showing BILF1 expression in P3HR1 cells after treatment with different concentrations of vorinostat, belistat, pabistamine, and romidesin is provided. DMSO-treated P3HR1 cells and untreated P3HR1 cells were used as controls.

[0137] Figure 4A The flow cytometry density map shows the binding of anti-BILF-1 antibody to B16 cells expressing BILF1. Figure 4B The nonspecific binding of AXM1, AXM6, and AXM7 to live cells, fixed cells, or intracellularly stained peripheral blood mononuclear cells (PBMCs) was demonstrated. Figure 4C Flow cytometry density maps of the binding of anti-BILF-1 antibodies (AXM1 and AXM6) to two different BILF1 variants with two mutations are shown: BILF1 (R219K, V263A) and BILF1 (A6V, V11M). Each mutation is associated with a BILF1 variant.

[0138] Figure 5 Binding curves of mAbs AXM1, AXM6, and AXM7 with cells expressing BILF1 are provided, along with the equilibrium dissociation constant (KD) for each mAb.

[0139] Figure 6A Flow cytometry density maps are provided, showing the percentage of Sytox Blue positive BILF1+ B16 cells after incubation with unconjugated mAb AXM1, AXM6, and isotype controls, as well as cross-linked secondary antibodies. Figure 6B Flow cytometry density maps are provided, showing the percentage of BILF1+GFP+B16 cells after incubation with unconjugated mAb AXM1, AXM6, and isotype controls, as well as cross-linked secondary antibodies. Figure 6CFlow cytometry density maps are provided, showing the percentage of BILF1+GFP+ B16 cells after incubation with unconjugated AXM1 and cross-linked secondary antibodies, PE / Texas Red conjugated AXM1, and cross-linked secondary antibodies alone.

[0140] Figure 7A Flow cytometry density maps are provided, showing the percentage of pHrodo red-positive BILF-1+ B16 cells after incubation with pH-sensitive pHrodo red-conjugated AXM1 antibody and isotype control antibody and co-staining with anti-mouse Fab secondary antibody. Figure 7B and Figure 7C A bar chart is provided showing the effect of treatment with mAb AXM1 or an allotype control followed by treatment with anti-mouse secondary antibody (2nd anti-mouse), anti-mouse secondary antibody conjugated with monomethylolpropionate F (2nd anti-mouse-MMAF), or anti-mouse secondary antibody conjugated with pyruvate DM (2nd anti-mouse-DMDM) on BILF-1+ B16 cells. Figure 7B ) and B16 cells ( Figure 7C Cell vitality. Figure 7D A bar chart is provided showing the effects of treatment with AXM1, AXM6, and AXM7 followed by anti-mouse secondary antibody (2... nd (Anti-mouse) or with anti-mouse secondary antibody conjugated with pyruvate DM (2) nd Cell viability of BILF-1+B16 cells after anti-mouse DMDM ​​treatment. Figure 7E A bar chart is provided showing the cell viability of BILF-1+ B16 cells after treatment with AXM1 directly conjugated to DMDM ​​(AXM1 DMDM) or an isotype control directly conjugated to DMDM ​​(isotype DMDM).

[0141] Figure 8 Incucyte plots are provided, showing the change over time in the mean percentage of phase objective confluence between BILF1+ B16 cells (left panel) and B16 cells (right panel) incubated with AXM1, isotype control, AXM1-DMDM, or isotype control-DMDM for 5 days.

[0142] Figure 9A Flow cytometry density maps are provided, showing the percentage of BILF-1+ EBV-positive nasopharyngeal carcinoma cells (NPCs) after AXM1 staining followed by treatment with anti-mouse secondary antibody, allotype control, or secondary antibody alone. Figure 9B Incucyte plots are provided, showing the change over time in the mean percentage of phase objectives confluence of EBV-positive NPC cells incubated for 4 days with different concentrations of AXM1 directly conjugated to DMDM ​​(AXM1 DMDM) and isotype control-DMDM (isotype DMDM). Figure 9C A bar chart is provided showing the area under the phase objective confluence curve (AUC) of EBV-positive NPC cells incubated for 4 days with different concentrations of AXM1 directly conjugated to DMDM ​​(AXM1 DMDM) and isotype control-DMDM (isotype DMDM).

[0143] Figure 10A Flow cytometry density maps are provided, showing the percentage of GFP+ B16 cells expressing BILF1 after staining with whole human mAb AXM1 containing cysteine ​​at position 91 of the light chain CDR3 region (whole human AXM1 (original C)) or whole human mAb AXM1 with cysteine ​​replaced by serine at position 91 (whole human AXM1 (C91S)) or isotype control. Figure 10B A bar chart is provided showing the results using fully human (Hu) AXM1 (original C) or Hu AXM1 (C91S), with a secondary antibody conjugated with pyruvate DM (2nd-DMDM), and alone. nd Cell viability of B16 cells (left) or BILF-1+ B16 cells (right) after treatment with a secondary antibody conjugated with pyromycin DM (isotype-DMDM), AXM1-DMDM or isotype control, or pyromycin DM-conjugated secondary antibody (isotype-DMDM). Figure 10C The binding curves of the fully human mAb AXM1 (C91S) in B16 cells expressing BILF1 are provided. Figure 10D Binding curves of fully human AXM1 variants—AXM1-DQAHRFL (AXM1-N32D, C91A, N92H, N93R, W94F), AXM1-DQVHRWI (AXM1-N32D, C91V, N92H, N93R, L96I), AXM1-HQAHHFL (AXM1-N32H, C91A, N92H, N93H, W94F), AXM1-HQVARWI (AXM1-N32H, C91V, N92A, N93R, L96I), and AXM1-NQVNSWI (AXM1-C91V, N93S, L96I)—with BILF1-expressing B16 cells were provided. Figure 10.E provides an Incucyte plot showing the change over time in the mean percentage of phase objective confluence between BILF1+ B16 cells incubated with the AXM1 variant and anti-human IgG DMDM ​​for 4 days. Figure 10F Flow cytometry density plots are provided, showing the percentage of binding of BILF1-expressing GFP+ B16 cells to serially diluted AXM1-HQAHHFL in neutral pH buffer (PBS + 2% FBS) and low pH buffer (PBS + 2% FBS + 50mM). Figure 10GELISA data are provided, showing the reactivity of the AXM1 antibody variant with human insulin and LPS. Elotuzumab and lenzrumuzumab were used as control antibodies. Figure 10H The binding curves of the fully human AXM1 FAB antibody to B16 cells expressing BILF1 are provided.

[0144] Figure 11 Flow cytometry data are shown, demonstrating that both AXM1 C91 and AXM1 C91S specifically bind to BILF1 expression in Zebra+ SNU719 cells induced by romidesin. To induce BILF1 expression, SNU719 cells were treated with 2.5 nM or 6.5 nM romidesin for 24 hours. Untreated SNU719 cells served as a control. After treatment, cells were stained with AXM1(C91), AXM1(C91S), or an isotype control, followed by staining with anti-human IgG secondary antibody. Cells were then stained with anti-Zebra FITC or isotype-FITC for further analysis.

[0145] Figure 12 Incucyte plots are provided, showing the change over time in the average percentage of phase objectives confluence between EBV-positive NPC cells incubated with DMDM-conjugated fully human AXM1 (C91S) or DMDM-conjugated fully human isotypes for 3 days.

[0146] Female C57Bl / 6J mice (n = 6) were subcutaneously injected with BILF1+ B16 cells, randomly divided into two groups, and treated with seven consecutive intravenous injections of human AXM1 (C91S)-DMDM antibody or human allotype-DMDM antibody. Figure 13A A summary chart of average tumor size is provided, and Figure 13B A graph showing the tumor size of each mouse as measured over a 27-day period is provided. Figure 13C Survival curves for each of the two groups of mice are shown. Figure 13D Summary plots are presented, depicting the average tumor size, as well as individual tumor size data for each mouse treated with PBS, hu AXM1-MMAE, hu isotype-MMAE, hu AXM1-DX8951, and hu isotype-DX8951. Figure 13E A summary graph showing the average tumor size of mice treated with PBS, hu AXM1-MMAE, and TA99-MMAE is presented.

[0147] Figure 14ADifferent designs of the mortar-and-stick bispecific CD3 T cell adaptor are provided. 2C11-AXM1 consists of an AXM1-Fab-knob connected to 2C11-scFv-AXM1-hole, and AXM1-2C11 consists of an AXM1-Fab-knob connected to AXM1-2C11-scFv-hole, wherein the GGGs adapter or AAA adapter connects 2C11 to CH2 in the Fc region. Figure 14B Flow cytometry density maps are provided, showing the percentage of BILF1+GFP+B16 cells (top panel) or GFP+B16 cells (bottom panel) stained with bispecific antibodies and secondary antibody controls of 2C11-AXM1, AXM1-2C11 (GGGs), AXM1-2C11 (AAA) and secondary antibody control. Figure 14C Flow cytometry density maps are provided, showing the percentage of CD3+ magnetically enriched mouse T cells stained with bispecific antibodies 2C11-AXM1, AXM1-2C11 (GGGs), AXM1-2C11 (AAA) and secondary antibody controls.

[0148] Figure 15A Flow cytometry density maps are provided, showing the percentage of live (GFP+) control GFP+B16 cells or BILF1+GFP+B16 cells co-cultured with CD3-enriched mouse T cells for 24 hours and treated with 10 ug / ml, 2 ug / ml or 0.4 ug / ml of 2C11-AXM1, AXM1-2C11 (GGGs) or AXM1-2C11 (AAA) bispecific antibodies. Figure 15B A bar chart is provided, showing Figure 15A The optical density (OD) of lactate dehydrogenase (LDH) in the supernatant of the co-culture experiment was measured. Figure 15C The figure provided shows the OD values ​​of LDH in the supernatant of mouse T cell:BILF1+ B16 cell coculture treated with bispecific antibodies of 2C11-AXM1, AXM1-2C11 (GGGs) and AXM1-2C11 (AAA) at concentrations ranging from 2 ug / ml to 0.00064 µg / ml (using 5-fold serial dilutions).

[0149] Figure 16A An 11-point titration curve is provided, showing the OD values ​​of LDH in the supernatant of mouse T cell:BILF1+ B16 cell co-cultures treated with different concentrations of 2C11-AXM1 bispecific antibody. The EC50 values ​​of the 2C11-AXM1 bispecific antibody are indicated. Figure 16BFlow cytometry density maps are provided, showing the percentage of viable (GFP+) BILF1+GFP+B16 cells and CD8+ T cells in mouse T cells treated with 14 different concentrations of 2C11-AXM1 bispecific antibody or AXM1 alone or 2C11 alone in BILF1+B16 cell cocultures.

[0150] Female C57Bl / 6J mice (n = 7) were subcutaneously injected with BILF1+ B16 cells, randomly divided into three groups, and treated with two intraperitoneal injections followed by five intravenous injections of PBS, 12.5 μg of 2C11-AXM1 bispecific antibody, or 12.5 μg of 2C11 antibody. Figure 17A A summary graph of the average tumor size for each of the three groups is provided, with measurements taken over 16 days. Figure 17B A graph showing the tumor size of each mouse treated with PBS or the 2C11-AXM1 bispecific antibody is provided. Figure 17C A graph showing the tumor size of each mouse treated with PBS or 2C11 alone is provided. Figure 17D A summary graph of the average tumor size in mice treated with PBS, B21M-2C11, and AXM1-2C11 is provided.

[0151] Figure 18A Flow cytometry density maps are shown, illustrating the percentage of OVCAR3 cells, BILF1+GFP+ OVCAR3 cells, and BILF1+GFP+ B16 cells bound to AXM1(C91S), non-fucosylated AXM1(C91S) (AF-AXM1(C91S)), non-fucosylated trastuzumab (AF-trastuzumab), and isotype controls. Figure 18B The percentage and mean fluorescence intensity (MFI) of BILF1+ OVCAR3 cells and BILF1+ B16 cells co-cultured with PBMCs at target cell to effector cell ratios of 1:40 and 1:20 (i.e., BILF1+ cells:PBMCs) in the presence of 5 µg / ml AXM1 (C91S), AF-AXM1 (C91S), AF-trastuzumab or allotype control are shown.

[0152] Figure 19A A biphasic decay plot is presented, showing the half-life of hu AXM1 (C91S) administered in C57BL / 6 mice at doses of 100 µg / mouse and 500 µg / mouse. Serum was collected from mice at 15 min, 5 h, 1 day, 2 days, 4 days, 9 days, and 14 days post-injection. The concentration of hu AXM1 at each time point was measured using a human IgG ELISA. Figure 19BIn vivo IVIS images of each mouse are shown, along with ROI fluorescence intensity maps of tumor and liver compartments, highlighting the biodistribution of AXM1 conjugated with the fluorescent dye IVISense-800 NHS (AXM1-IVIS 800) and the control antibody conjugated with IVISense 800 NHS (control antibody-IVIS 800). To examine the biodistribution of anti-BILF1 in BILF1+ tumor-bearing mice, B6(Cg)-Tyrc-2J / J mice were vaccinated with 5 × 10⁶ IVIS images. 6 BILF1+ B16 cells were used. Mice were then randomized and treated with either AXM1-IVIS 800 or the control antibody-IVIS 800. Twenty-four hours after injection, the mice were imaged using the IVIS in vivo imaging system.

[0153] Figure 20A A 3D structural representation is provided, mapping the binding of the antibody to the extracellular domain of BILF1 as measured by alanine scans based on flow cytometry (covering all extracellular residues of BILF1). Residues preferably bound by AXM1 are shown in black, and residues preferably bound by AXM6 are shown in white. Figure 20B A bar chart is provided to illustrate the preferred binding of AXM1 and AXM6 to residues on the extracellular domain of BILF1. Positive values ​​indicate possible AXM1 epitope residues, and negative values ​​indicate possible AXM6 epitope residues.

[0154] Figure 21 shows the Western blot analysis of BILF1-GS-GFP B16 cell lysates, including deglycosylated BILF1-GS-GFP lysates detected with anti-GFP and AXM1 antibodies. First, membrane protein lysates from BILF1-GS-GFP B16 cells were denatured at 100°C for 10 min. Then, the lysates were treated with PNGase F, O-glycosidase + neuraminidase, or O-glycosidase + neuraminidase + PNGase F at 37°C for 1.5 h or 4 h. After treatment, the samples were analyzed by Western blot using both anti-GFP and AXM1 antibodies. Figure 21A Images of protein blots processed for 1.5 hours are shown, and Figure 21B The results of a 4-hour treatment are shown. Untreated membrane protein lysates are included as a control. Detailed Implementation

[0155] Overview

[0156] This disclosure provides antibodies and antigen-binding fragments that specifically bind to the extracellular domain (ECD) of the Epstein-Barr virus (EBV) membrane protein BILF-1, as well as related nucleic acids, vectors, pharmaceutical compositions, cells, and methods of use, such as for the treatment of EBV infection and EBV-mediated diseases. The antibodies and antigen-binding fragments described herein can be used as therapeutic agents, diagnostic agents, or investigational agents.

[0157] Similar to other herpesviruses, EBV has an active lysis and dormant latent life cycle, thus causing lifelong infection in the host, during which the virus can switch between latency and lysis reactivation (Babcock et al., 1998). EBV infects human B cells via the complement receptor CD21 and establishes lifelong latency in B cells. Latency is divided into four phases (0, I, II, and III), and only 0 to 8 proteins, along with a few short RNAs and microRNAs, are expressed during latency. In lysis infection, host cells are hijacked to produce millions of new viruses, which is crucial for viral spread within the host and to new hosts (Lukac and Yuan, 2007). This cycle is driven by the expression of time-regulated genes of immediate early (IE), early (E), and late (L) lysis genes, which encode lysis proteins (Lukac and Yuan, 2007) (Murata, 2018). Early genes are classified as those transcribed prior to viral replication and subsequently crucial for it, as they encode, for example, the viral DNA polymerase (EBV-BALF5) (Lukac and Yuan, 2007). Furthermore, early proteins can interfere with host cellular processes such as surface expression of major histocompatibility complex I (MHC-I) or MHC-II, thereby effectively evading the host immune system and thus ensuring viral survival (Quinn et al., 2014; Zuo et al., 2009, 2011). One such early protein is BILF1, a viral G protein-coupled receptor. BILF1 is expressed not only during EBV cleavage activation but also belongs to a group of genes highly expressed in EBV-positive tumors during abortive cleavage cycles (Yap et al., 2022) (Figure 2). Therefore, BILF1 is highly expressed in many EBV-positive cancers and mediates cell transformation in vitro and tumorigenesis in vivo (Tierney et al., 2015). BILF1 has also been found to upregulate intracellular adhesion molecule-1 (ICAM-I), a molecule crucial for promoting cancer metastasis. Overexpression of BILF1 enhances VEGF secretion and signaling, promoting tumor formation in vitro and tumor implantation and growth in vivo (Lyngaa et al., 2010). BILF1 has been detected in various EBV+ cell lines and tissue samples at both the lysis and latent stages. Previously, BILF1 has been shown to be highly expressed in nasopharyngeal carcinoma (NPC) and gastric adenocarcinoma (STAD) (Yap et al., 2022) (Chakravorty et al., 2019) (Borozan et al., 2018). Therefore, BILF-1 is a promising target for antibody therapy.

[0158] This disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to the extracellular domain (ECD) of the Epstein-Barr virus (EBV) membrane protein BILF-1. In some embodiments, the antibodies or antigen-binding fragments thereof described herein bind to the EBV membrane protein BILF-1. In some embodiments, the antibody or antigen-binding fragment thereof binds to the ECD of BILF-1. In some embodiments, the antibody or antigen-binding fragment thereof binds to one or more of ECD1, ECD2, ECD3, or ECD4 of BILF-1. In some embodiments, the antibody or antigen-binding fragment thereof binds to ECD1 of BILF-1. In some embodiments, the antibody or antigen-binding fragment thereof binds to both ECD1 and ECD2 of BILF-1. In some embodiments, the antibody or antigen-binding fragment thereof binds to both ECD1 and ECD3 of BILF-1. In some embodiments, the antibody or antigen-binding fragment thereof binds to both ECD1 and ECD4 of BILF-1. In some embodiments, the antibody or antigen-binding fragment thereof binds to ECD1, ECD2, and ECD3 of BILF-1. In some embodiments, the antibody or its antigen-binding fragment binds to ECD1, ECD2, ECD3, and ECD4 of BILF-1. In some embodiments, the antibody or its antigen-binding fragment binds to ECD2 of BILF-1. In some embodiments, the antibody or its antigen-binding fragment binds to ECD2 and ECD3 of BILF-1. In some embodiments, the antibody or its antigen-binding fragment binds to ECD2 and ECD4 of BILF-1. In some embodiments, the antibody or its antigen-binding fragment binds to ECD2, ECD3, and ECD4 of BILF-1. In some embodiments, the antibody or its antigen-binding fragment binds to ECD3 of BILF-1. In some embodiments, the antibody or its antigen-binding fragment binds to ECD3 and ECD4 of BILF-1.

[0159] Table 1: Amino acid sequences of BILF1 and its extracellular domain

[0160]

[0161] The amino acid sequences of BILF-1 and its four extracellular domains are provided in Table 1. In some embodiments, the antibody or a fragment thereof specifically binds to ECD1 of BILF-1 by contacting one or more amino acid residues within the epitope consisting of SEQ ID NO: 2. In some embodiments, the antibody or a fragment thereof specifically binds to ECD2 of BILF-1 by contacting one or more amino acid residues within the epitope consisting of SEQ ID NO: 3. In some embodiments, the antibody or a fragment thereof specifically binds to ECD3 of BILF-1 by contacting one or more amino acid residues within the epitope consisting of SEQ ID NO: 4. In some embodiments, the antibody or a fragment thereof specifically binds to ECD4 of BILF-1 by contacting one or more amino acid residues within the epitope consisting of SEQ ID NO: 5. In some embodiments, the antibody or a fragment thereof specifically binds to one or more of ECD1, ECD2, ECD3 or ECD4 of BILF-1 by contacting one or more amino acid residues within the corresponding epitope, wherein the ECD1 epitope is composed of SEQ ID NO: 2, the ECD2 epitope is composed of SEQ ID NO: 3, the ECD3 epitope is composed of SEQ ID NO: 4, and the ECD4 epitope is composed of SEQ ID NO: 5.

[0162] This disclosure provides different epitopes on BILF-1 specifically bound to the antibodies or their antigen-binding fragments described herein. Methods for mapping epitopes of antibodies on their target antigens are known in the art and include, but are not limited to, site-directed mutagenesis mapping, hydrogen-deuterium exchange mass spectrometry (HDX-MS), high-throughput shotgun mutagenesis mapping, X-ray crystallography, and cryo-electron microscopy. For example, epitopes can be determined by alanine scanning mutagenesis, where systematic substitution of single amino acid residues allows for the identification of key residues essential for antibody-antigen binding. In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment of the present disclosure binds to BILF-1 by contacting one or more amino acid residues selected from the group consisting of: L2, S3, T4, P7, S9, T10, L14, V15, N17, M18, T19, S20, V21, N22, A23, T24, T29, K30, S31, Y32, E90, F91, S92, G95, T160, M161, G162, M173, E176, G177, P178, H183, T184, A191, T259, L262, V263, A264, R265, and G269 (amino acid numbers based on the full-length BILF-1 sequence shown in SEQ ID NO: 1). In some embodiments, the antibody or antigen-binding fragment thereof disclosed herein binds to BILF-1 by contacting at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid residues selected from the group consisting of SEQ ID NO: 1: L2, S3, T4, P7, S9, T10, L14, V15, N17, M18, T19, S20, V21, N22, A23, T24, T29, K30, S31, Y32, E90, F91, S92, G95, T160, M161, G162, M173, E176, G177, P178, H183, T184, A191, T259, L262, V263, A264, R265, and G269. In some embodiments, the antibody or antigen-binding fragment thereof disclosed herein binds to BILF-1 by contacting three or more amino acid residues selected from the group consisting of SEQ ID NO: 1: L2, S3, T4, P7, S9, T10, L14, V15, N17, M18, T19, S20, V21, N22, A23, T24, T29, K30, S31, Y32, E90, F91, S92, G95, T160, M161, G162, M173, E176, G177, P178, H183, T184, A191, T259, L262, V263, A264, R265, and G269.In some embodiments, the antibody or antigen-binding fragment thereof disclosed herein binds to BILF-1 by contacting one or more amino acid residues selected from the group consisting of SEQ ID NO: 1: M39, D164, A165, N166, L167, N168, R169, G170, P171, N172, R175, T179, K180, G181, M182, A185, V186, Q187, G188, L189, K190, A251, S253, L254, G255, F256, D257, C258, E260, S261, Y266, Y267, and P268. In some embodiments, the antibody or antigen-binding fragment thereof disclosed herein binds to BILF-1 by contacting at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10 amino acid residues selected from the group consisting of SEQ ID NO: 1: M39, D164, A165, N166, L167, N168, R169, G170, P171, N172, R175, T179, K180, G181, M182, A185, V186, Q187, G188, L189, K190, A251, S253, L254, G255, F256, D257, C258, E260, S261, Y266, Y267, and P268. In some embodiments, the antibody or antigen-binding fragment thereof disclosed herein binds to BILF-1 by contacting three or more amino acid residues selected from the group consisting of SEQ ID NO: 1: M39, D164, A165, N166, L167, N168, R169, G170, P171, N172, R175, T179, K180, G181, M182, A185, V186, Q187, G188, L189, K190, A251, S253, L254, G255, F256, D257, C258, E260, S261, Y266, Y267, and P268.

[0163] The anti-BILF1 antibody or its antigen-binding fragment described herein has the potential to bind to specific epitopes of BILF1 and disrupt its conformational structure, thereby affecting its downstream signaling. In some embodiments, the anti-BILF-1 antibody or its fragment specifically binds to amino acids in the transmembrane region of the EBV membrane protein BILF-1; and wherein the specific binding alters the conformational structure of BILF-1 and changes the function of BILF-1.

[0164] In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment described herein is a monoclonal antibody and / or a humanized antibody, or its antigen-binding fragment. In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment is a humanized antibody. In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment is a fully human antibody. In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment is a complete antibody, a fragment antigen-binding domain (Fab), an F(ab')2 domain, a single-chain variable fragment (scFv), a dimer single-chain variable fragment (di-scFv), or a single-domain antibody (sdAb). In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment is a complete antibody. In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment is a fragment antigen-binding domain (Fab). In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment is an F(ab')2 domain. In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment is a single-chain variable fragment (scFv). In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment is a dimer single-chain variable fragment (di-scFv). In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment is a single-domain antibody (sdAb), comprising an F(ab')2 domain, a single-chain variable fragment (scFv), or a dimer single-chain variable fragment.

[0165] In some embodiments, the anti-BILF1 antibody or its antigen-binding fragment of the present disclosure comprises an Fc region selected from the group consisting of IgA, IgD, IgE, IgG, and IgM Fc regions. In some embodiments, the Fc region is IgA. In some embodiments, the Fc region is IgA1. In some embodiments, the Fc region is IgA2. In some embodiments, the Fc region is IgD. In some embodiments, the Fc region is IgE. In some embodiments, the Fc region is IgG. In some embodiments, the Fc region is IgG1. In some embodiments, the Fc region is IgG2. In some embodiments, the Fc region is IgG3. In some embodiments, the Fc region is IgG4. In some embodiments, the Fc region is IgM. In some embodiments, the Fc region is a mouse Fc region. In some embodiments, the Fc region is a human Fc region.

[0166] The IgG Fc domain interacts with its homologous receptor, the Fcγ receptor (FcγR), which is expressed on the surface of effector immune cells. This interaction mediates a range of Fc effector functions and can enhance the therapeutic potential of clinical monoclonal antibodies for treating inflammatory and neoplastic diseases (Nimmerjahn et al., Cancer Immun. 12, 13 (2012)). The Fc region can be modified to provide enhanced effector functions, such as enhanced binding affinity to Fc receptors, enhanced antibody-dependent cytotoxicity (ADCC), or enhanced complement-dependent cytotoxicity (CDC). For IgG antibodies, these effector functions are governed by the binding of the Fc region to a family of receptors called Fcγ receptors (FcγR), which are expressed on a variety of immune cells. The formation of the Fc / FcγR complex recruits these cells to sites of antigen binding, typically leading to signal transduction and subsequent immune responses. Methods for optimizing the binding affinity of FcγR to the antibody Fc region to enhance effector functions are well known to those skilled in the art. Non-limiting examples of such methods include modifying the Fc region of an antibody to enhance its interaction with the associated Fc receptor and increase its potential to promote antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). Enhancement of ADCC activity has also been described following modification of an oligosaccharide covalently linked to the conserved Asn297 site of the Fc region of an IgG1 antibody. Methods for enhancing CDC activity may include allotype chimerism, wherein a portion of an IgG3 subclass is introduced into the corresponding region of an IgG1 subclass (e.g., recombinant antibody compositions, US2007148165). In some embodiments, the anti-BILF-1 antibody of this disclosure or its antigen-binding fragment comprises an IgG Fc region having high effector function in humans. In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment comprises a modified Fc region having at least one altered effector function relative to the wild-type Fc region. In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment comprises a modified Fc region having at least one altered pharmacokinetic (PK) characteristic relative to the wild-type Fc region. In some embodiments, the at least one altered effector function includes increased binding to one or more immune cells. In some embodiments, the one or more immune cells are natural killer (NK) cells, macrophages, neutrophils, dendritic cells, or a combination thereof. In some embodiments, the at least one altered effector function includes increased binding to NK cells. In some embodiments, the at least one altered effector function includes increased binding to macrophages. In some embodiments, the at least one altered effector function includes increased binding to neutrophils. In some embodiments, the at least one altered effector function includes increased binding to dendritic cells.In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment comprises a modified Fc region that has increased affinity for one or more of CD64 (FcγRI), CD32 (FcγRII), or CD16 (FcγRIII). In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment comprises a modified Fc region that has increased affinity for CD16. In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment comprises a modified Fc region that has increased affinity for CD16a (FcγRIIIa). In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment described herein comprises one or more mutations in the Fc region that enhance FcyRIIIa binding and / or reduce FcyRIIIb binding. Non-restrictive examples of such mutations may be performed at one or more amino acid positions selected from the group consisting of: L234, L235, G236, S239, F243, H268, D270, R292, S298, Y300, V305, K326, A330, 1332, E333, K334, and P396. Non-restrictive exemplary mutations include L234Y, L235Q, G236W, S239D, S239M, F243L, H268D, D270E, R292P, S298A, Y300L, V305I, K326D, A330L, A330M, I332E, E333A, K334A, K334E, and P396L.

[0167] Other exemplary Fc mutations include, but are not limited to, L234A / L235A (referred to as “LALA”) in human IgG1, L234A / L235A / P329G (referred to as “LALAPG”) in human IgG1, M252Y / S254T / T256E (referred to as “YTE”) in human IgG1, M428L / N434S (referred to as “LS”) in human IgG1, M252Y / S254T / T256E / H433K / N434F in human IgG1, and S241P in human IgG4. In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment described herein comprises a modified Fc region, wherein the modified Fc region is modified human IgG1 containing, relative to wild-type IgG1, a mutation selected from L234A / L235A, L234A / L235A / P329G, M252Y / S254T / T256E, M428L / N434S, and M252Y / S254T / T256E / H433K / N434F. In some embodiments, the modified Fc region is modified human IgG1 containing the L234A / L235A mutation. In some embodiments, the modified Fc region is modified human IgG1 containing the L234A / L235A / P329G mutation. In some embodiments, the modified Fc region is modified human IgG1 containing the M252Y / S254T / T256E mutation. In some embodiments, the modified Fc region is modified human IgG1 containing the M428L / N434S mutation.

[0168] Fucose (6-deoxy-L-galactose) is a monosaccharide found in many glycoproteins and glycolipids in vertebrates, invertebrates, plants, and bacteria. Fucosylation is the process of transferring fucose residues to various proteins and oligosaccharides and is regulated by several molecules, including fucosyltransferases, guanosine diphosphate (GDP)-fucose synthases, and GDP-fucose transporters. Human IgG1 antibody is a highly fucosylated glycoprotein. Two A-linked biantennary oligosaccharides, consisting of a core heptasaccharide with variable additions of fucose, galactose, bivalent N-acetylglucosamine, and sialic acid, are present at Asn-297 of IgG1. Antibody glycosylation can lead to unique effector functions such as antibody-dependent cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The efficiency of ADCC is affected by the level of antibody fucosylation. Generally, lower fucosylation is associated with a higher ADCC rate. Therefore, it is known that non-fucosylated antibodies or recombinant monoclonal antibodies with reduced fucose content exhibit increased binding affinity between the Fc region and the Fc receptor, thereby enhancing the immune response, particularly through ADCC. Methods for reducing fucosylation in the Fc region of an antibody are known in the art. In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment described herein has a reduced fucose content in the Fc region. In some embodiments, the oligosaccharide in the Fc region of the anti-BILF-1 antibody or its antigen-binding fragment does not contain any fucose. In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment described herein comprises an IgG1 Fc region, wherein the oligosaccharide in the IgG1 Fc region has a reduced fucose content or does not contain any fucose. In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment described herein has a carbohydrate structure lacking fucose linked (directly or indirectly) to the Fc region (i.e., non-fucosylated). The amount of fucose in such variants can range from 1% to 80%, from 1% to 65%, from 5% to 65%, or from 20% to 40%. As an example, the amount of fucose can be determined by calculating the average amount of fucose within the glycan chain at Asn297 relative to the sum of all glycan structures (e.g., complex, heterozygous, and high-mannose structures) linked to Asn297, as measured by MALDI-TOF mass spectrometry, as described in WO 2008 / 077546. Asn297 refers to the asparagine residue (EU number of Fc region residues) located at approximately position 297 in the Fc region; however, due to minor sequence variations in the antibody, Asn297 can also be located approximately ±3 amino acids upstream or downstream of position 297, i.e., between positions 294 and 300.

[0169] Complementary Determinant Region (CDR) and Framework Region (FR)

[0170] Natural antibodies consist of two identical heavy chains (HC) and two identical light chains (LC). Each heavy chain contains a heavy chain variable region (VH) and a heavy chain constant region. Each light chain consists of a light chain variable region (VL) and a light chain constant region. The variable region of each of the heavy and light chains is a hypervariable region responsible for antigen-binding specificity and contains three hypervariable loops called complementarity-determining regions (CDRs). The three CDRs (CDR1, CDR2, and CDR3) are separated by more conserved regions called framework regions (FRs). The four FRs (FR1, FR2, FR3, and FR4) are structurally conserved regions that form a β-sheet structure, thus exposing these loops on the surface of the variable domain. Each VH or VL consists of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. The amino acid sequences of CDR and FR can be determined using various well-known definitions in the art, such as those of Kabat, Chothia, the International ImMunoGeneTics Database (IMGT), and AbM (see, for example, Chothia and Lesk, 1987, Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol. 196, 901-917; Chothia C. et al., 1989, Conformations of immunoglobulin hypervariable regions. Nature 342, 877-883; Chothia C. et al., 1992, structural repertoire of the human VH segments J. Mol. Biol. 227, 799-817; Al-Lazikani et al., J. Mol. Biol 1997, 273(4)). References to CDRs identified by Kabat numbering are, for example, based on Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed. Public Health Service, National Institute of Health, Bethesda, Md. (1991). Chothia CDRs are identified as defined by Chothia (see, for example, Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). Unless otherwise stated, CDR sequences described herein are identified according to the IMGT definition.Therefore, the CDR of the antibody or fragment thereof described herein may vary depending on the definition used for identification, and may contain 1, 2, or 3 substitutions, additions, and / or deletions relative to any exemplary sequence. In some embodiments, the sequence of any of the CDRs provided herein contains 1, 2, or 3 substitutions, additions, and / or deletions. Therefore, the FR of the antibody or fragment thereof described herein may also vary depending on the definition used for identification of the CDR, and may contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substitutions, additions, and / or deletions relative to any exemplary sequence. In some embodiments, the sequence of any of the FRs provided herein contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 substitutions, additions, and / or deletions.

[0171] In any of the embodiments described herein, the anti-BILF-1 antibody or its antigen-binding fragment may contain one or more amino acid substitutions (e.g., conserved substitutions), insertions, and / or deletions in any exemplary amino acid sequence, including, for example, one or more (e.g., one, two, or three) substitutions, insertions, and / or deletions in any exemplary CDR sequence. This technology specifically considers anti-BILF-1 antibodies or their antigen-binding fragments having one or more (e.g., one, two, or three) substitutions, insertions, and / or deletions compared to a reference CDR sequence as described herein, but still maintaining a certain level of binding affinity for BILF-1. In some embodiments, an anti-BILF-1 antibody or its antigen-binding fragment having one or more (e.g., one, two, or three) substitutions, insertions, and / or deletions compared to a reference CDR sequence as described herein will, when tested under the same or similar conditions, maintain at least 80% (e.g., at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%) of the binding affinity exhibited by an anti-BILF-1 antibody or its antigen-binding fragment having the reference CDR sequence. For example, an anti-BILF-1 antibody or its antigen-binding fragment having one or more (e.g., one, two, or three) substitutions, insertions, and / or deletions compared to a reference CDR sequence as described herein will yield approximately 1 x 10-1 -11 -1x10 -6 The affinity (KD) of M binds to BILF-1 (e.g., human BILF-1), for example, approximately 1 x 10-1. -11 -1x10 -8 M, approximately 1x10 -11 -1x10 -9 M, approximately 1x10 -11 -1x10 -10 M, approximately 1x10 -10 -1x10 -7 M, approximately 1x10 -10 -1x10 -8 M, approximately 1x10-10 -1x10 -9 M, approximately 1x10 -11 -1x10 -7 M, approximately 1x10 -9 -1x10 -7 M, approximately 1x10 -9 -1x10 -8 M or approximately 1x10 -8 -1x10 -7 M.

[0172] The “Fc region” refers to the constant region of an antibody that does not include the first constant region immunoglobulin domain. Therefore, Fc refers to the last two constant regions of IgA, IgD, and IgG immunoglobulin domains, and the last three constant regions of IgE and IgM immunoglobulin domains, along with the N-terminus of the flexible hinge of these domains. For IgA and IgM, Fc may include the J-chain. For IgG, Fc contains immunoglobulin domains Cγ2 and Cγ3, and the hinge between Cγ1 and Cγ. It should be understood in the art that the boundaries of the Fc region can vary. For example, the Fc region of the human IgG heavy chain is generally defined as containing residues C226 or P230 to its carboxyl terminus, numbered using the EU index according to Kabat et al. (1991, NIH Publication 91-3242, National Technical Information Service, Springfield, Va.).

[0173] Exemplary amino acid sequences of the CDR and FR of the anti-BILF-1 antibody or antigen-binding fragment disclosed herein are presented in Tables 2, 3, 4, and 5. Based on heavy chain sequence similarity, the different anti-BILF-1 antibody clones were divided into 5 groups.

[0174] Table 2: Amino acid sequences of the frame region (FR) and complementarity-determining region (CDR) of the group 1 anti-BILF1 antibody

[0175]

[0176] Table 3: Amino acid sequences of anti-BILF1 antibodies FR and CDR in group 2

[0177]

[0178] Table 4: Amino acid sequences of anti-BILF1 antibodies FR and CDR in group 3

[0179]

[0180] Table 5: Amino acid sequences of anti-BILF1 antibodies FR and CDR in group 4

[0181]

[0182] Table 6: Amino acid sequences of anti-BILF1 antibodies FR and CDR in group 5

[0183]

[0184] In some embodiments, the antibody or fragment thereof described herein comprises the heavy chain (HC) CDR1 sequence SEQ ID NO:14, the HC CDR2 sequence SEQ ID NO:15, the HC CDR3 sequence SEQ ID NO:16, the light chain (LC) CDR1 sequence SEQ ID NO:17, the LC CDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO:19.

[0185] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 28, the HCCDR2 sequence SEQ ID NO: 29, the HC CDR3 sequence SEQ ID NO: 30, the LC CDR1 sequence SEQ ID NO: 31, the LCCDR2 sequence YAS, and the LC CDR3 sequence SEQ ID NO: 33.

[0186] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 42, the HCCDR2 sequence SEQ ID NO: 43, the HC CDR3 sequence SEQ ID NO: 44, the LC CDR1 sequence SEQ ID NO: 45, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 47.

[0187] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 56, the HCCDR2 sequence SEQ ID NO: 57, the HC CDR3 sequence SEQ ID NO: 58, the LC CDR1 sequence SEQ ID NO: 59, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 61.

[0188] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 70, the HCCDR2 sequence SEQ ID NO: 71, the HC CDR3 sequence SEQ ID NO: 72, the LC CDR1 sequence SEQ ID NO: 73, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 75.

[0189] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 84, the HCCDR2 sequence SEQ ID NO: 85, the HC CDR3 sequence SEQ ID NO: 86, the LC CDR1 sequence SEQ ID NO: 87, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 89.

[0190] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 98, the HCCDR2 sequence SEQ ID NO: 99, the HC CDR3 sequence SEQ ID NO: 100, the LC CDR1 sequence SEQ ID NO: 101, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 103.

[0191] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 112, the HCCDR2 sequence SEQ ID NO: 113, the HC CDR3 sequence SEQ ID NO: 114, the LC CDR1 sequence SEQ ID NO: 115, the LCCDR2 sequence YAS, and the LC CDR3 sequence SEQ ID NO: 117.

[0192] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 126, the HCCDR2 sequence SEQ ID NO: 127, the HC CDR3 sequence SEQ ID NO: 128, the LC CDR1 sequence SEQ ID NO: 129, the LCCDR2 sequence YAS, and the LC CDR3 sequence SEQ ID NO: 131.

[0193] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 140, the HCCDR2 sequence SEQ ID NO: 141, the HC CDR3 sequence SEQ ID NO: 142, the LC CDR1 sequence SEQ ID NO: 143, the LCCDR2 sequence YAS, and the LC CDR3 sequence SEQ ID NO: 145.

[0194] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 154, the HCCDR2 sequence SEQ ID NO: 155, the HC CDR3 sequence SEQ ID NO: 156, the LC CDR1 sequence SEQ ID NO: 157, the LCCDR2 sequence WAS, and the LC CDR3 sequence SEQ ID NO: 159.

[0195] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 168, the HCCDR2 sequence SEQ ID NO: 169, the HC CDR3 sequence SEQ ID NO: 170, the LC CDR1 sequence SEQ ID NO: 171, the LCCDR2 sequence YAS, and the LC CDR3 sequence SEQ ID NO: 173.

[0196] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 182, the HCCDR2 sequence SEQ ID NO: 183, the HC CDR3 sequence SEQ ID NO: 184, the LC CDR1 sequence SEQ ID NO: 185, the LCCDR2 sequence YAS, and the LC CDR3 sequence SEQ ID NO: 187.

[0197] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 196, the HCCDR2 sequence SEQ ID NO: 197, the HC CDR3 sequence SEQ ID NO: 198, the LC CDR1 sequence SEQ ID NO: 199, the LCCDR2 sequence AAS, and the LC CDR3 sequence SEQ ID NO: 201.

[0198] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 210, the HCCDR2 sequence SEQ ID NO: 211, the HC CDR3 sequence SEQ ID NO: 212, the LC CDR1 sequence SEQ ID NO: 213, the LCCDR2 sequence GTN, and the LC CDR3 sequence SEQ ID NO: 215.

[0199] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 224, the HCCDR2 sequence SEQ ID NO: 225, the HC CDR3 sequence SEQ ID NO: 226, the LC CDR1 sequence SEQ ID NO: 227, the LCCDR2 sequence GAS, and the LC CDR3 sequence SEQ ID NO: 229.

[0200] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, the HC CDR2 sequence SEQ ID NO: 15, the HC CDR3 sequence SEQ ID NO: 16, the light chain (LC) CDR1 sequence SEQ ID NO: 17, the LC CDR2 sequence GTS, the LC CDR3 sequence SEQ ID NO: 19, the HC frame region (FR) 1 sequence SEQ ID NO: 6, the HCFR2 sequence SEQ ID NO: 7, the HC FR3 sequence SEQ ID NO: 8, the HC FR4 sequence SEQ ID NO: 9, the LC FR1 sequence SEQ ID NO: 10, the LC FR2 sequence SEQ ID NO: 11, the LC FR3 sequence SEQ ID NO: 12, and the LC FR4 sequence SEQ ID NO: 13.

[0201] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 28, HCCDR2 sequence SEQ ID NO: 29, HC CDR3 sequence SEQ ID NO: 30, LC CDR1 sequence SEQ ID NO: 31, LCCDR2 sequence YAS, LC CDR3 sequence SEQ ID NO: 33, HC FR1 sequence SEQ ID NO: 20, HC FR2 sequence SEQ ID NO: 21, HC FR3 sequence SEQ ID NO: 22, HC FR4 sequence SEQ ID NO: 23, LC FR1 sequence SEQ ID NO: 24, LC FR2 sequence SEQ ID NO: 25, LC FR3 sequence SEQ ID NO: 26, and LC FR4 sequence SEQ ID NO: 27.

[0202] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 42, HCCDR2 sequence SEQ ID NO: 43, HC CDR3 sequence SEQ ID NO: 44, LC CDR1 sequence SEQ ID NO: 45, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 47, HC FR1 sequence SEQ ID NO: 34, HC FR2 sequence SEQ ID NO: 35, HC FR3 sequence SEQ ID NO: 36, HC FR4 sequence SEQ ID NO: 37, LC FR1 sequence SEQ ID NO: 38, LC FR2 sequence SEQ ID NO: 39, LC FR3 sequence SEQ ID NO: 40, and LC FR4 sequence SEQ ID NO: 41.

[0203] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 56, HCCDR2 sequence SEQ ID NO: 57, HC CDR3 sequence SEQ ID NO: 58, LC CDR1 sequence SEQ ID NO: 59, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 61, HC FR1 sequence SEQ ID NO: 48, HC FR2 sequence SEQ ID NO: 49, HC FR3 sequence SEQ ID NO: 50, HC FR4 sequence SEQ ID NO: 51, LC FR1 sequence SEQ ID NO: 52, LC FR2 sequence SEQ ID NO: 53, LC FR3 sequence SEQ ID NO: 54, and LC FR4 sequence SEQ ID NO: 55.

[0204] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 70, HCCDR2 sequence SEQ ID NO: 71, HC CDR3 sequence SEQ ID NO: 72, LC CDR1 sequence SEQ ID NO: 73, LCCDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 75, HC FR1 sequence SEQ ID NO: 62, HC FR2 sequence SEQ ID NO: 63, HC FR3 sequence SEQ ID NO: 64, HC FR4 sequence SEQ ID NO: 65, LC FR1 sequence SEQ ID NO: 66, LC FR2 sequence SEQ ID NO: 67, LC FR3 sequence SEQ ID NO: 68 and LC FR4 sequence SEQ ID NO: 69.

[0205] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 84, HCCDR2 sequence SEQ ID NO: 85, HC CDR3 sequence SEQ ID NO: 86, LC CDR1 sequence SEQ ID NO: 87, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 89, HC FR1 sequence SEQ ID NO: 76, HC FR2 sequence SEQ ID NO: 77, HC FR3 sequence SEQ ID NO: 78, HC FR4 sequence SEQ ID NO: 79, LC FR1 sequence SEQ ID NO: 80, LC FR2 sequence SEQ ID NO: 81, LC FR3 sequence SEQ ID NO: 82, and LC FR4 sequence SEQ ID NO: 83.

[0206] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 98, HCCDR2 sequence SEQ ID NO: 99, HC CDR3 sequence SEQ ID NO: 100, LC CDR1 sequence SEQ ID NO: 101, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 103, HC FR1 sequence SEQ ID NO: 90, HC FR2 sequence SEQ ID NO: 91, HC FR3 sequence SEQ ID NO: 92, HC FR4 sequence SEQ ID NO: 93, LC FR1 sequence SEQ ID NO: 94, LC FR2 sequence SEQ ID NO: 95, LC FR3 sequence SEQ ID NO: 96, and LC FR4 sequence SEQ ID NO: 97.

[0207] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 112, HCCDR2 sequence SEQ ID NO: 113, HC CDR3 sequence SEQ ID NO: 114, LC CDR1 sequence SEQ ID NO: 115, LCCDR2 sequence YAS, LC CDR3 sequence SEQ ID NO: 117, HC FR1 sequence SEQ ID NO: 104, HC FR2 sequence SEQ ID NO: 105, HC FR3 sequence SEQ ID NO: 106, HC FR4 sequence SEQ ID NO: 107, LC FR1 sequence SEQ ID NO: 108, LC FR2 sequence SEQ ID NO: 109, LC FR3 sequence SEQ ID NO: 110, and LC FR4 sequence SEQ ID NO: 111.

[0208] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 126, HCCDR2 sequence SEQ ID NO: 127, HC CDR3 sequence SEQ ID NO: 128, LC CDR1 sequence SEQ ID NO: 129, LCCDR2 sequence YAS, LC CDR3 sequence SEQ ID NO: 131, HC FR1 sequence SEQ ID NO: 118, HC FR2 sequence SEQ ID NO: 119, HC FR3 sequence SEQ ID NO: 120, HC FR4 sequence SEQ ID NO: 121, LC FR1 sequence SEQ ID NO: 122, LC FR2 sequence SEQ ID NO: 123, LC FR3 sequence SEQ ID NO: 124, and LC FR4 sequence SEQ ID NO: 125.

[0209] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 140, HCCDR2 sequence SEQ ID NO: 141, HC CDR3 sequence SEQ ID NO: 142, LC CDR1 sequence SEQ ID NO: 143, LCCDR2 sequence YAS, LC CDR3 sequence SEQ ID NO: 145, HC FR1 sequence SEQ ID NO: 132, HC FR2 sequence SEQ ID NO: 133, HC FR3 sequence SEQ ID NO: 134, HC FR4 sequence SEQ ID NO: 135, LC FR1 sequence SEQ ID NO: 136, LC FR2 sequence SEQ ID NO: 137, LC FR3 sequence SEQ ID NO: 138, and LC FR4 sequence SEQ ID NO: 139.

[0210] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 154, HCCDR2 sequence SEQ ID NO: 155, HC CDR3 sequence SEQ ID NO: 156, LC CDR1 sequence SEQ ID NO: 157, LCCDR2 sequence WAS, LC CDR3 sequence SEQ ID NO: 159, HC FR1 sequence SEQ ID NO: 146, HC FR2 sequence SEQ ID NO: 147, HC FR3 sequence SEQ ID NO: 148, HC FR4 sequence SEQ ID NO: 149, LC FR1 sequence SEQ ID NO: 150, LC FR2 sequence SEQ ID NO: 151, LC FR3 sequence SEQ ID NO: 152, and LC FR4 sequence SEQ ID NO: 153.

[0211] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 168, HCCDR2 sequence SEQ ID NO: 169, HC CDR3 sequence SEQ ID NO: 170, LC CDR1 sequence SEQ ID NO: 171, LCCDR2 sequence YAS, LC CDR3 sequence SEQ ID NO: 173, HC FR1 sequence SEQ ID NO: 160, HC FR2 sequence SEQ ID NO: 161, HC FR3 sequence SEQ ID NO: 162, HC FR4 sequence SEQ ID NO: 163, LC FR1 sequence SEQ ID NO: 164, LC FR2 sequence SEQ ID NO: 165, LC FR3 sequence SEQ ID NO: 166, and LC FR4 sequence SEQ ID NO: 167.

[0212] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 182, HCCDR2 sequence SEQ ID NO: 183, HC CDR3 sequence SEQ ID NO: 184, LC CDR1 sequence SEQ ID NO: 185, LCCDR2 sequence YAS, LC CDR3 sequence SEQ ID NO: 187, HC FR1 sequence SEQ ID NO: 174, HC FR2 sequence SEQ ID NO: 175, HC FR3 sequence SEQ ID NO: 176, HC FR4 sequence SEQ ID NO: 177, LC FR1 sequence SEQ ID NO: 178, LC FR2 sequence SEQ ID NO: 179, LC FR3 sequence SEQ ID NO: 180, and LC FR4 sequence SEQ ID NO: 181.

[0213] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 196, HCCDR2 sequence SEQ ID NO: 197, HC CDR3 sequence SEQ ID NO: 198, LC CDR1 sequence SEQ ID NO: 199, LCCDR2 sequence AAS, LC CDR3 sequence SEQ ID NO: 201, HC FR1 sequence SEQ ID NO: 188, HC FR2 sequence SEQ ID NO: 189, HC FR3 sequence SEQ ID NO: 190, HC FR4 sequence SEQ ID NO: 191, LC FR1 sequence SEQ ID NO: 192, LC FR2 sequence SEQ ID NO: 193, LC FR3 sequence SEQ ID NO: 194, and LC FR4 sequence SEQ ID NO: 195.

[0214] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 210, HCCDR2 sequence SEQ ID NO: 211, HC CDR3 sequence SEQ ID NO: 212, LC CDR1 sequence SEQ ID NO: 213, LCCDR2 sequence GTN, LC CDR3 sequence SEQ ID NO: 215, HC FR1 sequence SEQ ID NO: 202, HC FR2 sequence SEQ ID NO: 203, HC FR3 sequence SEQ ID NO: 204, HC FR4 sequence SEQ ID NO: 205, LC FR1 sequence SEQ ID NO: 206, LC FR2 sequence SEQ ID NO: 207, LC FR3 sequence SEQ ID NO: 208, and LC FR4 sequence SEQ ID NO: 209.

[0215] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 224, HCCDR2 sequence SEQ ID NO: 225, HC CDR3 sequence SEQ ID NO: 226, LC CDR1 sequence SEQ ID NO: 227, LCCDR2 sequence GAS, LC CDR3 sequence SEQ ID NO: 229, HC FR1 sequence SEQ ID NO: 216, HC FR2 sequence SEQ ID NO: 217, HC FR3 sequence SEQ ID NO: 218, HC FR4 sequence SEQ ID NO: 219, LC FR1 sequence SEQ ID NO: 220, LC FR2 sequence SEQ ID NO: 221, LC FR3 sequence SEQ ID NO: 222, and LC FR4 sequence SEQ ID NO: 223.

[0216] Antibody variants

[0217] Antibody variants with superior characteristics can be generated by introducing specific mutations into the sequence of the antibody. Non-limiting examples of superior characteristics that can be introduced by specific mutations include enhanced stability, increased specificity, reduced glycosylation, reduced degradation, and increased shelf life. In some embodiments of the anti-BILF-1 antibody or fragment thereof disclosed herein, the variable domains of the heavy chain or light chain, or both, are altered by at least one amino acid substitution. In some embodiments, amino acid substitution of CDR and framework residues by targeted or random mutagenesis methods can produce antibodies with enhanced binding, potency, or specificity characteristics. In some embodiments, amino acid substitution of framework residues reduces potential immunogenicity by altering the framework residues to a germline state. In some embodiments, amino acid substitution of framework or CDR residues can eliminate potential structural vulnerabilities that may lead to instability, aggregation, or heterogeneity of the antibodies or fragments thereof described herein. Non-limiting examples of undesirable hazards include unpaired cysteine ​​residues (which may lead to disulfide bond mismatch or variable thiol adduct formation), N-linked glycosylation sites (leading to structural and activity heterogeneity), and deamidation (e.g., NG, NS), isomerization (DG), oxidation (exposed methionine), and hydrolysis (DP) sites. In some embodiments, the amino acid sequence of the anti-BILF-1 antibody or fragment thereof disclosed herein contains one or more mutations. In some embodiments, the one or more mutations are located in the light chain. In some embodiments, the one or more mutations contain amino acid substitutions. In some embodiments, the one or more mutations contain mutations in amino acids selected from asparagine, cysteine, and leucine. In some embodiments, the one or more mutations are selected from the group consisting of: asparagine to histidine, cysteine ​​to alanine, asparagine to arginine, leucine to isoleucine, cysteine ​​to valine, asparagine to serine, and asparagine to alanine. In some embodiments, unpaired cysteine ​​residues in the amino acid sequence are eliminated by the one or more mutations. In some embodiments, the one or more mutations improve the binding affinity, stability, and / or pharmacokinetics of the antibody or fragment thereof described herein. In some embodiments, the one or more mutations improve the binding affinity of the antibody or a fragment thereof. In some embodiments, the one or more mutations improve the stability of the antibody or a fragment thereof. Tables 7 and 8 provide exemplary sequences of antibody variants of the anti-BILF-1 antibody clone AXM1 described in Table 2.

[0218] Table 7 provides exemplary light chain amino acid sequences of the CDRs and FRs of the anti-BILF-1 antibody variants of the anti-BILF-1 antibody clone AXM1 described in Table 2. Any of the three LC CDR groups (CDR1, CDR2, and CDR3) and / or four LC FR groups (FR1, FR2, FR3, and FR4) described in Table 7 may be used in conjunction with any of the three HC CDR groups (CDR1, CDR2, and CDR3) and / or four LC FR groups (FR1, FR2, FR3, and FR4) of this disclosure (e.g., as described in Tables 2, 3, 4, 5, 6, and 8).

[0219] Table 7: Amino acid sequences of AXM1 antibody variants with light chain mutations

[0220]

[0221] Table 8 provides exemplary heavy chain amino acid sequences of the CDR and FR of the anti-BILF-1 antibody variant of the anti-BILF-1 antibody clone AXM1 described in Table 2. Any of the three HC CDR (CDR1, CDR2, and CDR3) groups and / or four HC FR (FR1, FR2, FR3, and FR4) groups described in Table 8 may be used in conjunction with any of the three LC CDR groups and / or four LC FR groups of this disclosure (e.g., as described in Tables 2, 3, 4, 5, 6, and 7).

[0222] Table 8: Amino acid sequences of AXM1 antibody variants with heavy chain mutations

[0223]

[0224] Any of the three HC CDR groups and / or four HC FR groups of this disclosure (e.g., as described in Tables 2, 3, 4, 5, 6 and 8) may be used in conjunction with any of the three LCCDR groups and / or four LC FR groups of this disclosure (e.g., as described in Tables 2, 3, 4, 5, 6 and 7).

[0225] In some embodiments, the antibody or fragment thereof described herein comprises:

[0226] a. HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16;

[0227] HC CDR1 sequence SEQ ID NO: 28, HC CDR2 sequence SEQ ID NO: 29, HC CDR3 sequence SEQ ID NO: 30;

[0228] HC CDR1 sequence SEQ ID NO: 42, HC CDR2 sequence SEQ ID NO: 43, HC CDR3 sequence SEQ ID NO: 44;

[0229] HC CDR1 sequence SEQ ID NO: 56, HC CDR2 sequence SEQ ID NO: 57, HC CDR3 sequence SEQ ID NO: 58;

[0230] HC CDR1 sequence SEQ ID NO: 70, HC CDR2 sequence SEQ ID NO: 71, HC CDR3 sequence SEQ ID NO: 72;

[0231] HC CDR1 sequence SEQ ID NO: 84, HC CDR2 sequence SEQ ID NO: 85, HC CDR3 sequence SEQ ID NO: 86;

[0232] HC CDR1 sequence SEQ ID NO: 98, HC CDR2 sequence SEQ ID NO: 99, HC CDR3 sequence SEQ ID NO: 100;

[0233] HC CDR1 sequence SEQ ID NO: 112, HC CDR2 sequence SEQ ID NO: 113, HC CDR3 sequence SEQ ID NO: 114;

[0234] HC CDR1 sequence SEQ ID NO: 126, HC CDR2 sequence SEQ ID NO: 127, HC CDR3 sequence SEQ ID NO: 128;

[0235] HC CDR1 sequence SEQ ID NO: 140, HC CDR2 sequence SEQ ID NO: 141, HC CDR3 sequence SEQ ID NO: 142;

[0236] HC CDR1 sequence SEQ ID NO: 154, HC CDR2 sequence SEQ ID NO: 155, HC CDR3 sequence SEQ ID NO: 156;

[0237] HC CDR1 sequence SEQ ID NO: 168, HC CDR2 sequence SEQ ID NO: 169, HC CDR3 sequence SEQ ID NO: 170;

[0238] HC CDR1 sequence SEQ ID NO: 182, HC CDR2 sequence SEQ ID NO: 183, HC CDR3 sequence SEQ ID NO: 184;

[0239] HC CDR1 sequence SEQ ID NO: 196, HC CDR2 sequence SEQ ID NO: 197, HC CDR3 sequence SEQ ID NO: 198;

[0240] HC CDR1 sequence SEQ ID NO: 210, HC CDR2 sequence SEQ ID NO: 211, HC CDR3 sequence SEQ ID NO: 212;

[0241] HC CDR1 sequence SEQ ID NO: 224, HC CDR2 sequence SEQ ID NO: 225, HC CDR3 sequence SEQ ID NO: 226;

[0242] HC CDR1 sequence SEQ ID NO: 290, HC CDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292;

[0243] HC CDR1 sequence SEQ ID NO: 297, HC CDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299;

[0244] HC CDR1 sequence SEQ ID NO: 304, HC CDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306; or

[0245] HC CDR1 sequence SEQ ID NO: 311, HC CDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313; and

[0246] b. LC CDR1 sequence SEQ ID NO: 17, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 19;

[0247] LC CDR1 sequence SEQ ID NO: 31, LC CDR2 sequence YAS, and LC CDR3 sequence SEQ ID NO: 33;

[0248] LC CDR1 sequence SEQ ID NO: 45, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 47;

[0249] LC CDR1 sequence SEQ ID NO: 59, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 61;

[0250] LC CDR1 sequence SEQ ID NO: 73, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 75;

[0251] LC CDR1 sequence SEQ ID NO: 87, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 89;

[0252] LC CDR1 sequence SEQ ID NO: 101, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 103;

[0253] LC CDR1 sequence SEQ ID NO: 115, LC CDR2 sequence YAS, and LC CDR3 sequence SEQ ID NO: 117;

[0254] LC CDR1 sequence SEQ ID NO: 129, LC CDR2 sequence YAS, and LC CDR3 sequence SEQ ID NO: 131;

[0255] LC CDR1 sequence SEQ ID NO: 143, LC CDR2 sequence YAS, and LC CDR3 sequence SEQ ID NO: 145;

[0256] LC CDR1 sequence SEQ ID NO: 157, LC CDR2 sequence WAS, and LC CDR3 sequence SEQ ID NO: 159;

[0257] LC CDR1 sequence SEQ ID NO: 171, LC CDR2 sequence YAS, and LC CDR3 sequence SEQ ID NO: 173;

[0258] LC CDR1 sequence SEQ ID NO: 185, LC CDR2 sequence YAS, and LC CDR3 sequence SEQ ID NO: 187;

[0259] LC CDR1 sequence SEQ ID NO: 199, LC CDR2 sequence AAS, and LC CDR3 sequence SEQ ID NO: 201;

[0260] LC CDR1 sequence SEQ ID NO: 213, LC CDR2 sequence GTN, and LC CDR3 sequence SEQ ID NO: 215;

[0261] LC CDR1 sequence SEQ ID NO: 227, LC CDR2 sequence GAS, and LC CDR3 sequence SEQ ID NO: 229;

[0262] LC CDR1 sequence SEQ ID NO: 234, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 236;

[0263] LC CDR1 sequence SEQ ID NO: 241, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 243;

[0264] LC CDR1 sequence SEQ ID NO: 248, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 250;

[0265] LC CDR1 sequence SEQ ID NO: 255, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 257;

[0266] LC CDR1 sequence SEQ ID NO: 262, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 264;

[0267] LC CDR1 sequence SEQ ID NO: 269, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 271;

[0268] LC CDR1 sequence SEQ ID NO: 276, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 278; or

[0269] LC CDR1 sequence SEQ ID NO: 283, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 285.

[0270] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, the HCCDR2 sequence SEQ ID NO: 15, the HC CDR3 sequence SEQ ID NO: 16, the LC CDR1 sequence SEQ ID NO: 234, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 236.

[0271] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 14, the HCCDR2 sequence SEQ ID NO: 15, the HC CDR3 sequence SEQ ID NO: 16, the LC CDR1 sequence SEQ ID NO: 241, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 243.

[0272] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 14, the HCCDR2 sequence SEQ ID NO: 15, the HC CDR3 sequence SEQ ID NO: 16, the LC CDR1 sequence SEQ ID NO: 248, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 250.

[0273] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 14, the HCCDR2 sequence SEQ ID NO: 15, the HC CDR3 sequence SEQ ID NO: 16, the LC CDR1 sequence SEQ ID NO: 255, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 257.

[0274] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 14, the HCCDR2 sequence SEQ ID NO: 15, the HC CDR3 sequence SEQ ID NO: 16, the LC CDR1 sequence SEQ ID NO: 262, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 264.

[0275] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 14, the HCCDR2 sequence SEQ ID NO: 15, the HC CDR3 sequence SEQ ID NO: 16, the LC CDR1 sequence SEQ ID NO: 269, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 271.

[0276] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, the HCCDR2 sequence SEQ ID NO: 15, the HC CDR3 sequence SEQ ID NO: 16, the LC CDR1 sequence SEQ ID NO: 276, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 278.

[0277] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 14, the HCCDR2 sequence SEQ ID NO: 15, the HC CDR3 sequence SEQ ID NO: 16, the LC CDR1 sequence SEQ ID NO: 283, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 285.

[0278] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, the HCCDR2 sequence SEQ ID NO: 291, the HC CDR3 sequence SEQ ID NO: 292, the LC CDR1 sequence SEQ ID NO: 234, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 236.

[0279] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, the HCCDR2 sequence SEQ ID NO: 291, the HC CDR3 sequence SEQ ID NO: 292, the LC CDR1 sequence SEQ ID NO: 241, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 243.

[0280] In some embodiments, the antibody or fragment thereof described herein comprises the HC CDR1 sequence SEQ ID NO: 290, the HCCDR2 sequence SEQ ID NO: 291, the HC CDR3 sequence SEQ ID NO: 292, the LC CDR1 sequence SEQ ID NO: 248, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 250.

[0281] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, the HCCDR2 sequence SEQ ID NO: 291, the HC CDR3 sequence SEQ ID NO: 292, the LC CDR1 sequence SEQ ID NO: 255, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 257.

[0282] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, the HCCDR2 sequence SEQ ID NO: 291, the HC CDR3 sequence SEQ ID NO: 292, the LC CDR1 sequence SEQ ID NO: 262, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 264.

[0283] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, the HCCDR2 sequence SEQ ID NO: 291, the HC CDR3 sequence SEQ ID NO: 292, the LC CDR1 sequence SEQ ID NO: 269, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 271.

[0284] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, the HCCDR2 sequence SEQ ID NO: 291, the HC CDR3 sequence SEQ ID NO: 292, the LC CDR1 sequence SEQ ID NO: 276, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 278.

[0285] In some embodiments, the antibodies or fragments thereof described herein are SEQ ID NO: 290 (HC CDR1), SEQ ID NO: 291 (HCCDR2), SEQ ID NO: 292 (HC CDR3), SEQ ID NO: 283 (LC CDR1), SEQ ID NO: 285 (LC CDR2 GTS).

[0286] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, the HCCDR2 sequence SEQ ID NO: 298, the HC CDR3 sequence SEQ ID NO: 299, the LC CDR1 sequence SEQ ID NO: 234, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 236.

[0287] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, the HCCDR2 sequence SEQ ID NO: 298, the HC CDR3 sequence SEQ ID NO: 299, the LC CDR1 sequence SEQ ID NO: 241, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 243.

[0288] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, the HCCDR2 sequence SEQ ID NO: 298, the HC CDR3 sequence SEQ ID NO: 299, the LC CDR1 sequence SEQ ID NO: 248, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 250.

[0289] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, the HCCDR2 sequence SEQ ID NO: 298, the HC CDR3 sequence SEQ ID NO: 299, the LC CDR1 sequence SEQ ID NO: 255, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 257.

[0290] In some embodiments, the antibodies or fragments thereof described herein are SEQ ID NO: 297 (HC CDR1), SEQ ID NO: 298 (HCCDR2), SEQ ID NO: 299 (HC CDR3), SEQ ID NO: 262 (LC CDR1), GTS (LC CDR2), and SEQ ID NO: 264 (LC CDR3).

[0291] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, the HCCDR2 sequence SEQ ID NO: 298, the HC CDR3 sequence SEQ ID NO: 299, the LC CDR1 sequence SEQ ID NO: 269, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 271.

[0292] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, the HCCDR2 sequence SEQ ID NO: 298, the HC CDR3 sequence SEQ ID NO: 299, the LC CDR1 sequence SEQ ID NO: 276, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 278.

[0293] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, the HCCDR2 sequence SEQ ID NO: 298, the HC CDR3 sequence SEQ ID NO: 299, the LC CDR1 sequence SEQ ID NO: 283, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 285.

[0294] In some embodiments, the antibodies or fragments thereof described herein are SEQ ID NO: 304 for HC CDR1, SEQ ID NO: 305 for HCCDR2, SEQ ID NO: 306 for HC CDR3, SEQ ID NO: 234 for LC CDR1, SEQ ID NO: 234 for LCCDR2, and SEQ ID NO: 236 for LC CDR3.

[0295] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, the HCCDR2 sequence SEQ ID NO: 305, the HC CDR3 sequence SEQ ID NO: 306, the LC CDR1 sequence SEQ ID NO: 241, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 243.

[0296] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, the HCCDR2 sequence SEQ ID NO: 305, the HC CDR3 sequence SEQ ID NO: 306, the LC CDR1 sequence SEQ ID NO: 248, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 250.

[0297] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, the HCCDR2 sequence SEQ ID NO: 305, the HC CDR3 sequence SEQ ID NO: 306, the LC CDR1 sequence SEQ ID NO: 255, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 257.

[0298] In some embodiments, the antibodies or fragments thereof described herein are SEQ ID NO: 304 (HC CDR1), SEQ ID NO: 305 (HCCDR2), SEQ ID NO: 306 (HC CDR3), SEQ ID NO: 262 (LC CDR1), GTS (LC CDR2), and SEQ ID NO: 264 (LC CDR3).

[0299] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, the HCCDR2 sequence SEQ ID NO: 305, the HC CDR3 sequence SEQ ID NO: 306, the LC CDR1 sequence SEQ ID NO: 269, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 271.

[0300] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, the HCCDR2 sequence SEQ ID NO: 305, the HC CDR3 sequence SEQ ID NO: 306, the LC CDR1 sequence SEQ ID NO: 276, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 278.

[0301] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, the HCCDR2 sequence SEQ ID NO: 305, the HC CDR3 sequence SEQ ID NO: 306, the LC CDR1 sequence SEQ ID NO: 283, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 285.

[0302] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, the HCCDR2 sequence SEQ ID NO: 312, the HC CDR3 sequence SEQ ID NO: 313, the LC CDR1 sequence SEQ ID NO: 234, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 236.

[0303] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, the HCCDR2 sequence SEQ ID NO: 312, the HC CDR3 sequence SEQ ID NO: 313, the LC CDR1 sequence SEQ ID NO: 241, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 243.

[0304] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, the HCCDR2 sequence SEQ ID NO: 312, the HC CDR3 sequence SEQ ID NO: 313, the LC CDR1 sequence SEQ ID NO: 248, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 250.

[0305] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, the HCCDR2 sequence SEQ ID NO: 312, the HC CDR3 sequence SEQ ID NO: 313, the LC CDR1 sequence SEQ ID NO: 255, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 257.

[0306] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, the HCCDR2 sequence SEQ ID NO: 312, the HC CDR3 sequence SEQ ID NO: 313, the LC CDR1 sequence SEQ ID NO: 262, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 264.

[0307] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, the HCCDR2 sequence SEQ ID NO: 312, the HC CDR3 sequence SEQ ID NO: 313, the LC CDR1 sequence SEQ ID NO: 269, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 271.

[0308] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, the HCCDR2 sequence SEQ ID NO: 312, the HC CDR3 sequence SEQ ID NO: 313, the LC CDR1 sequence SEQ ID NO: 276, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 278.

[0309] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, the HCCDR2 sequence SEQ ID NO: 312, the HC CDR3 sequence SEQ ID NO: 313, the LC CDR1 sequence SEQ ID NO: 283, the LCCDR2 sequence GTS, and the LC CDR3 sequence SEQ ID NO: 285.

[0310] In some embodiments, the antibody or fragment thereof described herein comprises:

[0311] a. HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9;

[0312] HC CDR1 sequence SEQ ID NO: 290, HC CDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289;

[0313] HC CDR1 sequence SEQ ID NO: 297, HC CDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296;

[0314] HC CDR1 sequence SEQ ID NO: 304, HC CDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303; or

[0315] HC CDR1 sequence SEQ ID NO: 311, HC CDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310; and

[0316] b. LC CDR1 sequence SEQ ID NO: 234, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 236, LC FR1 sequence SEQ ID NO: 230, LC FR2 sequence SEQ ID NO: 231, LC FR3 sequence SEQ ID NO: 232 and LC FR4 sequence SEQ ID NO: 233;

[0317] LC CDR1 sequence SEQ ID NO: 241, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 243, LC FR1 sequence SEQ ID NO: 237, LC FR2 sequence SEQ ID NO: 238, LC FR3 sequence SEQ ID NO: 239 and LC FR4 sequence SEQ ID NO: 240;

[0318] LC CDR1 sequence SEQ ID NO: 248, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 250, LC FR1 sequence SEQ ID NO: 244, LC FR2 sequence SEQ ID NO: 245, LC FR3 sequence SEQ ID NO: 246 and LC FR4 sequence SEQ ID NO: 247;

[0319] LC CDR1 sequence SEQ ID NO: 255, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 257, LC FR1 sequence SEQ ID NO: 251, LC FR2 sequence SEQ ID NO: 252, LC FR3 sequence SEQ ID NO: 253 and LC FR4 sequence SEQ ID NO: 254;

[0320] LC CDR1 sequence SEQ ID NO: 262, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 264, LC FR1 sequence SEQ ID NO: 258, LC FR2 sequence SEQ ID NO: 259, LC FR3 sequence SEQ ID NO: 260 and LC FR4 sequence SEQ ID NO: 261;

[0321] LC CDR1 sequence SEQ ID NO: 269, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 271, LC FR1 sequence SEQ ID NO: 265, LC FR2 sequence SEQ ID NO: 266, LC FR3 sequence SEQ ID NO: 267 and LC FR4 sequence SEQ ID NO: 268;

[0322] LC CDR1 sequence SEQ ID NO: 276, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 278, LC FR1 sequence SEQ ID NO: 272, LC FR2 sequence SEQ ID NO: 273, LC FR3 sequence SEQ ID NO: 274 and LC FR4 sequence SEQ ID NO: 275; or

[0323] LC CDR1 sequence SEQ ID NO: 283, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 285, LC FR1 sequence SEQ ID NO: 279, LC FR2 sequence SEQ ID NO: 280, LC FR3 sequence SEQ ID NO: 281 and LC FR4 sequence SEQ ID NO: 282.

[0324] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, HCCDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 234, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 236, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 230, LC FR2 sequence SEQ ID NO: 231, LC FR3 sequence SEQ ID NO: 232, and LC FR4 sequence SEQ ID NO: 233.

[0325] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, HCCDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 241, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 243, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 237, LC FR2 sequence SEQ ID NO: 238, LC FR3 sequence SEQ ID NO: 239, and LC FR4 sequence SEQ ID NO: 240.

[0326] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, HCCDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 248, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 250, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 244, LC FR2 sequence SEQ ID NO: 245, LC FR3 sequence SEQ ID NO: 246, and LC FR4 sequence SEQ ID NO: 247.

[0327] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, HCCDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 255, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 257, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 251, LC FR2 sequence SEQ ID NO: 252, LC FR3 sequence SEQ ID NO: 253, and LC FR4 sequence SEQ ID NO: 254.

[0328] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, HCCDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 262, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 264, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 258, LC FR2 sequence SEQ ID NO: 259, LC FR3 sequence SEQ ID NO: 260, and LC FR4 sequence SEQ ID NO: 261.

[0329] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, HCCDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 269, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 271, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 265, LC FR2 sequence SEQ ID NO: 266, LC FR3 sequence SEQ ID NO: 267, and LC FR4 sequence SEQ ID NO: 268.

[0330] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, HCCDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 276, LCCDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 278, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 272, LC FR2 sequence SEQ ID NO: 273, LC FR3 sequence SEQ ID NO: 274 and LC FR4 sequence SEQ ID NO: 275.

[0331] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 14, HCCDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 283, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 285, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 279, LC FR2 sequence SEQ ID NO: 280, LC FR3 sequence SEQ ID NO: 281, and LC FR4 sequence SEQ ID NO: 282.

[0332] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, HCCDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, LC CDR1 sequence SEQ ID NO: 234, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 236, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289, LC FR1 sequence SEQ ID NO: 230, LC FR2 sequence SEQ ID NO: 231, LC FR3 sequence SEQ ID NO: 232, and LC FR4 sequence SEQ ID NO: 233.

[0333] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, HCCDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, LC CDR1 sequence SEQ ID NO: 241, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 243, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289, LC FR1 sequence SEQ ID NO: 237, LC FR2 sequence SEQ ID NO: 238, LC FR3 sequence SEQ ID NO: 239, and LC FR4 sequence SEQ ID NO: 240.

[0334] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, HCCDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, LC CDR1 sequence SEQ ID NO: 248, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 250, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289, LC FR1 sequence SEQ ID NO: 244, LC FR2 sequence SEQ ID NO: 245, LC FR3 sequence SEQ ID NO: 246, and LC FR4 sequence SEQ ID NO: 247.

[0335] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, HCCDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, LC CDR1 sequence SEQ ID NO: 255, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 257, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289, LC FR1 sequence SEQ ID NO: 251, LC FR2 sequence SEQ ID NO: 252, LC FR3 sequence SEQ ID NO: 253, and LC FR4 sequence SEQ ID NO: 254.

[0336] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, HCCDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, LC CDR1 sequence SEQ ID NO: 262, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 264, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289, LC FR1 sequence SEQ ID NO: 258, LC FR2 sequence SEQ ID NO: 259, LC FR3 sequence SEQ ID NO: 260, and LC FR4 sequence SEQ ID NO: 261.

[0337] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, HCCDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, LC CDR1 sequence SEQ ID NO: 269, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 271, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289, LC FR1 sequence SEQ ID NO: 265, LC FR2 sequence SEQ ID NO: 266, LC FR3 sequence SEQ ID NO: 267, and LC FR4 sequence SEQ ID NO: 268.

[0338] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, HCCDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, LC CDR1 sequence SEQ ID NO: 276, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 278, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289, LC FR1 sequence SEQ ID NO: 272, LC FR2 sequence SEQ ID NO: 273, LC FR3 sequence SEQ ID NO: 274, and LC FR4 sequence SEQ ID NO: 275.

[0339] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 290, HCCDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, LC CDR1 sequence SEQ ID NO: 283, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 285, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289, LC FR1 sequence SEQ ID NO: 279, LC FR2 sequence SEQ ID NO: 280, LC FR3 sequence SEQ ID NO: 281, and LC FR4 sequence SEQ ID NO: 282.

[0340] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, HCCDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, LC CDR1 sequence SEQ ID NO: 234, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 236, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296 NO: 313, LC FR1 sequence SEQ ID NO: 230, LC FR2 sequence SEQ ID NO: 231, LC FR3 sequence SEQ ID NO: 232, and LC FR4 sequence SEQ ID NO: 233.

[0341] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, HCCDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, LC CDR1 sequence SEQ ID NO: 241, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 243, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296 NO: 313, LC FR1 sequence SEQ ID NO: 237, LC FR2 sequence SEQ ID NO: 238, LC FR3 sequence SEQ ID NO: 239, and LC FR4 sequence SEQ ID NO: 240.

[0342] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, HCCDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, LC CDR1 sequence SEQ ID NO: 248, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 250, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296 NO: 313, LC FR1 sequence SEQ ID NO: 244, LC FR2 sequence SEQ ID NO: 245, LC FR3 sequence SEQ ID NO: 246, and LC FR4 sequence SEQ ID NO: 247.

[0343] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, HCCDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, LC CDR1 sequence SEQ ID NO: 255, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 257, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296 NO: 313, LC FR1 sequence SEQ ID NO: 251, LC FR2 sequence SEQ ID NO: 252, LC FR3 sequence SEQ ID NO: 253, and LC FR4 sequence SEQ ID NO: 254.

[0344] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, HCCDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, LC CDR1 sequence SEQ ID NO: 262, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 264, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296 NO: 313, LC FR1 sequence SEQ ID NO: 258, LC FR2 sequence SEQ ID NO: 259, LC FR3 sequence SEQ ID NO: 260, and LC FR4 sequence SEQ ID NO: 261.

[0345] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, HCCDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, LC CDR1 sequence SEQ ID NO: 269, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 271, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296 NO: 313, LC FR1 sequence SEQ ID NO: 265, LC FR2 sequence SEQ ID NO: 266, LC FR3 sequence SEQ ID NO: 267, and LC FR4 sequence SEQ ID NO: 268.

[0346] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, HCCDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, LC CDR1 sequence SEQ ID NO: 276, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 278, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296 NO: 313, LC FR1 sequence SEQ ID NO: 272, LC FR2 sequence SEQ ID NO: 273, LC FR3 sequence SEQ ID NO: 274, and LC FR4 sequence SEQ ID NO: 275.

[0347] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 297, HCCDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, LC CDR1 sequence SEQ ID NO: 283, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 285, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296 NO: 313, LC FR1 sequence SEQ ID NO: 279, LC FR2 sequence SEQ ID NO: 280, LC FR3 sequence SEQ ID NO: 281, and LC FR4 sequence SEQ ID NO: 282.

[0348] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, HCCDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, LC CDR1 sequence SEQ ID NO: 234, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 236, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303, LC FR1 sequence SEQ ID NO: 230, LC FR2 sequence SEQ ID NO: 231, LC FR3 sequence SEQ ID NO: 232, and LC FR4 sequence SEQ ID NO: 233.

[0349] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, HCCDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, LC CDR1 sequence SEQ ID NO: 241, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 243, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303, LC FR1 sequence SEQ ID NO: 237, LC FR2 sequence SEQ ID NO: 238, LC FR3 sequence SEQ ID NO: 239, and LC FR4 sequence SEQ ID NO: 240.

[0350] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, HCCDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, LC CDR1 sequence SEQ ID NO: 248, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 250, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303, LC FR1 sequence SEQ ID NO: 244, LC FR2 sequence SEQ ID NO: 245, LC FR3 sequence SEQ ID NO: 246, and LC FR4 sequence SEQ ID NO: 247.

[0351] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, HCCDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, LC CDR1 sequence SEQ ID NO: 255, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 257, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303, LC FR1 sequence SEQ ID NO: 251, LC FR2 sequence SEQ ID NO: 252, LC FR3 sequence SEQ ID NO: 253, and LC FR4 sequence SEQ ID NO: 254.

[0352] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, HCCDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, LC CDR1 sequence SEQ ID NO: 262, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 264, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303, LC FR1 sequence SEQ ID NO: 258, LC FR2 sequence SEQ ID NO: 259, LC FR3 sequence SEQ ID NO: 260, and LC FR4 sequence SEQ ID NO: 261.

[0353] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, HCCDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, LC CDR1 sequence SEQ ID NO: 269, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 271, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303, LC FR1 sequence SEQ ID NO: 265, LC FR2 sequence SEQ ID NO: 266, LC FR3 sequence SEQ ID NO: 267, and LC FR4 sequence SEQ ID NO: 268.

[0354] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, HCCDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, LC CDR1 sequence SEQ ID NO: 276, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 278, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303, LC FR1 sequence SEQ ID NO: 272, LC FR2 sequence SEQ ID NO: 273, LC FR3 sequence SEQ ID NO: 274, and LC FR4 sequence SEQ ID NO: 275.

[0355] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 304, HCCDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, LC CDR1 sequence SEQ ID NO: 283, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 285, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303, LC FR1 sequence SEQ ID NO: 279, LC FR2 sequence SEQ ID NO: 280, LC FR3 sequence SEQ ID NO: 281, and LC FR4 sequence SEQ ID NO: 282.

[0356] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, HCCDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, LC CDR1 sequence SEQ ID NO: 234, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 236, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310, LC FR1 sequence SEQ ID NO: 230, LC FR2 sequence SEQ ID NO: 231, LC FR3 sequence SEQ ID NO: 232, and LC FR4 sequence SEQ ID NO: 233.

[0357] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, HCCDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, LC CDR1 sequence SEQ ID NO: 241, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 243, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310, LC FR1 sequence SEQ ID NO: 237, LC FR2 sequence SEQ ID NO: 238, LC FR3 sequence SEQ ID NO: 239, and LC FR4 sequence SEQ ID NO: 240.

[0358] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, HCCDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, LC CDR1 sequence SEQ ID NO: 248, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 250, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310, LC FR1 sequence SEQ ID NO: 244, LC FR2 sequence SEQ ID NO: 245, LC FR3 sequence SEQ ID NO: 246, and LC FR4 sequence SEQ ID NO: 247.

[0359] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, HCCDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, LC CDR1 sequence SEQ ID NO: 255, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 257, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310, LC FR1 sequence SEQ ID NO: 251, LC FR2 sequence SEQ ID NO: 252, LC FR3 sequence SEQ ID NO: 253, and LC FR4 sequence SEQ ID NO: 254.

[0360] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, HCCDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, LC CDR1 sequence SEQ ID NO: 262, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 264, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310, LC FR1 sequence SEQ ID NO: 258, LC FR2 sequence SEQ ID NO: 259, LC FR3 sequence SEQ ID NO: 260, and LC FR4 sequence SEQ ID NO: 261.

[0361] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, HCCDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, LC CDR1 sequence SEQ ID NO: 269, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 271, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310, LC FR1 sequence SEQ ID NO: 265, LC FR2 sequence SEQ ID NO: 266, LC FR3 sequence SEQ ID NO: 267, and LC FR4 sequence SEQ ID NO: 268.

[0362] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, HCCDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, LC CDR1 sequence SEQ ID NO: 276, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 278, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310, LC FR1 sequence SEQ ID NO: 272, LC FR2 sequence SEQ ID NO: 273, LC FR3 sequence SEQ ID NO: 274, and LC FR4 sequence SEQ ID NO: 275.

[0363] In some embodiments, the antibodies or fragments thereof described herein comprise the HC CDR1 sequence SEQ ID NO: 311, HCCDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, LC CDR1 sequence SEQ ID NO: 283, LCCDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 285, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310, LC FR1 sequence SEQ ID NO: 279, LC FR2 sequence SEQ ID NO: 280, LC FR3 sequence SEQ ID NO: 281, and LC FR4 sequence SEQ ID NO: 282.

[0364] Table 9: Exemplary amino acid sequences of the heavy chain variable region (VH) and light chain variable region (VL) of the anti-BILF-1 antibody

[0365]

[0366] In some embodiments, exemplary amino acid sequences of the heavy and light chain variable regions of the antibodies or fragments thereof described herein are provided in Table 9. In some embodiments, the antibodies or fragments thereof described herein comprise a heavy chain variable region (VH) comprising or consisting of the following: amino acid sequences shown in any one of SEQ ID NO: 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 354, 355, 356, 357, or the amino acid sequences shown in SEQ ID NO: The amino acid sequences shown in any one of 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 354, 355, 356, and 357 are at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical). In some embodiments, the antibody or fragment thereof described herein comprises a light chain variable region (VL) comprising or consisting of the following: an amino acid sequence shown in any one of SEQ ID NO: 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 346, 347, 348, 349, 350, 351, 352, 353, or a sequence thereof. The amino acid sequences shown in any one of the following: 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 346, 347, 348, 349, 350, 351, 352, and 353 are at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical).

[0367] In some embodiments, exemplary amino acid sequences of the heavy and light chain variable regions of the antibodies or fragments thereof described herein are provided in Table 9. In some embodiments, the antibodies or fragments thereof described herein comprise a heavy chain variable region (VH) comprising or consisting of the following: an amino acid sequence shown in any one of SEQ ID NO: 314, 354, 355, 356, 357, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in any one of SEQ ID NO: 314, 354, 355, 356, 357. In some embodiments, the antibody or fragment thereof described herein comprises a light chain variable region (VL) comprising or consisting of the following: an amino acid sequence represented by any one of SEQ ID NO: 315, 346, 347, 348, 349, 350, 351, 352, 353, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence represented by any one of SEQ ID NO: 315, 346, 347, 348, 349, 350, 351, 352, 353.

[0368] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 314, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 314; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 315, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 315.

[0369] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 314, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 314; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 346, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 346.

[0370] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 314, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 314; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 347, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 347.

[0371] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 314, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 314; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 348, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 348.

[0372] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 314, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 314; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 349, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 349.

[0373] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 314, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 314; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 350, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 350.

[0374] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 314, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 314; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 351, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 351.

[0375] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 314, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 314; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 352, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 352.

[0376] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 314, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 314; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 352, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 353.

[0377] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 316, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 316; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 317, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 317.

[0378] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 318, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 318; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 319, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 319.

[0379] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 320, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 320; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 321, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 321.

[0380] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 322, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 322; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 323, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 323.

[0381] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 324, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 324; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 325, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 325.

[0382] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 326, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 326; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 327, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 327.

[0383] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 328, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 328; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 329, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 329.

[0384] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 330, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 330; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 331, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 331.

[0385] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 332, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 332; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 333, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 333.

[0386] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 334, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 334; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 335, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 335.

[0387] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 336, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 336; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 337, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 337.

[0388] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 338, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 338; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 339, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 339.

[0389] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 340, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 340; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 341, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 341.

[0390] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 342, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 342; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 343, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 343.

[0391] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 344, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 344; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 345, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 345.

[0392] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 354, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 354; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 315, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 315.

[0393] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 354, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 354; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 346, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 346.

[0394] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 354, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 354; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 347, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 347.

[0395] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 354, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 354; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 348, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 348.

[0396] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 354, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 354; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 349, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 349.

[0397] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 354, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 354; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 350, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 350.

[0398] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 354, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 354; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 351, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 351.

[0399] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 354, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 354; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 352, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 352.

[0400] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 354, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 354; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 352, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 353.

[0401] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 355, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 355; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 315, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 315.

[0402] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 355, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 355; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 346, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 346.

[0403] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 355, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 355; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 347, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 347.

[0404] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 355, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 355; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 348, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 348.

[0405] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 355, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 355; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 349, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 349.

[0406] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 355, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 355; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 350, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 350.

[0407] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 355, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 355; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 351, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 351.

[0408] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 355, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 355; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 352, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 352.

[0409] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 355, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 355; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 352, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 353.

[0410] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 356, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 356; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 315, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 315.

[0411] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 356, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 356; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 346, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 346.

[0412] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 356, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 356; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 347, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 347.

[0413] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 356, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 356; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 348, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 348.

[0414] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 356, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 356; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 349, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 349.

[0415] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 356, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 356; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 350, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 350.

[0416] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 356, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 356; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 351, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 351.

[0417] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 356, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 356; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 352, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 352.

[0418] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 356, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 356; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 352, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 353.

[0419] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 357, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 357; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 315, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 315.

[0420] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 357, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 357; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 346, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 346.

[0421] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 357, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 357; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 347, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 347.

[0422] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 357, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 357; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 348, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 348.

[0423] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 357, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 357; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 349, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 349.

[0424] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 357, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 357; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 350, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 350.

[0425] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 357, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 357; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 351, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 351.

[0426] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 357, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 357; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 352, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 352.

[0427] In some embodiments, the antibody or fragment thereof described herein comprises: (i) a heavy chain variable region (VH) comprising or consisting of the amino acid sequence shown in SEQ ID NO: 357, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 357; and / or (ii) a VL comprising or consisting of the amino acid sequence shown in SEQ ID NO: 352, or an amino acid sequence that is at least about 80% identical (e.g., at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical) to the amino acid sequence shown in SEQ ID NO: 353.

[0428] Antibody drug conjugates

[0429] Chemotherapy agents often lack specificity for cancer cells, leading to undesirable side effects due to toxicity to non-cancerous tissues. Antibody-drug conjugates (ADCs) typically consist of an antibody conjugated to a payload such as a cytotoxic drug. This antibody specifically binds to cell or tissue-specific antigens, allowing selective delivery of the cytotoxic agent to specific cells or tissues and reducing the systemic toxicity of conventional small-molecule chemotherapeutic agents. A successful ADC must bind to and be internalized to the target antigen to deliver the toxic payload to target cells without significantly binding to non-target cells. BILF-1 has been shown to be constitutively internalized, making it a promising target for ADC design. This document discloses ADCs comprising the anti-BILF-1 antibody described herein or an antigen-binding fragment thereof, and one or more payloads. In some embodiments, the anti-BILF-1 antibody described herein or an antigen-binding fragment thereof is conjugated to one or more payloads. Exemplary payloads include, but are not limited to, alkylating agents, antitumor antibiotics, topoisomerase inhibitors, mitotic inhibitors, corticosteroids, nitrosoureas, antimetabolites, and any combination thereof. In some embodiments, the one or more payloads comprise a cytotoxic agent. In some embodiments, the cytotoxic agent is monomethylolpropamine F (MMAF), monomethylolpropamine E (MMAE), or pyruvic DM (DMDM). In some embodiments, the anti-BILF-1 antibody described herein or its antigen-binding fragment is conjugated to the cytotoxic agent. In some embodiments, the cytotoxic agent is pyruvic DM. In some embodiments, the payload is released in target cells (e.g., BILF-1 positive cells).

[0430] The anti-BILF-1 antibody or its antigen-binding fragment described herein can be conjugated to a payload using a bifunctional crosslinking agent or adapter. The adapter can directly or indirectly link the antibody or antigen-binding fragment to the payload. The adapter has at least two reactive groups, one of which reacts with the antibody and the other with the payload to link the antibody to the payload, thereby forming a conjugate. The adapter can also chemically link the payload to the antibody, such that the payload and antibody are chemically coupled to each other (e.g., covalently). Any suitable bifunctional adapter can be used in combination with the anti-BILF-1 antibody, its antigen-binding fragment, and the payload described herein, provided that the adapter provides retention of the payload (e.g., cytotoxicity) and targeting characteristics of the antibody or antigen-binding fragment.

[0431] The linker to the antibody can be achieved in various ways, such as via surface lysine residues, reductive coupling with oxidized carbohydrates, and release of cysteine ​​residues via the reduction of interchain disulfide bonds. Various antibody-drug conjugate linking systems are known in the art, including those based on hydrazone, disulfide bonds, and peptides. Exemplary linkers may comprise, for example, a hydrazone moiety, an acylhydrazine moiety, a disulfide bond moiety, a glucuronidase-cleavable moiety, a cathepsin B-cleavable moiety, a dipeptide-containing moiety, an amide moiety, a maleimide moiety, a maleimide hexanoyl (me) moiety, a p-aminobenzyloxycarbonyl (PABC) moiety, or combinations thereof.

[0432] In some embodiments, the linker is a cleavable linker. Cleavable linkers are generally readily cleaved under physiological conditions, particularly intracellularly via cleavage by, for example, lysosomes or endosome proteases to release the linked payload. In some embodiments, cleavable linkers are designed to release the free payload in its unmodified form. Cleavable linkers may include, for example, disulfide linkers, acid-labile linkers, peptidase-labile linkers, glycosidase-sensitive linkers, photostable linkers, and esterase-labile linkers. Typically, peptidyl linkers are at least two or at least three amino acids long. Cleavable linkers utilize the environmental differences between systemic circulation and tumor cells to provide efficient and accurate release of free cytotoxic drugs. In some embodiments, cleavable linkers are chemically cleaved via hydrazone or disulfide bonds. In other embodiments, cleavable linkers are enzymatically cleaved via peptide or glucuronide bonds. Acid-labile (pH-sensitive) linkers are relatively stable under neutral pH conditions (such as those in blood) but unstable below pH 5.5 or 5.0. Acid-labile linkers include, for example, hydrazones, thioureas, cis-aconitine, orthoesters, acetals, ketals, etc. Disulfide-based linkers are chemically sensitive cleavable linkers that are sensitive to reduced glutathione (GSH) under reducing conditions. GSH plays a crucial role in maintaining intracellular redox homeostasis during cell survival, cell proliferation, and differentiation. In some embodiments, disulfide-based linkers can be used in ADCs comprising the anti-BILF-1 antibody described herein or its antigen-binding fragment to target cancer cells in which intracellular GSH levels may be significantly elevated compared to blood levels.

[0433] In some embodiments, the linker is a peptide-based linker comprising a peptidase-instable moiety sensitive to intracellular proteases, such as lysosomal or endosomal proteases. Exemplary proteases for releasing payloads from ADCs include, for example, cathepsins B and D and plasmin, all of which are known to hydrolyze dipeptide drug derivatives, resulting in the release of the active drug within the target cell. In some embodiments, the peptidase-instable linker comprises a dipeptide moiety. In some embodiments, the peptidase-instable linker comprises a maleimide hexanoyl (me) moiety or a p-aminobenzyloxycarbonyl (PABC) moiety. In some embodiments, the peptidase-instable linker is sensitive to cleavage by the thiol-dependent protease cathepsin B. Lysosomal proteases, such as cathepsin B, are commonly overexpressed in cancer cells and are therefore particularly well-suited for releasing payloads in cancer cells. Peptide linkers that can be cleaved by intracellular proteases (such as cathepsin B) include, but are not limited to, valine-citrulline (Val-Cit), phenylalanine-lysine (Phe-Lys), valine-alanine (Val-Ala), phenylalanine-leucine (Phe-Leu), phenylalanine-arginine (Phe-Lys), the tetrapeptide linker Gly-Phe-Leu-Gly, and maleimide hexanoyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PABC). Other peptide linkers include, but are not limited to, Ala-Val, Val-Ala-Val, Lys-Lys, Pro-Val-Gly-Val-Val, Ala-Asn-Val, Val-Leu-Lys, Ala-Ala-Asn, Cit-Cit, Val-Lys, Lys, Cit, Ser, and Glu. In some embodiments, the linker is the mc-vc-PAB linker. Exemplary mc-vc-PAB connectors include mc-vc-PABC, mc-vc-PAB-PNP, mc-vc-PAB-NH2, and mc-vc-PAB-OH.

[0434] Bispecific antibodies

[0435] Antibody specificity refers to the selective recognition of a specific epitope of an antigen by an antibody. As used herein, the term "bispecific" antibody refers to an antibody having binding specificity to two different antigens. The bispecific antibodies of this disclosure have two or more antigen-binding sites and bind to two different antigens or two different epitopes of the same antigen. In some embodiments, the anti-BILF-1 antibody of this disclosure or its antigen-binding fragment is a bispecific antibody. In some embodiments, the anti-BILF-1 antibody or its fragment is a bispecific antibody comprising a first antigen-binding domain (ABD) that specifically binds to BILF-1 and a second ABD domain that specifically binds to a cell surface receptor. In some embodiments, the cell surface receptor is expressed on an immune cell, can form a heterodimer with BILF-1, is co-expressed with BILF-1, or a combination thereof. In some embodiments, the cell surface receptor is expressed on an immune cell. In some embodiments, the bispecific antibody or its fragment increases the binding of BILF-1-expressing cells to the immune cell. In some embodiments, the immune cell is a T cell or a natural killer (NK) cell. In some embodiments, the immune cell is a T cell. In some embodiments, the immune cell is an NK cell. In some embodiments, the cell surface receptor bound by the second ABD domain may form a heterodimer with BILF-1. In some embodiments, the cell surface receptor is co-expressed with BILF-1. In some embodiments, the cell surface receptor is CD3, CD16, IL-8 receptor, CD19, BCMA, CD38, vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), EBV latent membrane protein 1 (LMP1), or EBV latent membrane protein 2 (LMP2). In some embodiments, the cell surface receptor is CD3. In some embodiments, the cell surface receptor is CD16. In some embodiments, the cell surface receptor is IL-8. In some embodiments, the cell surface receptor is CD19. In some embodiments, the cell surface receptor is BCMA. In some embodiments, the cell surface receptor is CD38. In some embodiments, the cell surface receptor is VEGFR. In some embodiments, the cell surface receptor is EGFR. In some embodiments, the cell surface receptor is LMP1. In some embodiments, the cell surface receptor is LMP2. In some embodiments, a mechanism referred to as a "mortar and pestle" is used to promote the formation of heterodimers in bispecific antibody engineering.The "mortar and pestle" form refers to amino acid engineering that creates spatial effects to promote heterodimer formation while discouraging homodimer formation, as described below: Ridgway et al., Protein Engineering 9(7):6l7 (1996); Atwell et al., J. Mol. Biol. 1997 270:26; U.S. Patent No. 8,216,805; and WO1996 / 027011, all of which are hereby incorporated by reference in their entirety. For example, the heavy chain with the mortar may contain mutations of Y349C, T366S, L368A, and Y407V, and the pestle may contain mutations of S354C and T366W. In some embodiments, the anti-BILF-1 antibody or its antigen-binding fragment of the present disclosure is a bispecific antibody in the mortar and pestle form. In some embodiments, the bispecific antibody described herein has a 2-valent antibody to BILF-1 and a monovalent antibody to a second antigen-binding domain. As used herein, antibody "valence" refers to the total number of antigen-binding sites of the antibody.

[0436] In some embodiments, the anti-BILF-1 antibody or fragment thereof described herein includes a linker. For example, the linker may be used to fuse an scFv portion to an Fc region. In some embodiments, the scFv portion is fused to CH2 of the Fc region. In some embodiments, the linker is a peptide linker. In some embodiments, the linker is a glycine-serine linker. In some embodiments, the linker includes the sequence of GGGS (SEQ ID NO: 358). In some embodiments, the linker includes the sequence of AAA.

[0437] T-cell adaptor

[0438] T-cell adaptors are molecules that bridge the gap between target cells and T cells. Bispecific T-cell adaptors (BiTEs) are T-cell adaptors with bispecific affinities for two antigens. Several molecules based on the fundamental concept of having two antibody-like binding domains have been developed. BiTEs are a class of developed bispecific antibody-type molecules primarily used as anticancer drugs. They direct the host's immune system, more specifically the cytotoxic activity of T cells, towards target cells, such as cancer cells. In these molecules, one binding domain binds to T cells, for example, via the CD3 receptor, while the other binding domain binds to target cells, such as tumor cells (via targeting tumor-specific antigens). Because the bispecific molecule binds to both target cells and T cells simultaneously, it brings the target cell into close proximity to the T cell, allowing the T cell to exert its effects, such as cytotoxicity against cancer cells. The formation of the T-cell:bispecific antibody:cancer cell complex induces signaling in T cells, leading to the release of, for example, cytotoxic mediators. Ideally, the agent induces the desired signaling only in the presence of the target cell, resulting in selective killing. The terms "bispecific T-cell adaptor," "BiTE," or "BiTEs" in this disclosure refer to molecules having two antigen-binding domains that can bind the same or different antigens. In some embodiments, the anti-BILF-1 antibody or a fragment thereof of this disclosure is a T-cell adaptor. In some embodiments, the anti-BILF-1 antibody or a fragment thereof is a BiTE. In some embodiments, the T-cell adaptor comprises an anti-BILF-1 binding domain and an anti-CD3 binding domain. In some embodiments, the T-cell adaptor comprises an anti-BILF-1 binding domain and an anti-CD28 binding domain. Other T-cell adaptors include, but are not limited to, trispecific T-cell adaptors (TriTE), biaffinity retargeting antibodies (DART), TeTriTE, and tetraspecific T-cell adaptors.

[0439] Immune activators

[0440] An immune activator is a molecule that triggers immune activation. Non-limiting examples of immune activators include Toll-like receptor (TLR) agonists, interferon gene-stimulating factor (STING) agonists, and cytokines such as IL-2, IL-15, or TNF superfamily ligands. In some embodiments, the anti-BILF-1 antibody of this disclosure or a fragment thereof is conjugated or fused to an immune activator. In some embodiments, the immune activator is a TLR agonist, a STING agonist, or a cytokine. In some embodiments, the immune activator is a TLR agonist. Non-limiting examples of TLR agonists include TLR-3, TLR-7, TLR-9, and TLR-9 agonists. In some embodiments, the immune activator is a STING agonist. In some embodiments, the immune activator is a cytokine. In some embodiments, the cytokine is IL-2. In some embodiments, the cytokine is IL-15. In some embodiments, the cytokine is a TNF superfamily ligand. Non-limiting examples of TNF superfamily ligands include TRAIL, 4-1BBL, interleukin-21 (IL-21), IFN-α, IFN-β, CD40, GITR-L, OX40L, and CD70.

[0441] Chimeric antigen receptor

[0442] Chimeric antigen receptors (CARs) are typically designed in a modular manner, comprising at least an extracellular target-binding domain, a transmembrane domain anchoring the CAR to the cell membrane, and one or more intracellular signaling domains (also known as co-stimulatory domains) that transmit activation signals within the cell. The domains present in the CAR construct are operatively linked to suitable adapter sequences. As used herein, “chimeric antigen receptor” or “CAR” refers to an artificial recombinant polypeptide comprising at least an extracellular domain, a transmembrane domain, and an intracellular signaling domain that binds to a specific antigen. The extracellular domain of the CAR can target tumor-specific antigens or tumor-associated antigens. Immune cells, such as T lymphocytes, can be genetically engineered to express the CAR. Binding of the extracellular antigen-binding domain of the CAR to the target antigen results in the killing of cells expressing the target antigen by cells expressing the CAR. The extracellular domain of the CAR can be derived from an antibody. In some embodiments, the extracellular domain of the CAR can be derived from an anti-BILF-1 antibody or a fragment thereof disclosed herein. CAR T cells targeting BILF-1 can effectively kill EBV-infected cells, such as EBV+ B cells or cancer cells. In some embodiments, the anti-BILF-1 antibody or a fragment thereof disclosed herein is fused with a transmembrane domain and an intracellular signaling domain to form a CAR. In some embodiments, the anti-BILF-1 antibody or a fragment thereof is a single-chain variable fragment (scFv). In some embodiments, the anti-BILF-1 antibody or a fragment thereof disclosed herein is an scFv that is fused with a transmembrane domain and an intracellular T cell signaling domain via a spacer region (hinge region) to form a CAR.

[0443] Nucleic acid and vector

[0444] This disclosure also provides isolated nucleic acid molecules containing nucleic acid sequences encoding the anti-BILF-1 antibody or fragments thereof described herein. The isolated nucleic acids described herein were prepared using standard techniques well known to those skilled in the art. The amino acid sequences of the anti-BILF-1 antibody or fragments thereof described herein can be used to determine suitable nucleic acid sequences encoding the specific antibodies disclosed herein. Nucleic acid sequences can be optimized to reflect specific codon “preferences” for various expression systems according to standard methods well known to those skilled in the art.

[0445] In some embodiments, the amino acid sequence of any one of the sequences provided in Tables 2, 3, 4, 5, 6, 7, 8, and 9 of the isolated nucleic acid molecules described herein. In some embodiments, the amino acid sequence of any one of the three CDR sequence groups provided in Tables 2, 3, 4, 5, 6, 7, 8, and 9 of the isolated nucleic acid molecules described herein.

[0446] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 14, SEQ ID NO: 15 and SEQ ID NO: 16.

[0447] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 17, GTS, and SEQ ID NO: 19.

[0448] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 28, SEQ ID NO: 29 and SEQ ID NO: 30.

[0449] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 31, YAS, and SEQ ID NO: 33.

[0450] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 42, SEQ ID NO: 43, and SEQ ID NO: 44.

[0451] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 45, GTS, and SEQ ID NO: 47.

[0452] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 58.

[0453] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 59, GTS, and SEQ ID NO: 61.

[0454] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71, and SEQ ID NO: 72.

[0455] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 73, GTS, and SEQ ID NO: 75.

[0456] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 84, SEQ ID NO: 85, and SEQ ID NO: 86.

[0457] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 87, GTS, and SEQ ID NO: 89.

[0458] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 98, SEQ ID NO: 99, and SEQ ID NO: 100.

[0459] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 101, GTS, and SEQ ID NO: 103.

[0460] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 112, SEQ ID NO: 113 and SEQ ID NO: 114.

[0461] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 115, YAS, and SEQ ID NO: 117.

[0462] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 126, SEQ ID NO: 127 and SEQ ID NO: 128.

[0463] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 129, YAS, and SEQ ID NO: 131.

[0464] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 140, SEQ ID NO: 141, and SEQ ID NO: 142.

[0465] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 143, YAS, and SEQ ID NO: 145.

[0466] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 154, SEQ ID NO: 155, and SEQ ID NO: 156.

[0467] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 157, WAS, and SEQ ID NO: 159.

[0468] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 168, SEQ ID NO: 169 and SEQ ID NO: 170.

[0469] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 171, YAS, and SEQ ID NO: 173.

[0470] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 182, SEQ ID NO: 183, and SEQ ID NO: 184.

[0471] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 185, YAS, and SEQ ID NO: 187.

[0472] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 196, SEQ ID NO: 197 and SEQ ID NO: 198.

[0473] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 199, AAS, and SEQ ID NO: 201.

[0474] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 210, SEQ ID NO: 211, and SEQ ID NO: 212.

[0475] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 213, GTN, and SEQ ID NO: 215.

[0476] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 224, SEQ ID NO: 225 and SEQ ID NO: 226.

[0477] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 227, GAS, and SEQ ID NO: 229.

[0478] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 234, GTS, and SEQ ID NO: 236.

[0479] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 241, GTS, and SEQ ID NO: 243.

[0480] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 248, GTS, and SEQ ID NO: 250.

[0481] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 255, GTS, and SEQ ID NO: 257.

[0482] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 262, GTS, and SEQ ID NO: 264.

[0483] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 269, GTS, and SEQ ID NO: 271.

[0484] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 276, GTS, and SEQ ID NO: 278.

[0485] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 283, GTS, and SEQ ID NO: 285.

[0486] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 290, SEQ ID NO: 291 and SEQ ID NO: 292.

[0487] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 297, SEQ ID NO: 298, and SEQ ID NO: 299.

[0488] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 304, SEQ ID NO: 305, and SEQ ID NO: 306.

[0489] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequences of SEQ ID NO: 311, SEQ ID NO: 312 and SEQ ID NO: 313.

[0490] In some embodiments, the isolated nucleic acid molecules described herein encode the amino acid sequence of any of SEQ ID NO: 314-357.

[0491] In some embodiments, the isolated nucleic acid contains a heterologous promoter that drives the expression of the antibody or a fragment thereof described herein. Non-limiting examples of heterologous promoters include cytomegalovirus (CMV), CMV Immediate Early (CMV-IE), CMV / EF1-α, and simian virus 40 (SV40) promoters. In some embodiments, the promoter is an inducible promoter. In some embodiments, the promoter is a constitutive promoter.

[0492] This disclosure also provides plasmids or vectors comprising one or more isolated nucleic acid molecules described herein. The vector may be any non-viral or viral vector known in the art or described herein.

[0493] Suitable vectors can be selected or constructed, containing appropriate regulatory sequences, including promoter sequences, terminator sequences, polyadenylation sequences, enhancer sequences, marker genes, and other appropriate sequences.

[0494] In some embodiments, the vector is adapted to direct the production of protein products in cells. In some embodiments, the vector is a non-viral vector. Non-limiting examples of non-viral vectors include transposon vectors, naked DNA (e.g., DNA plasmids), liposomes, or lipid nanoparticles.

[0495] In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is an adeno-associated virus vector (AAV), an adenovirus vector (AV), a lentiviral vector (LV), a retroviral vector (RV), a herpes simplex virus vector (HSV), or a poxvirus vector.

[0496] For example, viral and non-viral vectors and delivery systems are described in the following: Sung and Kim 2019, Biomaterials Research 23:8; Mali, 2013, Indian Journal of Human Genetics, 19(1):3-8; Hardee et al., 2017, Genes 8:65; Bulcha et al., 2020, Signal Transduction and Targeted Therapy; Ghosh et al., 2020, Applied Biosafety: Journal of ABSA International 25(1):7-18. The full text of each of these articles is hereby incorporated by reference.

[0497] In some embodiments, the vector is a recombinant vector. In some embodiments, the vector comprises a transposon system. Non-limiting examples of transposon systems include PiggyBac, Sleeping Beauty, Frog Prince, Himall, Passport, Minos, hAT, Toll, Tol2, AciDs, PIF, Harbinger, Harbinger3-DR, and Hsmarl, and any corresponding derivatives having the same, lower, and / or higher transposon activity. In some embodiments, the transposon system comprises two elements: a DNA element flanked by two terminal inverted repeat sequences, and a transposase that catalyzes the movement of the transposon.

[0498] In some embodiments, the vector comprises an inducible expression system. Non-limiting examples of inducible expression systems include cumate, tetracycline, rapamycin, FKCsA, abscisic acid, tamoxifen, blue light, and ribo-switched inducible expression systems. In some embodiments, the inducible expression system comprises a cumate switch in combination with the EF1α-CymR repressor-T2A-Puro cassette. The cumate switch system provides tight control via binding to the CmR repressor in the absence of cumate.

[0499] In some embodiments, the vector comprises a target-specific nuclease. Non-limiting examples of target-specific nucleases include zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), broad-spectrum nucleases, and clustered regularly spaced short palindromic repeats (CRISPR)-associated (Cas) nucleases.

[0500] In some embodiments, the vector comprises a CRISPR nuclease and a "guide RNA" or "sgRNA" that guides the Cas nuclease to a desired nucleic acid sequence. In some embodiments, the Cas nuclease has DNA cleavage activity.

[0501] Non-restricted examples of Cas nucleases include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 and Csxl2), Cas1O, Cpfl, C2c3, C2c2 and C2cl, Csyl, Csy2, Csy3, Csel, Cse2, Cscl, Csc2, Csa5, Csn2, C Csm2, Csm3, Csm4, Csm5, Csm6, Cmrl, Cmr3, Cmr4, Cmr5, Cmr6, Cpfl, Csbl, Csb2, Csb3, Csxl7, Csxl4, CsxlO, Csxl6, CsaX, Csx3, Csxl, Csxl5, Csfl, Csf2, Csf3, Csf4, their homologs, their variants, their mutants, and their derivatives. Cas nucleases are mainly of three types (Type I, Type II, and Type III) and 10 subtypes, including 5 Type I, 3 Type II, and 2 Type III proteins (see, for example, Hochstrasser and Doudna, Trends Biochem Sci, 2015:40(l):58-66). Type II Cas nucleases include, but are not limited to, Cas1, Cas2, Csn2, and Cas9. These Cas nucleases are known to those skilled in the art. For example, the amino acid sequence of the wild-type Cas9 polypeptide of Streptococcus pyogenes is provided in, for example, NBCI reference number NP 269215, and the amino acid sequence of the wild-type Cas9 polypeptide of Streptococcus thermophilus is provided in, for example, NBCI reference number WP_011681470.

[0502] In some embodiments, the vector comprises one or more promoters, one or more poly-A sequences, one or more selectable markers, and / or a start point. Selection of cells containing the vector is facilitated by incorporating genes into the vector that allow transfected cells to survive and grow under selective conditions. Several such genes have been identified. These genes include, in particular: (1) neo, a prokaryotic gene encoding resistance to the aminoglycoside antibiotic G418; (2) *Escherichia coli* guanine phosphoribosyltransferase (gpt), which encodes resistance to mycophenolic acid (MPA) in the presence of xanthine [Mulligan et al., Proc. Nat. Acad. Sci. USA, 78:2072-2076 (1981)]; (3) dihydrofolate reductase (DHFR), which allows DHFR cells to grow in the absence of nucleosides and to amplify the gene in the presence of increased methotrexate concentrations; (4) the *hisD* gene of *Salmonella typhimurium*, which allows growth in the presence of histamine (Hartman et al., Proc. Nat. Acad. Sci. USA, 85:8047-8051, (1988)); and (5) the *trpB* gene of *Escherichia coli* (Hartman et al., Proc. Nat. USA). Acad. Sci. USA, 85:8047-8051, (1988)), which allows growth in the presence of indole (without tryptophan); (6) glutamine synthase genes, which allow growth in glutamine-deficient media; (7) puromycin resistance genes (e.g., N-acetyltransferase [pac]); and (8) ampicillin resistance genes (e.g., bla). The availability of these selection markers (alone or in various combinations) provides flexibility for producing mammalian cell lines expressing high levels of recombinant products.

[0503] cell

[0504] This disclosure also provides cells comprising one or more of the isolated nucleic acid molecules, plasmids, or vectors described herein. In some embodiments, the cells are prokaryotic cells. In some embodiments, the cells are eukaryotic cells. In some embodiments, the cells are mammalian cells (e.g., mouse, bovine, monkey, pig, horse, cattle, or human cells). In some embodiments, the cells are human cells. In some embodiments, the cells are suitable for the manufacture of therapeutic proteins, such as Chinese hamster ovary (CHO) cells, HEK cells, or mouse myeloma cells. In some embodiments, the cells are CHO cells. In some embodiments, the cells are HEK293 cells. In some embodiments, the cells are Expi293F cells, a derivative of HEK 293 cells.

[0505] The nucleic acid molecules, plasmids, and / or vectors described herein can be introduced into cells by any method known in the art. Non-limiting examples of such methods include transfection, viral infection, conjugation, protoplast fusion, lipid transfection, electroporation, nuclear transfection, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran-mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct microinjection, nanoparticle-mediated nucleic acid delivery, etc. In some embodiments, the nucleic acid molecules, plasmids, and / or vectors described herein are introduced into cells via lipid transfection. In some embodiments, the nucleic acid molecules, plasmids, and / or vectors described herein are introduced into cells via electroporation. In some embodiments, the nucleic acid molecules, plasmids, and / or vectors described herein are introduced into cells via nuclear transfection. In some embodiments, the nucleic acid molecules, plasmids, and / or vectors are introduced into cells via transfection. The transfection protocol can be any protocol known in the art (e.g., those described in Kim and Eberwine. Anal Bioanal Chem. 2010; 397(8):3173-3178). In some embodiments, two or more nucleic acid molecules, plasmids, and / or vectors described herein are introduced into the same cell. In some embodiments, two or more nucleic acid molecules, plasmids, and / or vectors described herein are co-transfected into the cell. In some embodiments, the nucleic acid molecule, plasmid, and / or vector is introduced using a method comprising integrating a nucleic acid sequence or a portion thereof into the cell genome. In some embodiments, the polynucleotide or a portion thereof is stably integrated (e.g., covalently inserted into the chromosome via homologous recombination, non-homologous end joining, transposition, etc.).

[0506] In some embodiments, the nucleic acid molecules, plasmids, and / or vectors described herein direct the production of protein products in the cell. In some embodiments, the nucleic acid molecules, plasmids, and / or vectors described herein direct the production of the anti-BILF-1 antibody or fragments thereof disclosed herein in the cell.

[0507] After one or more nucleic acid molecules, plasmids, and / or vectors described herein are introduced into cells, the cells are grown under conditions suitable for the expression of the encoded polypeptide. In some embodiments, the cells are grown under conditions suitable for the expression of the anti-BILF-1 antibody or a fragment thereof disclosed herein. Suitable cell culture methods for protein production are known in the art. Cells may be cultured according to the manufacturer's instructions and / or according to an optimized protocol. In some embodiments, cells are grown in a suspension. In some embodiments, cells are grown in a serum-free medium. In some embodiments, cells are grown in the presence of serum.

[0508] purification

[0509] The anti-BILF-1 antibody or fragment thereof described herein can be isolated from cells using appropriate purification protocols employing standard protein purification techniques. Various purification techniques for antibodies or antibody fragments are known in the art.

[0510] The purification process may include a step of removing cell lysates. For example, cell cultures may be passed through a filter (e.g., a 0.22 or 0.44 µM filter) to produce clear cell lysates. The purification process may include a binding step, wherein the antibody or a fragment thereof is contacted with a first surface that interacts with it based on a first characteristic of the antibody or fragment thereof (e.g., charge, size, hydrophobicity, or affinity). The purification process may additionally include a washing step, wherein a first buffer is applied to the first surface, wherein the first buffer selectively removes the polypeptide from the first surface without disrupting the interaction between the first surface and the antibody or fragment thereof. The purification process may additionally include an elution step, wherein a second buffer is applied to the first surface to disrupt the interaction between the first surface and the antibody or fragment thereof. Optionally, the purification process may additionally include other steps, wherein the antibody or a fragment thereof is contacted with a second surface that interacts with it based on a second characteristic of the antibody or fragment thereof. The purification process may also include other washing and elution steps. In some embodiments, the purification of the anti-BILF-1 antibody or a fragment thereof disclosed herein comprises affinity chromatography. Non-limiting examples of affinity chromatography for antibody purification include magnetic or non-magnetic beads or resins covalently bound to recombinant protein G, recombinant protein A, and / or recombinant protein L. In some embodiments, purification of the anti-BILF-1 antibody or a fragment thereof involves binding the antibody or a fragment thereof to recombinant protein G.

[0511] Pharmaceutical Composition

[0512] This disclosure also provides pharmaceutical compositions comprising one or more of the anti-BILF-1 antibodies or antigen-binding fragments thereof disclosed herein. In some embodiments, the pharmaceutical composition comprises two or more anti-BILF-1 antibodies or fragments thereof described herein. In some embodiments, the pharmaceutical composition further comprises a second antibody or antigen-binding fragment thereof that specifically binds to LMP-1 and / or LMP-2. In some embodiments, the pharmaceutical composition further comprises a second antibody or antigen-binding fragment thereof that specifically binds to LMP-2. In some embodiments, the pharmaceutical composition further comprises one or more therapeutic agents that increase the expression of EBV membrane proteins in EBV-infected cells. In some embodiments, the EBV-infected cells comprise B cells. In some embodiments, the one or more therapeutic agents that increase the expression of EBV membrane proteins in EBV-infected cells are selected from the group consisting of: valproic acid, trichostatin A (TSA), 5-azacytidine (5-AZA), romidesin, pabistal, vorinostat, decitabine, netenostat, deraxixirox, rituximab, and combinations thereof. In some embodiments, the one or more therapeutic agents that increase the expression of EBV membrane proteins in EBV-infected cells comprise romidesin. In some embodiments, the one or more therapeutic agents comprise decitabine. In some embodiments, the one or more therapeutic agents comprise 5-AZA. In some embodiments, the one or more therapeutic agents comprise netenostat. In some embodiments, the one or more therapeutic agents comprise deferasirox. In some embodiments, the one or more therapeutic agents comprise TSA. In some embodiments, the one or more therapeutic agents comprise decitabine, 5-AZA, and romidesin. In some embodiments, the one or more therapeutic agents comprise parbistat.

[0513] In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable diluent, carrier, or excipient. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable excipient. Pharmaceutically acceptable carriers, diluents, and excipients may be any known in the art. In some embodiments, pharmaceutically acceptable carriers, diluents, and excipients are those that can be used to prepare generally safe, non-toxic, and desirable formulations and include excipients acceptable for use in mammals (e.g., humans or primates). Such excipients may be solid, liquid, semi-solid, or, in the case of an aerosol composition, gas. Examples of such carriers, excipients, and diluents include, but are not limited to, water, saline, Ringer's solution, dextran solution, and 5% human serum albumin. Supplemental active compounds may also be incorporated into these formulations. Solutions or suspensions used in these formulations may contain sterile diluents such as water for injection, saline solution, fixative oil, polyethylene glycol, glycerol, propylene glycol, or other synthetic solvents; antibacterial compounds such as benzyl alcohol or methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating compounds such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetate, citrate, or phosphate; detergents such as Tween 20 to prevent aggregation; and compounds for adjusting tension, such as sodium chloride or glucose. pH may be adjusted with an acid or base, such as hydrochloric acid or sodium hydroxide. In some embodiments, the pharmaceutical composition is sterile.

[0514] The pharmaceutical composition may further comprise a sterile aqueous solution or dispersant, and a sterile powder for the ad hoc preparation of a sterile injectable solution or dispersant. For intravenous administration, suitable carriers include physiological saline, antibacterial water, or phosphate-buffered saline (PBS). In some cases, the composition is sterile and should be fluid enough to be drawn into or delivered from a syringe to the subject. In some embodiments, it is stable under the conditions of manufacture and storage and is protected against contamination by microorganisms such as bacteria and fungi. The carrier may be a solvent or dispersion medium containing, for example, water, ethanol, polyols (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, etc.) and suitable mixtures thereof. Appropriate fluidity can be maintained, for example, by using a coating such as lecithin, by maintaining the desired particle size in the case of a dispersion, and by using surfactants. Antimicrobial action can be achieved by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, including isotonic agents, such as sugars, polyols, such as mannitol, sorbitol, and sodium chloride, in the composition is preferred. Prolonged absorption of the internal composition can be achieved by including agents that delay absorption (e.g., aluminum monostearate and gelatin) in the composition.

[0515] The sterile solution can be prepared by incorporating the required amount of one or more anti-BILF-1 antibodies or fragments thereof described herein with one or a combination of the above-listed components as needed into a suitable solvent, followed by filtration and sterilization.

[0516] Treatment

[0517] This disclosure also provides methods for treating subjects who have or are at risk of having one or more EBV infection or EBV-mediated diseases or conditions, comprising administering to the subject one or more anti-BILF-1 antibodies or fragments thereof and / or one or more pharmaceutical compositions disclosed herein. The anti-BILF-1 antibodies or fragments thereof and / or pharmaceutical compositions described herein are administered in an amount sufficient to improve symptoms of EBV infection or EBV-mediated diseases or conditions.

[0518] Symptoms of EBV infection or EBV-mediated disease or symptoms described herein can be assessed using standard methods known to those skilled in the art, and can be reduced (e.g., the subject's symptoms can improve) by 5% or more (e.g., 5%, 10%, 15%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%) compared to symptoms prior to administration of the anti-BILF-1 antibody or its fragment and / or pharmaceutical composition described herein. These effects can occur, for example, at 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 15 weeks, 20 weeks, 25 weeks, or longer after administration of the anti-BILF-1 antibody or its fragment and / or pharmaceutical composition described herein. Patients can be evaluated at 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, or longer after administration of the anti-BILF-1 antibody or its fragment and / or pharmaceutical composition, depending on the dose and route of administration used for treatment.

[0519] In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases or symptoms, the subject is EBV positive. In some embodiments, the subject has latent EBV infection. In some embodiments, the EBV infection is characterized as latent type O, latent type I, latent type II, or latent type III. In some embodiments, the EBV infection is chronic active EBV infection or acute active EBV infection.

[0520] In some embodiments of a method for treating a subject who has or is at risk of having one or more of an EBV infection or an EBV-mediated disease or condition, wherein the EBV-mediated disease is one or more diseases selected from the group consisting of EBV-mediated lymphoproliferative disorders (LPD), EBV-mediated cancer, EBV-mediated autoimmune diseases, infectious mononucleosis, and combinations thereof.

[0521] In some embodiments, the one or more EBV-mediated diseases include hemophagocytic lymphohistiocytosis (HLH), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL). In some embodiments, the NHL is Burkitt lymphoma, diffuse large B-cell lymphoma, B-cell NHL, T-cell NHL, or NK-cell NHL. In some embodiments, the T-cell or NK-cell NHL includes peripheral T-cell lymphoma (PTCL) and / or angioimmunoblastic T-cell lymphoma (AILT).

[0522] In some embodiments, the one or more EBV-mediated diseases include EBV-mediated lymphoproliferative disorders (LPDs). In some embodiments, the EBV-mediated LPD is post-transplant lymphoproliferative disorder (PTLD) or HIV-related LPD.

[0523] In some embodiments, the one or more EBV-mediated diseases include EBV-mediated cancer. In some embodiments, the EBV-mediated cancer is a non-lymphoid malignancy selected from the group consisting of nasopharyngeal carcinoma (NPC), gastric cancer (GC), gastric adenocarcinoma, and leiomyosarcoma.

[0524] In some embodiments, the one or more EBV-mediated diseases include EBV-mediated autoimmune diseases. In some embodiments, the EBV-mediated autoimmune disease is one or more diseases selected from the group consisting of: multiple sclerosis (MS), systemic lupus erythematosus (SLE), Sjögren's syndrome, type 1 diabetes mellitus (T1D), rheumatoid arthritis (RA), dermatomyositis, and combinations thereof.

[0525] In some embodiments, the one or more EBV-mediated diseases include infectious mononucleosis.

[0526] In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases or conditions, the subject is immunocompromised. In some embodiments, the subject is about to receive, is receiving, or has received an organ transplant including therapeutic immunosuppression. In some embodiments, the organ transplant is a bone marrow transplant.

[0527] Several drugs have previously been shown to induce a lytic phase in EBV+ cells, which can lead to the upregulation of EBV membrane proteins in EBV+ cells (EBV-infected cells). In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases or conditions, these methods include administering to the subject one or more of the anti-BILF-1 antibodies or fragments thereof disclosed herein, and one or more additional therapeutic agents. In some embodiments, the one or more therapeutic agents increase the expression of EBV membrane proteins in EBV-infected cells. In some embodiments, the EBV-infected cells comprise B cells. In some embodiments, the one or more additional therapeutic agents are selected from the group consisting of: valproic acid, trichostatin A (TSA), 5-azacytidine (5-AZA), romidesin, pabistal, vorinostat, decitabine, netenostat, deraxixirox, rituximab, and combinations thereof. In some embodiments, the one or more therapeutic agents comprise decitabine. In some embodiments, the one or more therapeutic agents comprise 5-AZA. In some embodiments, the one or more therapeutic agents comprise netenostat. In some embodiments, the one or more therapeutic agents comprise deferasirox. In some embodiments, the one or more therapeutic agents comprise TSA. In some embodiments, the one or more therapeutic agents comprise romidesin. In some embodiments, the one or more therapeutic agents comprise decitabine, 5-AZA, and romidesin. In some embodiments, the one or more therapeutic agents comprise parbistat.

[0528] In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases or conditions, the one or more antibodies or fragments thereof or pharmaceutical compositions described herein administered to the subject increase the killing of EBV-infected cells in the subject by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, or more compared to an untreated control. In some embodiments, one or more antibodies or fragments thereof or pharmaceutical compositions described herein reduce the cell-free EBV DNA load in the subject by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, or more compared to an untreated control. In some embodiments, one or more antibodies or fragments thereof or pharmaceutical compositions described herein reduce the EBV-positive cell count, and optionally the EBV-positive cancer cell count, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, or more compared to an untreated control. In some embodiments, one or more antibodies, fragments thereof, or pharmaceutical compositions described herein improve the subject's overall survival, progression-free survival, time to progression, or any combination thereof. In some embodiments, one or more antibodies, fragments thereof, or pharmaceutical compositions described herein reduce the number and / or severity of one or more adverse events in the subject.

[0529] In some embodiments of the treatment methods described herein, the subject has an EBV-mediated autoimmune disease, and one or more antibodies or fragments or pharmaceutical compositions disclosed herein reduce the subject’s disability progression, optionally measured by the Kurtzke Extended Disability Status Scale (EDSS) or the SLE Disease Activity Index (SLEDAI).

[0530] In some embodiments of the treatment methods described herein, the subject has EBV-mediated multiple sclerosis, and one or more antibodies or fragments thereof or pharmaceutical compositions disclosed herein reduce the subject's relapse rate and / or central nervous system (CNS) lesion burden.

[0531] In some embodiments of methods for treating subjects who have or are at risk of having one or more of EBV infection or EBV-mediated diseases or conditions, these methods include genotyping the EBV in the subject and administering the pharmaceutical composition to the subject if the EBV genotype is associated with a high risk of EBV-mediated disease. In some embodiments, the method includes measuring the expression of EBV proteins in activated B cells in a subject with an autoimmune disease and administering the pharmaceutical composition to the subject if the activated B cells express one or more EBV proteins. In some embodiments, the one or more EBV proteins are selected from the group consisting of EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-LP, LMP-1, LMP-2A, LMP-2B, and combinations thereof.

[0532] The anti-BILF-1 antibody or fragments thereof and / or pharmaceutical compositions described herein may be administered to a subject by any means of delivery, including, for example, parenteral injection (e.g., subcutaneous, intraperitoneal, intravenous, intramuscular, or to the interstitial space of tissues), or administration of the powder composition rectally, orally (e.g., tablets, sprays), vaginally, topically, transdermally (e.g., see WO99 / 27961), or percutaneously, intranasally, ocularly, ocularly, pulmonaryly, or other mucosal, and / or inhaled. Multiple doses may be administered via the same or different routes. In some embodiments of the treatment methods described herein, these methods include administering one or more of the pharmaceutical compositions disclosed herein to the subject via parenteral administration. In some embodiments, the parenteral administration is intravenous administration.

[0533] The anti-BILF-1 antibody or its fragments and / or pharmaceutical compositions described herein may be administered to a subject once or more. For example, the anti-BILF-1 antibody or its fragments and / or pharmaceutical compositions described herein may be administered once, twice, three times, four times, five times, six times, seven times, eight times, nine times, ten times or more. Dosage may be administered at any known interval. For example, dosage may be administered every six hours, every eight hours, every 12 hours, every 18 hours, daily, every two days, twice a week, weekly, twice a month, or monthly.

[0534] Dosage and dosing regimens may depend on various factors readily determined by the physician, such as the nature of the disease or symptom, the characteristics of the subject, and the subject's medical history. In some embodiments, the effective amount of the anti-BILF-1 antibody or a fragment thereof is from about 10 mg to about 10,000 mg / day. In some embodiments, the effective amount of the anti-BILF-1 antibody or a fragment thereof is from about 100 mg to about 5,000 mg / day. In some embodiments, the effective amount of the anti-BILF-1 antibody or a fragment thereof is from about 1,000 mg to about 3,000 mg / day. In some embodiments, the effective amount of the anti-BILF-1 antibody or a fragment thereof is from about 0.1 mg / kg to about 300 mg / kg / day. In some embodiments, the effective amount of the anti-BILF-1 antibody or a fragment thereof is from about 1 mg / kg to about 100 mg / kg / day. In some embodiments, the effective amount of the anti-BILF-1 antibody or a fragment thereof is from about 10 mg / kg to about 30 mg / kg.

[0535] How to use

[0536] The anti-BILF-1 antibody or fragment thereof described herein can be used as a research agent. For example, the antibody or fragment thereof can be linked to non-fluorescent or fluorescent materials. Non-limiting examples of non-fluorescent materials include resins, non-magnetic or magnetic beads, and streptavidin. The antibody or fragment thereof can be linked to a fluorescent dye using methods well known in the art or using a commercially available antibody labeling kit. The labeled antibody or fragment thereof can be used to identify EBV+ cells. Non-limiting examples of research applications for the anti-BILF-1 antibody or fragment thereof described herein include flow cytometry, fluorescence-activated cell sorting, histology, Western blotting, ELISA, ELISpot, immunohistochemistry, immunoprecipitation, peptide arrays, and inhibition assays.

[0537] Terms and Concepts

[0538] Numerous terms and concepts are discussed below. They are intended to facilitate understanding of various embodiments of the invention in conjunction with the remainder of this document and the accompanying drawings. These terms and concepts may be further clarified and understood based on accepted conventions in the field of the invention and the description provided throughout this document and / or the accompanying drawings. Some other terms may be explicitly or implicitly defined in other parts of this document and the accompanying drawings, and may be used and understood based on accepted conventions in the field of the invention and the description provided throughout this document and / or the accompanying drawings. Terms not explicitly defined may also be defined and understood based on accepted conventions in the field of the invention and interpreted in the context of this document and / or the accompanying drawings.

[0539] Unless the context otherwise requires, singular terms shall have plural meaning, and plural terms shall have singular meaning. Generally, the nomenclature and techniques used in conjunction with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry are those that are well-known and commonly used. Unless otherwise stated, known methods and techniques are generally performed according to well-known conventional methods and as described in various general and more specific references. Standard techniques are available for recombinant technologies, molecular biology, microbiology, chemical synthesis, chemical analysis, drug preparation, formulation and delivery, and patient treatment. The nomenclature used in conjunction with the laboratory procedures and techniques described in this disclosure is those that are well-known and commonly used.

[0540] Unless otherwise specified, the terms “a,” “an,” and “the” may refer to one or more. Unless explicitly stated that only alternatives are referred to or that alternatives are mutually exclusive, the term “or” is used to mean “and / or,” but this disclosure supports the definition of “and / or” as referring only to alternatives. As used herein, “another” may mean at least a second or more.

[0541] As used herein (including the claims), unless it is explicitly stated that it refers only to alternatives or that the alternatives are mutually exclusive, the term "or" is used to mean "and / or".

[0542] The terms “about” and “approximately” are used as equivalents. Any numbers used in this application, with or without “about” or “approximately”, are intended to cover any normal fluctuations as understood by one of ordinary skill in the art. In some embodiments, unless otherwise stated or clearly indicated from the context (unless such a value would exceed 100% of the possible value), the terms “about” or “approximately” refer to a quantity, level, value, number, frequency, percentage, size, volume, weight, or length that varies in any direction (greater or less) by up to 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less compared to the reference quantity, level, value, number, frequency, percentage, size, volume, weight, or length.

[0543] An "agonist" is a biological structure (e.g., an antibody) or chemical agent that increases or enhances the physiological effects of another drug or molecule. In some cases, the agonist specifically binds to another drug or molecule. Agonists include full agonists and partial agonists.

[0544] As used herein, the term "amino acid" is intended to refer to naturally occurring and non-naturally occurring amino acids, as well as amino acid analogs and mimics. Naturally occurring amino acids include the 20 (L)-amino acids used during protein biosynthesis, as well as other amino acids such as 4-hydroxyproline, hydroxylysine, desmodium, isodesmodium, homocysteine, citrulline, and ornithine. Non-naturally occurring amino acids include, for example, (D)-amino acids, leucine, valine, p-fluorophenylalanine, ethionine, etc., which are known to those skilled in the art. Amino acid analogs include modified forms of naturally occurring and non-naturally occurring amino acids. Such modifications may include, for example, substitution or replacement of chemical groups and moieties on the amino acid, or derivatization of the amino acid. Amino acid mimics include, for example, organic structures that exhibit functionally similar properties, such as the charge and charge spacing characteristic of the reference amino acid. For example, an organic structure mimicking arginine (Arg or R) would have a positively charged moiety located in a similar molecular space and having the same degree of migration of the e-amino group in the side chain as the naturally occurring Arg amino acid. The mimics also include confining structures to maintain optimal spacing and charge interactions between the amino acids or amino acid functional groups. Those skilled in the art know or can determine which structures constitute functionally equivalent amino acid analogs and amino acid mimics.

[0545] As used herein, the term "antibody" encompasses not only complete polyclonal or monoclonal antibodies, but also their fragments (such as dAb, Fab, Fab', F(ab')2, Fv), single chains (scFv), their synthetic variants, naturally occurring variants, fusion proteins containing an antibody portion having an antigen-binding fragment with desired specificity, humanized antibodies, chimeric antibodies, and any other modified conformation of immunoglobulin molecules containing an antigen-binding site or fragment (epitope recognition site) with desired specificity. Certain characteristics and properties of antibodies (and their antigen-binding fragments) are described in more detail herein.

[0546] Antibodies or their antigen-binding fragments can be of virtually any type. As is well known in the art, an antibody is an immunoglobulin molecule capable of specifically binding to a target through at least one epitope recognition site located in the variable region of an immunoglobulin molecule.

[0547] As used herein, the term “complementarity-determining region” (“CDR”) describes a discontinuous antigen-binding site (also known as an antigen-binding region) found within the variable region of both heavy and light chain polypeptides. The CDR is also referred to as a “hypervariant region,” and this term is used interchangeably with “CDR” herein to refer to the variable region portion that forms the antigen-binding region.

[0548] As used herein, the term "antigen-binding fragment" refers to a polypeptide fragment containing at least one CDR of an immunoglobulin heavy chain and / or light chain that binds to a target antigen (e.g., BILF-1). In this regard, the antigen-binding fragment of an antibody described herein may comprise 1, 2, 3, 4, 5, or all six CDRs from the VH and VL regions of an antibody that binds to a target molecule (e.g., BILF-1).

[0549] The term "antigen" refers to a molecule or part of a molecule that can be bound by a selective binding agent, such as an antibody, and further, can be used in animals to generate antibodies that can bind to epitopes of that antigen. An antigen may have one or more epitopes. As used herein, the term "antigen" includes substances capable of inducing an immune response against the substance under appropriate conditions and reacting with the products of that immune response. More broadly, the term "antigen" includes any substance to which an antibody binds, or any substance for which an antibody is desired, whether or not the substance is immunogenic. For such antigens, antibodies can be identified independently of any immune response by recombinant methods.

[0550] An epitope is a portion of an antigen or other macromolecule capable of forming a binding pocket that interacts with a variable region of an antibody or its antigen-binding fragment. This binding interaction may manifest as an intermolecular contact with one or more amino acid residues of a CDR. Antigen binding may involve CDR3 or a pair of CDR3s. An epitope may be a linear peptide sequence (i.e., “continuous”) or may consist of a non-continuous amino acid sequence (i.e., “conformal” or “discontinuous”). An antibody or its antigen-binding fragment may recognize one or more amino acid sequences. Thus, an epitope may define more than one distinct amino acid sequence. For example, an epitope may be determined by peptide mapping and sequence analysis techniques well known to those skilled in the art. In a particular embodiment, an epitope comprises, consists of, or is substantially composed of about, at least about, or no more than about 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 consecutive amino acids (i.e., linear epitopes) or non-continuous amino acids (i.e., conformational epitopes) of a reference sequence or target molecule described herein.

[0551] The binding properties of antibodies or their antigen-binding fragments can be quantified using methods well known in the art (Davies et al., 2003). In some embodiments, antibodies or their antigen-binding fragments specifically bind to target molecules, such as cell surface receptors, cancer or immunomodulatory antigens, or their epitopes or complexes, with an equilibrium dissociation constant of about ≤10⁻⁶ M to about ≤10⁻¹¹ M. In some embodiments, this equilibrium dissociation constant is about ≤10⁻⁹ M to about ≤10⁻¹⁰ M. In some embodiments, the antibody or its antigen-binding fragment has an affinity (KD or EC50) of about, at least about, or less than about 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, or 50 nM for the target molecule to which it specifically binds.

[0552] A molecule (such as a peptide or antibody) is said to exhibit “specific binding” or “preferential binding” if it reacts or associates with a specific cell, substance, or epitope more frequently, rapidly, for a longer duration, and / or with a greater affinity than alternative cells, substances, or epitopes. An antibody is said to “specifically bind” or “preferentially bind” to a target molecule or epitope if it binds (e.g., in statistically significant amounts) with greater affinity, strength, ease, and / or duration of binding to other substances or epitopes. Typically, one member of a pair of molecules exhibiting specific binding has a region or cavity on its surface that specifically binds to and is therefore complementary to the specific spatial and / or polar organization of the other member of the pair. Thus, the members of the pair have the property of specifically binding to each other. For example, an antibody that specifically or preferentially binds to a specific epitope is an antibody that binds to that specific epitope with greater affinity, strength, ease, and / or duration of binding than to other epitopes. By reading this definition, it should also be understood that, for example, an antibody (or part or epitope) that specifically or preferentially binds to a first target may specifically or preferentially bind to or not bind to a second target. The term also applies, for example, to cases where an antibody is specific to a particular epitope carried by multiple antigens, in which case the specific binding member carrying the antigen-binding fragment or domain will be able to bind to various antigens carrying that epitope; for example, it may cross-react with multiple different forms of target antigens from multiple species sharing a common epitope.

[0553] Immune binding generally refers to the non-covalent interaction between an immunoglobulin molecule and its specific antigen, caused, for example, by electrostatic, ionic, hydrophilic and / or hydrophobic attraction or repulsion, steric forces, hydrogen bonds, van der Waals forces, and other interactions, by way of illustration and not limitation. The strength or affinity of an immune-binding interaction can be expressed by the dissociation constant (KD) of the interaction, where a smaller KD indicates a greater affinity. The immune-binding properties of a selected peptide can be quantified using methods well known in the art. One such method requires measuring the rates of formation and dissociation of the antigen-binding site / antigen complex, where these rates depend on the concentration of the complexing partner, the affinity of the interaction, and geometric parameters that also affect the rates in both directions. Thus, the “binding rate constant” (Kon) and the “dissociation rate constant” (Koff) can be determined by calculating the concentration and the actual association and dissociation rates. The ratio of Koff / Kon eliminates all parameters unrelated to affinity and is therefore equal to the dissociation constant KD. As used herein, the term “affinity” includes the equilibrium constant of the reversible binding of two agents and is expressed as KD or EC50. The affinity of a binding protein for a ligand, such as the affinity of an antibody for an epitope, can be, for example, from about 100 nanomoles (nM) to about 0.1 nM, from about 100 nM to about 1 picomoles (pM), or from about 100 nM to about 1 femtomoles (fM). As used herein, the term “affinity” refers to the resistance of a complex of two or more agents to dissociation after dilution. In some embodiments, affinity is expressed as half-maximum effective concentration (EC50), which is the concentration of an agent (such as an antibody) disclosed herein that induces a half-maximum response between baseline and maximum after a specified exposure time. EC50 is commonly used as a measure of antibody potency.

[0554] Antibodies can be prepared using any of a variety of techniques known to those skilled in the art. See, for example, Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988. Monoclonal antibodies specific to a target peptide can be prepared, for example, using the technique of (Köhler and Milstein, 1976) and its modifications. Methods also include expressing human antibodies using transgenic animals, such as mice. See, for example, (Neuberger, 1996); Lonberg et al., Handbook of Experimental Pharmacology 113:49-101, 1994; and (Lonberg and Huszar, 1995). Specific examples include REGENEREX®'s VELOCIMMUNE® platform (see, for example, U.S. Patent No. 6,596,541).

[0555] Antibodies can also be generated or identified using phage display or yeast display libraries (see, for example, U.S. Patent No. 7,244,592; (Chao et al., 2006)). Non-limiting examples of available libraries include clonal or synthetic libraries, such as the Human Combinatorial Antibody Library (HuCAL), in which the structural diversity of a human antibody library is represented by genes for seven heavy chain and seven light chain variable regions. Combinations of these genes produce 49 frames in the master library. A large human antibody library can be reproduced by superimposing highly variable genetic cassettes (CDRs = complementarity-determining regions) onto these frames. Human libraries designed with donor-derived fragments encoding light chain variable regions, heavy chain CDR-3, synthetic DNA encoding heavy chain CDR-1 diversity, and synthetic DNA encoding heavy chain CDR-2 diversity are also included. Other libraries suitable for use will be apparent to those skilled in the art.

[0556] In some embodiments, antibodies or antigen-binding fragments thereof, as described herein, comprise heavy and light chain CDR sets, respectively inserted between heavy and light chain framework region (FR) sets that support the CDRs and define their spatial relationship relative to each other. As used herein, the term "CDR set" refers to three hypervariable regions of the V region of the heavy or light chain. Starting from the N-terminus of the heavy or light chain, these regions are referred to as "CDR1," "CDR2," and "CDR3," respectively. Thus, the antigen-binding site comprises six CDRs, comprising a CDR set from each of the V regions of the heavy and light chains. A polypeptide containing a single CDR (e.g., CDR1, CDR2, or CDR3) is referred to herein as a "molecular recognition unit." Crystallographic analysis of several antigen-antibody complexes has demonstrated that the amino acid residues of the CDRs form extensive contacts with the binding antigen, with the largest antigen contact being with the heavy chain CDR3. Therefore, the molecular recognition unit is primarily responsible for the specificity of the antigen-binding site.

[0557] As used herein, the term "FR group" refers to the four flanking amino acid sequences of a CDR that frames the V region CDR group of the heavy or light chain. Some FR residues can contact and bind antigens; however, the FRs are primarily responsible for folding the V region into an antigen-binding site, especially the FR residues directly adjacent to the CDR. Within the FR, certain amino acid residues and certain structural features are highly conserved. In this respect, all V region sequences contain an internal disulfide ring of approximately 90 amino acid residues. When the V region folds into a binding site, the CDR exhibits an overhanging ring motif that forms the antigen-binding surface. It is generally believed that there are conserved structural regions in the FR that influence the folding shape of the CDR ring into certain "typical" structures—regardless of the exact CDR amino acid sequence. Furthermore, certain FR residues are known to participate in stabilizing the non-covalent interdomain contacts of the antibody heavy and light chain interactions.

[0558] The structure and location of immunoglobulin variable domains can be determined by referring to Kabat, E.A. et al., Sequences of Proteins of Immunological Interest. 4th ed., US Department of Health and Human Services. 1987 and its updates.

[0559] This also includes “monoclonal” antibodies, which refer to a homogeneous group of antibodies, wherein a monoclonal antibody consists of amino acids (naturally and non-naturally present) that selectively bind to an epitope. Monoclonal antibodies are highly specific, targeting a single epitope. The term “monoclonal antibody” encompasses not only complete and full-length monoclonal antibodies, but also their fragments (such as Fab, Fab', F(ab')2, Fv), single chains (ScFv), their variants, fusion proteins containing an antigen-binding portion, humanized monoclonal antibodies, chimeric monoclonal antibodies, and any other modified conformation of an immunoglobulin molecule containing an antigen-binding fragment (epitope recognition site) with the desired specificity and the ability to bind to an epitope. It is not intended to limit itself to the source of the antibody or the method of its preparation (e.g., by hybridoma, phage selection, recombinant expression, transgenic animals). The term includes complete immunoglobulins as well as the fragments described above under the definition of “antibody.”

[0560] The proteolytic enzyme papain preferentially cleaves IgG molecules to produce several fragments, each of which (F(ab) fragments) contains a covalent heterodimer with an intact antigen-binding site. The enzyme pepsin is capable of cleaving IgG molecules to provide several fragments, including the F(ab')2 fragment containing two antigen-binding sites. The Fv fragments used according to some embodiments can be produced by preferential proteolytic cleavage of IgM, and in rare cases by preferential proteolytic cleavage of IgG or IgA immunoglobulin molecules. However, Fv fragments are more commonly derived using recombinant techniques known in the art. Fv fragments comprise non-covalent VH::VL heterodimers, which include antigen-binding sites that retain most of the antigen recognition and binding ability of the native antibody molecule. See (Inbar et al., 1972); (Hochman et al., 1976); and (Matsueda et al., 1980).

[0561] In some embodiments, single-chain Fv (scFV) antibodies are considered. For example, Kappa bodies (Ill et al., 1997); microantibodies (Martin et al., 1994); biantibodies (Holliger et al., 1993); or Janusins ​​(Traunecker et al., 1991); and (Traunecker et al., 1992), can be prepared using standard molecular biology techniques in accordance with the teachings of this application regarding the selection of antibodies with desired specificity.

[0562] Single-chain Fv (scFv) polypeptides are covalently linked VH::VL heterodimers expressed by gene fusion, including VH and VL encoding genes linked by peptide-coding linkers (Huston et al., 1988). Various methods have been described to identify the chemical structures that convert naturally aggregated—but chemically separated—light and heavy chain polypeptide chains in the antibody V region into scFv molecules that fold into a three-dimensional structure substantially similar to the antigen-binding site. See, for example, U.S. Patents 5,091,513 and 5,132,405 to Huston et al.; and U.S. Patent 4,946,778 to Ladner et al.

[0563] Some embodiments include "pre-antibody" or antibodies whose binding sites are masked or otherwise remain inert before being activated by proteolytic cleavage in target or diseased tissue. Some of these and related embodiments include one or more masking portions that spatially obstruct the antibody's antigen-binding site and fuse with the antibody via one or more proteolytically cleavable linkers (see, for example, (Polu and Lowman, 2014)).

[0564] In some embodiments, the antibodies described herein are in the form of biantibodies. A biantibody is a multimer of polypeptides, each polypeptide containing a first domain containing a binding region of an immunoglobulin light chain and a second domain containing a binding region of an immunoglobulin heavy chain. These two domains are linked (e.g., via peptide linkers) but cannot associate with each other to form an antigen-binding site: the antigen-binding site is formed by the association of the first domain of one polypeptide within the multimer with the second domain of another polypeptide within the multimer (WO94 / 13804).

[0565] The dAb fragment of the antibody is composed of VH domains (Ward et al., 1989).

[0566] When bispecific or multispecific antibodies are to be used, these can be conventional bispecific antibodies, which can be manufactured in a variety of ways (Holliger and Winter, 1993), such as by chemical methods or by hybridization hybridoma, or can be any of the bispecific antibody fragments mentioned above. Bispecific antibodies and scFv can be constructed without the Fc region, using only variable domains, which may reduce the impact of anti-idiotype reactions. Intact bispecific antibodies can be prepared by mortar and pestle engineering (Ridgway et al., 1996).

[0567] In contrast to intact bispecific antibodies, bispecific biantibodies can also be particularly useful because they can be readily constructed and expressed in *E. coli*. Biantibodies with appropriate binding specificity (as well as many other peptides, such as antibody fragments) can be readily selected from a library using phage display (WO94 / 13804). If one arm of the biantibody is to be kept constant, for example, having specificity against antigen X, a library with a variation in the other arm can be prepared, and an antibody with appropriate specificity can be selected.

[0568] In some embodiments, the antibodies described herein are provided in the form of UniBody®. UniBody® is an IgG4 antibody with its hinge region removed (see GenMab Utrecht, The Netherlands; also see, for example, US20090226421). This proprietary antibody technology creates a stable, smaller antibody form expected to have a longer therapeutic window than current small antibody forms. IgG4 antibodies are considered inert and therefore do not interact with the immune system. Fully human IgG4 antibodies can be modified by removing the hinge region of the antibody to obtain a half-molecule fragment with different stability properties relative to the corresponding full IgG4 (GenMab, Utrecht). Halving the IgG4 molecule leaves only one region on UniBody® capable of binding to a homologous antigen (e.g., a disease target), and thus UniBody® binds monovalently to only one site on the target cell. For certain cancer cell surface antigens, this monovalent binding may not stimulate cancer cell growth as much as seen with bivalent antibodies having the same antigen specificity, and therefore UniBody® technology may provide a treatment option for some types of cancer that may be refractory to conventional antibody therapies. The small size of UniBody® may be beneficial in treating some forms of cancer, allowing the molecule to distribute better in larger solid tumors and potentially improving efficacy.

[0569] In some embodiments, the antibodies of this disclosure may be in the form of Nanobody®. Nanobodies® are encoded by a single gene and can be efficiently produced in virtually all prokaryotic and eukaryotic hosts, such as *Escherichia coli* (see, for example, U.S. Patent No. 6,765,087), molds (e.g., *Aspergillus* or *Trichoderma*), and yeasts (e.g., *Saccharomyces*, *Kluyveromyces*, *Hansenula*, or *Pichia pastoris* (see, for example, U.S. Patent No. 6,838,254). The production process is scalable, and multiple kilograms of Nanobodies® have been produced. Nanobodies can be formulated as ready-to-use solutions with long shelf lives. The Nanoclone® method (see, for example, WO 06 / 079372) is a proprietary method for generating nanobodies against desired targets, based on automated, high-throughput selection using B cells.

[0570] In some embodiments, the antibodies or antigen-binding fragments thereof described herein are humanized. These embodiments refer to chimeric molecules, typically prepared using recombinant techniques, having an antigen-binding site derived from an immunoglobulin of a non-human species and the remaining immunoglobulin structure of the molecule based on the structure and / or sequence of human immunoglobulins. The antigen-binding site may comprise an intact variable domain fused to a constant domain or a CDR simply transplanted to an appropriate frame region within the variable domain. Epitope binding sites may be wild-type or modified with one or more amino acid substitutions. This eliminates the possibility of the constant region acting as an immunogen in a human individual, but the possibility of an immune response to an exogenous variable region remains (Lobuglio et al., 1989; Queen et al., 1989; Riechmann et al., 1988). Illustrative methods for antibody humanization include those described in U.S. Patent No. 7,462,697.

[0571] Another approach focuses not only on providing human-derived constant regions but also on modifying variable regions to reshape them as closely as possible to human form. The variable regions of both heavy and light chains are known to contain three complementarity-determining regions (CDRs) that vary in response to the epitope in question and determine binding capacity, flanked by four framework regions (FRs), which are relatively conserved in a given species and are considered the scaffolds of the CDRs. When preparing nonhuman antibodies for a specific epitope, the variable regions can be “reshaped” or “humanized” by grafting CDRs derived from the nonhuman antibody onto the FRs present in the human antibody to be modified. The application of this method in various antibodies has been reported by: (Sato et al., 1993); (Riechmann et al., 1988); (Verhoeyen et al., 1988); (Kettleborough et al., 1991); (Maeda et al., 1991); (Gorman et al., 1991); (Tempest et al., 1991); (Co et al., 1991); (Carter et al., 1992); and (Co et al., 1992). In some embodiments, the humanized antibody retains all CDR sequences (e.g., a humanized mouse antibody containing all six CDRs from a mouse antibody). In other embodiments, the humanized antibody has one or more CDRs (one, two, three, four, five, six) modified with respect to the original antibody, which are also referred to as one or more CDRs “derived” from one or more CDRs from the original antibody.

[0572] In some embodiments, the antibodies described herein are “chimeric” antibodies. In this respect, a chimeric antibody consists of an antigen-binding fragment of an antibody operatively linked to or otherwise fused to a heterologous Fc portion of a different antibody. In some embodiments, the Fc domain or heterologous Fc domain is of human origin. In some embodiments, the Fc domain or heterologous Fc domain is of mouse origin. In other embodiments, the heterologous Fc domain may be derived from an Ig class different from the parent antibody, including IgA (including subclasses IgA1 and IgA2), IgD, IgE, IgG (including subclasses IgG1, IgG2, IgG3, and IgG4), and IgM. In further embodiments, the heterologous Fc domain may consist of CH2 and CH3 domains derived from one or more of different Ig classes. As described above regarding humanized antibodies, the antigen-binding fragment of a chimeric antibody may contain only one or more of the CDRs of the antibody described herein (e.g., 1, 2, 3, 4, 5, or 6 CDRs of the antibody described herein), or may contain the entire variable domain (VL, VH, or both).

[0573] As used herein, subjects at “risk” for developing a disease or adverse reaction may or may not have a detectable disease or disease symptoms, and may or may not have exhibited a detectable disease or disease symptoms prior to the treatments described herein. “Risk” means that a subject has one or more risk factors that are measurable parameters associated with disease development, as described herein and known in the art. Subjects with one or more of these risk factors have a higher probability of developing a disease or adverse reaction than subjects without one or more of these risk factors. In some embodiments, a subject at “risk” is EBV positive (EBV-positive) and, in some cases, has a latent EBV infection, such as classified as latent type I, latent type II, or latent type III.

[0574] "Biocompatible" means that a material or compound does not usually impair the biological function of cells or subjects and does not cause any degree of unacceptable toxicity (including allergies and disease states).

[0575] The term "association" refers to the direct association between two molecules resulting from interactions such as covalent, electrostatic, hydrophobic, and ionic and / or hydrogen bonding (including interactions such as salt bridges and water bridges).

[0576] The term "coding sequence" refers to any nucleic acid sequence that contributes to the encoding of a gene's polypeptide product. In contrast, the term "non-coding sequence" refers to any nucleic acid sequence that does not directly contribute to the encoding of a gene's polypeptide product.

[0577] Throughout this disclosure, unless the context otherwise requires, the terms “comprise,” “have,” and “include” are open-ended connecting verbs. Any form or tense of one or more of these verbs, such as “comprises / comprising,” “has / having,” and “includes / including,” is also open-ended and will be understood to imply inclusion of the stated step or element or group of steps or elements, but does not exclude any other step or element or group of steps or elements. For example, any method that “comprises,” “has,” or “includes” one or more steps is not limited to having only those one or more steps and may also cover other steps not listed. Similarly, any composition or apparatus that “comprises,” “has,” or “includes” one or more features is not limited to having only those one or more features and may cover other features not listed.

[0578] The phrase “consisting of…” means including and limited to what follows the phrase “consisting of…”. Therefore, the phrase “consisting of…” indicates that the listed element is necessary or mandatory, and other elements may be absent. The phrase “substantially constitutes…” means including any element listed following the phrase, and is limited to other elements that do not interfere with or promote the activity or effect specified for the listed element in this disclosure. Therefore, the phrase “substantially constitutes…” indicates that the listed element is necessary or mandatory, but other elements are optional and may be present or absent depending on whether they have a substantial effect on the activity or effect of the listed element.

[0579] Therefore, in pharmaceutical manufacturing, it is generally desirable to remove most or all trace amounts of endotoxins from pharmaceutical products and / or pharmaceutical containers, as even small amounts can cause adverse reactions in humans. Pyrogen-free ovens can be used for this purpose, as temperatures exceeding 300°C are typically required to decompose most endotoxins. For example, based on primary packaging materials such as syringes or vials, a combination of a glass temperature of 250°C and a holding time of 30 minutes is often sufficient to achieve a 3-log reduction in endotoxin levels. Other methods for endotoxin removal are considered, including, for example, chromatographic and filtration methods as described herein and known in the art.

[0580] Endotoxins can be detected using conventional techniques known in the art. For example, the assay of horseshoe crab (LMS) blood-derived lysate is a very sensitive method for detecting the presence of endotoxins. In this assay, very low levels of LPS can cause detectable coagulation of the lysate due to the powerful enzymatic cascade that amplifies the reaction. Endotoxins can also be quantified by enzyme-linked immunosorbent assay (ELISA). To be substantially endotoxin-free, endotoxin levels can be less than about 0.001, 0.005, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.08, 0.09, 0.1, 0.5, 1.0, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8, 9, or 10 EU / mg of the active compound. Typically, 1 ng of lipopolysaccharide (LPS) corresponds to about 1–10 EU.

[0581] The term "half-maximum effective concentration" or "EC50" refers to the concentration of a drug (e.g., an antibody) as described herein that induces a half-maximum response between baseline and maximum after a specified exposure time; thus, the EC50 of a graded dose-response curve represents the concentration of the compound at which 50% of its maximum effect is observed. EC50 also represents the plasma concentration required to achieve a 50% maximum effect in vivo. Similarly, "EC90" refers to the concentration of a drug or composition at which 90% of its maximum effect is observed. "EC90" can be calculated from "EC50" and the Hill slope, or determined directly from the data using conventional knowledge in the art. In some embodiments, the EC50 of the agent (e.g., antibody) is less than about 0.01, 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 200, or 500 nM. In some embodiments, the agent will have an EC50 value of about 1 nM or less.

[0582] "Immune response" refers to any immunological response originating from the immune system, including responses from the cellular and humoral, innate and adaptive immune systems. Exemplary cellular immune cells include, for example, lymphocytes, macrophages, T cells, B cells, NK cells, neutrophils, eosinophils, dendritic cells, mast cells, monocytes, and all their subsets. Cellular responses include, for example, effector functions, cytokine release, phagocytosis, cell burial, translocation, transport, proliferation, differentiation, activation, inhibition, cell-cell interactions, apoptosis, etc. Humoral responses include, for example, IgG, IgM, IgA, and IgE responses and their corresponding effector functions.

[0583] The "half-life" of a pharmaceutical agent (such as an antibody) can refer to the time required for the agent to lose half of its pharmacological, physiological, or other activity, relative to that activity when administered to the serum or tissues of a organism, or relative to any other defined time point. The "half-life" can also refer to the time required for the amount or concentration of the agent to decrease to half of the initial amount when administered to the serum or tissues of a organism, relative to that amount or concentration when administered to the serum or tissues of a organism, or relative to any other defined time point. Half-life can be measured in serum and / or any one or more selected tissues.

[0584] The terms “modification” and “alteration” include “increase,” “enhancement,” or “stimulation,” as well as “decrease” or “reduction,” typically relative to a statistically or physiologically significant amount or degree. An “increased,” “stimulating,” or “enhanced” amount is typically a “statistically significant” amount and may include increases of 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 100, or more times (e.g., 500, 1000 times) in the amount produced by the no-composition (e.g., where no agent is present) or control composition, including all integers and ranges between them, such as 1.5, 1.6, 1.7, 1.8, etc. A “reduced” or “decreased” amount is typically a “statistically significant” amount and may include reductions of 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100% (inclusive of all integers and ranges) for the amount produced by the no-composition (e.g., no-drug) or control composition. Examples of comparisons and “statistically significant” amounts are described herein.

[0585] The terms “polypeptide,” “protein,” and “peptide” are used interchangeably and refer to an amino acid polymer without any particular length limitation. The term “enzyme” includes polypeptide or protein catalysts. These terms include modifications such as myristylation, sulfation, glycosylation, phosphorylation, and the addition or deletion of signal sequences. The terms “polypeptide” or “protein” refer to one or more amino acid chains, each chain containing amino acids covalently linked by peptide bonds, and said polypeptide or protein may comprise multiple chains non-covalently and / or covalently linked by peptide bonds, having the sequence of a native protein, i.e., a protein produced by naturally occurring and particularly non-recombinant cells or genetically engineered or recombinant cells, and comprising a molecule having the amino acid sequence of a native protein, or a molecule having one or more amino acids of the native sequence with deletions, additions, and / or substitutions. In some embodiments, the polypeptide is a “recombinant” polypeptide produced by a recombinant cell containing one or more recombinant DNA molecules, which are typically composed of a combination of heterologous polynucleotide sequences or polynucleotide sequences otherwise not found in the cell.

[0586] The terms "polynucleotide" and "nucleic acid" include mRNA, RNA, cRNA, cDNA, and DNA. The term generally refers to a polymeric form of nucleotides at least 10 bases in length, i.e., a modified form of ribonucleotides, deoxynucleotides, or any type of nucleotide. The term includes both single-stranded and double-stranded DNA. The terms "isolated DNA," "isolated polynucleotide," and "isolated nucleic acid" refer to molecules that have been isolated from the total genomic DNA of a particular species. Therefore, an isolated DNA segment encoding a polypeptide refers to a DNA segment containing one or more coding sequences that is substantially isolated from or purified free from the total genomic DNA of the species from which the DNA segment was obtained. This also includes non-coding polynucleotides that do not encode polypeptides (e.g., primers, probes, oligonucleotides). It also includes recombinant vectors, including, for example, expression vectors, viral vectors, plasmids, phage particles, bacteriophages, viruses, etc.

[0587] Additional coding or non-coding sequences may, but need not, be present within the polynucleotide described herein, and the polynucleotide may, but need not, be linked to other molecules and / or supporting materials. Therefore, polynucleotides, or expressible polynucleotides, regardless of the length of the coding sequence itself, can be combined with other sequences (e.g., expression control sequences).

[0588] As used herein, the term "isolated" polypeptide or protein means that the subject protein (1) is free from at least some of the other proteins that it normally coexists with in nature, (2) is substantially free from other proteins of the same origin (e.g., of the same species), (3) is expressed by cells of a different species, (4) has been isolated from at least about 50% of the polynucleotides, lipids, carbohydrates or other materials associated with it in nature, (5) is not associated with the protein portion of the "isolated protein" that it is associated with in nature (through covalent or non-covalent interactions), (6) is operatively associated with polypeptides that it is not associated with in nature (t...

Claims

1. An isolated antibody or an antigen-binding fragment thereof, said isolated antibody or antigen-binding fragment thereof specifically binding to the extracellular domain (ECD) of Epstein-Barr virus (EBV) membrane protein BILF-1.

2. The isolated antibody or fragment thereof according to claim 1, wherein the antibody or fragment thereof specifically binds to one or more BILF-1 extracellular domains selected from the group consisting of: ECD1, ECD2, ECD3, ECD4, and combinations thereof.

3. The isolated antibody or fragment thereof according to claim 2, wherein the antibody or fragment thereof specifically binds to ECD1 of BILF-1 by contacting one or more amino acid residues within the epitope comprising SEQ ID NO:

2.

4. The isolated antibody or fragment thereof according to claim 2 or claim 3, wherein the antibody or fragment thereof specifically binds to BILF-1 ECD2 by contacting one or more amino acid residues within the epitope comprising SEQ ID NO:

3.

5. The isolated antibody or fragment thereof according to any one of claims 2 to 4, wherein the antibody or fragment thereof specifically binds to ECD3 of BILF-1 by contacting one or more amino acid residues within the epitope comprising SEQ ID NO:

4.

6. The isolated antibody or fragment thereof according to any one of claims 2 to 5, wherein the antibody or fragment thereof specifically binds to BILF-1 ECD4 by contacting one or more amino acid residues within the epitope comprising SEQ ID NO:

5.

7. The isolated antibody or fragment thereof according to any one of claims 1 to 6, wherein the antibody or fragment thereof specifically binds to the ECD of BILF-1 by contacting one or more amino acid residues selected from the group consisting of SEQ ID NO: 1: L2, S3, T4, P7, S9, T10, L14, V15, N17, M18, T19, S20, V21, N22, A23, T24, T29, K30, S31, Y32, E90, F91, S92, G95, T160, M161, G162, M173, E176, G177, P178, H183, T184, A191, T259, L262, V263, A264, R265, and G269.

8. The isolated antibody or fragment thereof according to claim 7, wherein the antibody or fragment thereof specifically binds to the ECD of BILF-1 by contacting three or more amino acid residues selected from the group consisting of SEQ ID NO: 1: L2, S3, T4, P7, S9, T10, L14, V15, N17, M18, T19, S20, V21, N22, A23, T24, T29, K30, S31, Y32, E90, F91, S92, G95, T160, M161, G162, M173, E176, G177, P178, H183, T184, A191, T259, L262, V263, A264, R265, and G269.

9. The isolated antibody or fragment thereof according to any one of claims 1 to 6, wherein the antibody or fragment thereof specifically binds to the ECD of BILF-1 by contacting one or more amino acid residues selected from the group consisting of SEQ ID NO: 1: M39, D164, A165, N166, L167, N168, R169, G170, P171, N172, R175, T179, K180, G181, M182, A185, V186, Q187, G188, L189, K190, A251, S253, L254, G255, F256, D257, C258, E260, S261, Y266, Y267 and P268.

10. The isolated antibody or fragment thereof according to claim 9, wherein the antibody or fragment thereof specifically binds to the ECD of BILF-1 by contacting three or more amino acid residues selected from the group consisting of SEQ ID NO: 1: M39, D164, A165, N166, L167, N168, R169, G170, P171, N172, R175, T179, K180, G181, M182, A185, V186, Q187, G188, L189, K190, A251, S253, L254, G255, F256, D257, C258, E260, S261, Y266, Y267 and P268.

11. The isolated antibody or fragment thereof according to any one of claims 1 to 10, wherein the antibody or fragment thereof specifically binds to amino acids in the transmembrane region adjacent to the EBV membrane protein; and wherein the specific binding alters the conformational structure of BILF-1 and changes the function of BILF-1.

12. The isolated antibody or fragment thereof according to any one of claims 1 to 11, wherein the antibody or fragment thereof is a monoclonal antibody and / or a humanized antibody, or an antigen-binding fragment thereof.

13. The isolated antibody or fragment thereof according to any one of claims 1 to 12, wherein the antibody or fragment thereof is an intact immunoglobulin, a fragment antigen-binding domain (Fab), an F(ab')2 domain, a single-chain variable fragment (scFv), a dimer single-chain variable fragment (di-scFv), or a single-domain antibody (sdAb).

14. The isolated antibody or fragment thereof according to any one of claims 1 to 13, wherein the isolated antibody or fragment thereof comprises an Fc region selected from the group consisting of IgA, IgD, IgE, IgG and IgM Fc regions; and optionally, wherein the Fc region is a human Fc region.

15. The isolated antibody or fragment thereof according to claim 14, wherein the isolated antibody or fragment thereof comprises an Fc region selected from the group consisting of: IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4.

16. The isolated antibody or fragment thereof according to claim 14 or claim 15, wherein the isolated antibody or fragment thereof comprises an IgG Fc region having high effector function in humans.

17. The isolated antibody or fragment thereof according to claim 16, wherein the IgG Fc region is IgG1 or IgG3.

18. The isolated antibody or fragment thereof according to any one of claims 1 to 17, wherein the isolated antibody or fragment thereof comprises a modified Fc region having at least one altered effector function and / or pharmacokinetic (PK) property relative to the wild-type Fc region.

19. The isolated antibody or fragment thereof according to claim 18, wherein the at least one altered effector function includes increased binding to natural killer (NK) cells, macrophages, neutrophils and / or dendritic cells.

20. The isolated antibody or fragment thereof according to claim 18 or claim 19, wherein the modified Fc region has increased affinity for CD16a (FcγRIIIa), optionally wherein the modified Fc region is non-fucosylated.

21. The isolated antibody or fragment thereof according to any one of claims 1 to 20, wherein the antibody or fragment thereof comprises: a) Heavy chain (HC) complementarity-determining region (CDR) 1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HCCDR3 sequence SEQ ID NO: 16; HC CDR1 sequence SEQ ID NO: 290, HC CDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292; HC CDR1 sequence SEQ ID NO: 297, HC CDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299; HC CDR1 sequence SEQ ID NO: 304, HC CDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306; or HC CDR1 sequence SEQ ID NO: 311, HC CDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313; and b) Light chain (LC) complementarity-determining region (CDR) 1 sequence SEQ ID NO: 17, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 19; LC CDR1 sequence SEQ ID NO: 234, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 236; LC CDR1 sequence SEQ ID NO: 241, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 243; LC CDR1 sequence SEQ ID NO: 248, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 250; LC CDR1 sequence SEQ ID NO: 255, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 257; LC CDR1 sequence SEQ ID NO: 262, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 264; LC CDR1 sequence SEQ ID NO: 269, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 271; LC CDR1 sequence SEQ ID NO: 276, LC CDR2 sequence GTS, and LC CDR3 sequence SEQ ID NO: 278; or LC CDR1 sequence SEQ ID NO: 283, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO:

285.

22. The isolated antibody or fragment thereof according to any one of claims 1 to 20, wherein the antibody or fragment thereof comprises: a) Heavy chain (HC) complementarity-determining region (CDR) 1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HCCDR3 sequence SEQ ID NO: 16, light chain (LC) CDR1 sequence SEQ ID NO: 17, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 19; b) HC CDR1 sequence SEQ ID NO: 28, HC CDR2 sequence SEQ ID NO: 29, HC CDR3 sequence SEQ ID NO: 30, LC CDR1 sequence SEQ ID NO: 31, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 33; c) HC CDR1 sequence SEQ ID NO: 42, HC CDR2 sequence SEQ ID NO: 43, HC CDR3 sequence SEQ ID NO: 44, LC CDR1 sequence SEQ ID NO: 45, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 47; d) HC CDR1 sequence SEQ ID NO: 56, HC CDR2 sequence SEQ ID NO: 57, HC CDR3 sequence SEQ ID NO: 58, LC CDR1 sequence SEQ ID NO: 59, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 61; e) HC CDR1 sequence SEQ ID NO: 70, HC CDR2 sequence SEQ ID NO: 71, HC CDR3 sequence SEQ ID NO: 72, LC CDR1 sequence SEQ ID NO: 73, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 75; f) HC CDR1 sequence SEQ ID NO: 84, HC CDR2 sequence SEQ ID NO: 85, HC CDR3 sequence SEQ ID NO: 86, LC CDR1 sequence SEQ ID NO: 87, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 89; g) HC CDR1 sequence SEQ ID NO: 98, HC CDR2 sequence SEQ ID NO: 99, HC CDR3 sequence SEQ ID NO: 100, LC CDR1 sequence SEQ ID NO: 101, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 103; h) HC CDR1 sequence SEQ ID NO: 112, HC CDR2 sequence SEQ ID NO: 113, HC CDR3 sequence SEQ ID NO: 114, LC CDR1 sequence SEQ ID NO: 115, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 117; i) HC CDR1 sequence SEQ ID NO: 126, HC CDR2 sequence SEQ ID NO: 127, HC CDR3 sequence SEQ ID NO: 128, LC CDR1 sequence SEQ ID NO: 129, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 131; j) HC CDR1 sequence SEQ ID NO: 140, HC CDR2 sequence SEQ ID NO: 141, HC CDR3 sequence SEQ ID NO: 142, LC CDR1 sequence SEQ ID NO: 143, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 145; k) HC CDR1 sequence SEQ ID NO: 154, HC CDR2 sequence SEQ ID NO: 155, HC CDR3 sequence SEQ ID NO: 156, LC CDR1 sequence SEQ ID NO: 157, LC CDR2 sequence WAS and LC CDR3 sequence SEQ ID NO: 159; l) HC CDR1 sequence SEQ ID NO: 168, HC CDR2 sequence SEQ ID NO: 169, HC CDR3 sequence SEQ ID NO: 170, LC CDR1 sequence SEQ ID NO: 171, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 173; m) HC CDR1 sequence SEQ ID NO: 182, HC CDR2 sequence SEQ ID NO: 183, HC CDR3 sequence SEQ ID NO: 184, LC CDR1 sequence SEQ ID NO: 185, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 187; n) HC CDR1 sequence SEQ ID NO: 196, HC CDR2 sequence SEQ ID NO: 197, HC CDR3 sequence SEQ ID NO: 198, LC CDR1 sequence SEQ ID NO: 199, LC CDR2 sequence AAS and LC CDR3 sequence SEQ ID NO: 201; o) HC CDR1 sequence SEQ ID NO: 210, HC CDR2 sequence SEQ ID NO: 211, HC CDR3 sequence SEQ ID NO: 212, LC CDR1 sequence SEQ ID NO: 213, LC CDR2 sequence GTN and LC CDR3 sequence SEQ ID NO: 215; p) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 234, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 236; q) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 241, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 243; r) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 248, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 250; s) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 255, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 257; t) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 262, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 264; u) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 269, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 271; v) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 276, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 278; or w)HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 283, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO:

285.

23. The isolated antibody or fragment thereof according to any one of claims 1 to 20, wherein the antibody or fragment thereof comprises: a) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9; HC CDR1 sequence SEQ ID NO: 290, HC CDR2 sequence SEQ ID NO: 291, HC CDR3 sequence SEQ ID NO: 292, HC FR1 sequence SEQ ID NO: 286, HC FR2 sequence SEQ ID NO: 287, HC FR3 sequence SEQ ID NO: 288, HC FR4 sequence SEQ ID NO: 289; HC CDR1 sequence SEQ ID NO: 297, HC CDR2 sequence SEQ ID NO: 298, HC CDR3 sequence SEQ ID NO: 299, HC FR1 sequence SEQ ID NO: 293, HC FR2 sequence SEQ ID NO: 294, HC FR3 sequence SEQ ID NO: 295, HC FR4 sequence SEQ ID NO: 296; HC CDR1 sequence SEQ ID NO: 304, HC CDR2 sequence SEQ ID NO: 305, HC CDR3 sequence SEQ ID NO: 306, HC FR1 sequence SEQ ID NO: 300, HC FR2 sequence SEQ ID NO: 301, HC FR3 sequence SEQ ID NO: 302, HC FR4 sequence SEQ ID NO: 303; or HC CDR1 sequence SEQ ID NO: 311, HC CDR2 sequence SEQ ID NO: 312, HC CDR3 sequence SEQ ID NO: 313, HC FR1 sequence SEQ ID NO: 307, HC FR2 sequence SEQ ID NO: 308, HC FR3 sequence SEQ ID NO: 309, HC FR4 sequence SEQ ID NO: 310; and b) LC CDR1 sequence SEQ ID NO: 17, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 19, LC FR1 sequence SEQ ID NO: 10, LC FR2 sequence SEQ ID NO: 11, LC FR3 sequence SEQ ID NO: 12 and LC FR4 sequence SEQ ID NO: 13; LC CDR1 sequence SEQ ID NO: 234, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 236, LCFR1 sequence SEQ ID NO: 230, LC FR2 sequence SEQ ID NO: 231, LC FR3 sequence SEQ ID NO: 232 and LCFR4 sequence SEQ ID NO: 233; LC CDR1 sequence SEQ ID NO: 241, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 243, LCFR1 sequence SEQ ID NO: 237, LC FR2 sequence SEQ ID NO: 238, LC FR3 sequence SEQ ID NO: 239 and LCFR4 sequence SEQ ID NO: 240; LC CDR1 sequence SEQ ID NO: 248, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 250, LCFR1 sequence SEQ ID NO: 244, LC FR2 sequence SEQ ID NO: 245, LC FR3 sequence SEQ ID NO: 246 and LCFR4 sequence SEQ ID NO: 247; LC CDR1 sequence SEQ ID NO: 255, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 257, LCFR1 sequence SEQ ID NO: 251, LC FR2 sequence SEQ ID NO: 252, LC FR3 sequence SEQ ID NO: 253 and LCFR4 sequence SEQ ID NO: 254; LC CDR1 sequence SEQ ID NO: 262, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 264, LCFR1 sequence SEQ ID NO: 258, LC FR2 sequence SEQ ID NO: 259, LC FR3 sequence SEQ ID NO: 260 and LCFR4 sequence SEQ ID NO: 261; LC CDR1 sequence SEQ ID NO: 269, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 271, LCFR1 sequence SEQ ID NO: 265, LC FR2 sequence SEQ ID NO: 266, LC FR3 sequence SEQ ID NO: 267 and LCFR4 sequence SEQ ID NO: 268; LC CDR1 sequence SEQ ID NO: 276, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 278, LCFR1 sequence SEQ ID NO: 272, LC FR2 sequence SEQ ID NO: 273, LC FR3 sequence SEQ ID NO: 274 and LCFR4 sequence SEQ ID NO: 275; or LC CDR1 sequence SEQ ID NO: 283, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 285, LCFR1 sequence SEQ ID NO: 279, LC FR2 sequence SEQ ID NO: 280, LC FR3 sequence SEQ ID NO: 281 and LCFR4 sequence SEQ ID NO:

282.

24. The isolated antibody or fragment thereof according to any one of claims 1 to 20, wherein the antibody or fragment thereof comprises: a) Heavy chain (HC) complementarity-determining region (CDR) 1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, Light chain (LC) CDR1 sequence SEQ ID NO: 17, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 19, HC frame region (FR) 1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 10, LC FR2 sequence SEQ ID NO: 11, LC FR3 sequence SEQ ID NO: 12 and LC FR4 sequence SEQ ID NO: 13; b) HC CDR1 sequence SEQ ID NO: 28, HC CDR2 sequence SEQ ID NO: 29, HC CDR3 sequence SEQ ID NO: 30, LC CDR1 sequence SEQ ID NO: 31, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 33, HC FR1 sequence SEQ ID NO: 20, HC FR2 sequence SEQ ID NO: 21, HC FR3 sequence SEQ ID NO: 22, HC FR4 sequence SEQ ID NO: 23, LC FR1 sequence SEQ ID NO: 24, LC FR2 sequence SEQ ID NO: 25, LC FR3 sequence SEQ ID NO: 26 and LC FR4 sequence SEQ ID NO: 27; c) HC CDR1 sequence SEQ ID NO: 42, HC CDR2 sequence SEQ ID NO: 43, HC CDR3 sequence SEQ ID NO: 44, LC CDR1 sequence SEQ ID NO: 45, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 47, HC FR1 sequence SEQ ID NO: 34, HC FR2 sequence SEQ ID NO: 35, HC FR3 sequence SEQ ID NO: 36, HC FR4 sequence SEQ ID NO: 37, LC FR1 sequence SEQ ID NO: 38, LC FR2 sequence SEQ ID NO: 39, LC FR3 sequence SEQ ID NO: 40 and LC FR4 sequence SEQ ID NO: 41; d) HC CDR1 sequence SEQ ID NO: 56, HC CDR2 sequence SEQ ID NO: 57, HC CDR3 sequence SEQ ID NO: 58, LC CDR1 sequence SEQ ID NO: 59, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 61, HC FR1 sequence SEQ ID NO: 48, HC FR2 sequence SEQ ID NO: 49, HC FR3 sequence SEQ ID NO: 50, HC FR4 sequence SEQ ID NO: 51, LC FR1 sequence SEQ ID NO: 52, LC FR2 sequence SEQ ID NO: 53, LC FR3 sequence SEQ ID NO: 54 and LC FR4 sequence SEQ ID NO: 55; e) HC CDR1 sequence SEQ ID NO: 70, HC CDR2 sequence SEQ ID NO: 71, HC CDR3 sequence SEQ ID NO: 72, LC CDR1 sequence SEQ ID NO: 73, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 75, HC FR1 sequence SEQ ID NO: 62, HC FR2 sequence SEQ ID NO: 63, HC FR3 sequence SEQ ID NO: 64, HC FR4 sequence SEQ ID NO: 65, LC FR1 sequence SEQ ID NO: 66, LC FR2 sequence SEQ ID NO: 67, LC FR3 sequence SEQ ID NO: 68 and LC FR4 sequence SEQ ID NO: 69; f) HC CDR1 sequence SEQ ID NO: 84, HC CDR2 sequence SEQ ID NO: 85, HC CDR3 sequence SEQ ID NO: 86, LC CDR1 sequence SEQ ID NO: 87, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 89, HC FR1 sequence SEQ ID NO: 76, HC FR2 sequence SEQ ID NO: 77, HC FR3 sequence SEQ ID NO: 78, HC FR4 sequence SEQ ID NO: 79, LC FR1 sequence SEQ ID NO: 80, LC FR2 sequence SEQ ID NO: 81, LC FR3 sequence SEQ ID NO: 82 and LC FR4 sequence SEQ ID NO: 83; g) HC CDR1 sequence SEQ ID NO: 98, HC CDR2 sequence SEQ ID NO: 99, HC CDR3 sequence SEQ ID NO: 100, LC CDR1 sequence SEQ ID NO: 101, LC CDR2 sequence GTS and LC CDR3 sequence SEQ ID NO: 103, HCFR1 sequence SEQ ID NO: 90, HC FR2 sequence SEQ ID NO: 91, HC FR3 sequence SEQ ID NO: 92, HC FR4 sequence SEQ ID NO: 93, LC FR1 sequence SEQ ID NO: 94, LC FR2 sequence SEQ ID NO: 95, LC FR3 sequence SEQ ID NO: 96 and LC FR4 sequence SEQ ID NO: 97; h) HC CDR1 sequence SEQ ID NO: 112, HC CDR2 sequence SEQ ID NO: 113, HC CDR3 sequence SEQ ID NO: 114, LC CDR1 sequence SEQ ID NO: 115, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 117, HC FR1 sequence SEQ ID NO: 104, HC FR2 sequence SEQ ID NO: 105, HC FR3 sequence SEQ ID NO: 106, HC FR4 sequence SEQ ID NO: 107, LC FR1 sequence SEQ ID NO: 108, LC FR2 sequence SEQ ID NO: 109, LC FR3 sequence SEQ ID NO: 110 and LC FR4 sequence SEQ ID NO: 111; i) HC CDR1 sequence SEQ ID NO: 126, HC CDR2 sequence SEQ ID NO: 127, HC CDR3 sequence SEQ ID NO: 128, LC CDR1 sequence SEQ ID NO: 129, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 131, HC FR1 sequence SEQ ID NO: 118, HC FR2 sequence SEQ ID NO: 119, HC FR3 sequence SEQ ID NO: 120, HC FR4 sequence SEQ ID NO: 121, LC FR1 sequence SEQ ID NO: 122, LC FR2 sequence SEQ ID NO: 123, LC FR3 sequence SEQ ID NO: 124 and LC FR4 sequence SEQ ID NO: 125; j) HC CDR1 sequence SEQ ID NO: 140, HC CDR2 sequence SEQ ID NO: 141, HC CDR3 sequence SEQ ID NO: 142, LC CDR1 sequence SEQ ID NO: 143, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 145, HC FR1 sequence SEQ ID NO: 132, HC FR2 sequence SEQ ID NO: 133, HC FR3 sequence SEQ ID NO: 134, HC FR4 sequence SEQ ID NO: 135, LC FR1 sequence SEQ ID NO: 136, LC FR2 sequence SEQ ID NO: 137, LC FR3 sequence SEQ ID NO: 138 and LC FR4 sequence SEQ ID NO: 139; k) HC CDR1 sequence SEQ ID NO: 154, HC CDR2 sequence SEQ ID NO: 155, HC CDR3 sequence SEQ ID NO: 156, LC CDR1 sequence SEQ ID NO: 157, LC CDR2 sequence WAS and LC CDR3 sequence SEQ ID NO: 159, HC FR1 sequence SEQ ID NO: 146, HC FR2 sequence SEQ ID NO: 147, HC FR3 sequence SEQ ID NO: 148, HC FR4 sequence SEQ ID NO: 149, LC FR1 sequence SEQ ID NO: 150, LC FR2 sequence SEQ ID NO: 151, LC FR3 sequence SEQ ID NO: 152 and LC FR4 sequence SEQ ID NO: 153; l) HC CDR1 sequence SEQ ID NO: 168, HC CDR2 sequence SEQ ID NO: 169, HC CDR3 sequence SEQ ID NO: 170, LC CDR1 sequence SEQ ID NO: 171, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 173, HC FR1 sequence SEQ ID NO: 160, HC FR2 sequence SEQ ID NO: 161, HC FR3 sequence SEQ ID NO: 162, HC FR4 sequence SEQ ID NO: 163, LC FR1 sequence SEQ ID NO: 164, LC FR2 sequence SEQ ID NO: 165, LC FR3 sequence SEQ ID NO: 166 and LC FR4 sequence SEQ ID NO: 167; m) HC CDR1 sequence SEQ ID NO: 182, HC CDR2 sequence SEQ ID NO: 183, HC CDR3 sequence SEQ ID NO: 184, LC CDR1 sequence SEQ ID NO: 185, LC CDR2 sequence YAS and LC CDR3 sequence SEQ ID NO: 187, HC FR1 sequence SEQ ID NO: 174, HC FR2 sequence SEQ ID NO: 175, HC FR3 sequence SEQ ID NO: 176, HC FR4 sequence SEQ ID NO: 177, LC FR1 sequence SEQ ID NO: 178, LC FR2 sequence SEQ ID NO: 179, LC FR3 sequence SEQ ID NO: 180 and LC FR4 sequence SEQ ID NO: 181; n) HC CDR1 sequence SEQ ID NO: 196, HC CDR2 sequence SEQ ID NO: 197, HC CDR3 sequence SEQ ID NO: 198, LC CDR1 sequence SEQ ID NO: 199, LC CDR2 sequence AAS and LC CDR3 sequence SEQ ID NO: 201, HC FR1 sequence SEQ ID NO: 188, HC FR2 sequence SEQ ID NO: 189, HC FR3 sequence SEQ ID NO: 190, HC FR4 sequence SEQ ID NO: 191, LC FR1 sequence SEQ ID NO: 192, LC FR2 sequence SEQ ID NO: 193, LC FR3 sequence SEQ ID NO: 194 and LC FR4 sequence SEQ ID NO: 195; o) HC CDR1 sequence SEQ ID NO: 210, HC CDR2 sequence SEQ ID NO: 211, HC CDR3 sequence SEQ ID NO: 212, LC CDR1 sequence SEQ ID NO: 213, LC CDR2 sequence GTN and LC CDR3 sequence SEQ ID NO: 215, HC FR1 sequence SEQ ID NO: 202, HC FR2 sequence SEQ ID NO: 203, HC FR3 sequence SEQ ID NO: 204, HC FR4 sequence SEQ ID NO: 205, LC FR1 sequence SEQ ID NO: 206, LC FR2 sequence SEQ ID NO: 207, LC FR3 sequence SEQ ID NO: 208 and LC FR4 sequence SEQ ID NO: 209; p) HC CDR1 sequence SEQ ID NO: 224, HC CDR2 sequence SEQ ID NO: 225, HC CDR3 sequence SEQ ID NO: 226, LC CDR1 sequence SEQ ID NO: 227, LC CDR2 sequence GAS and LC CDR3 sequence SEQ ID NO: 229, HC FR1 sequence SEQ ID NO: 216, HC FR2 sequence SEQ ID NO: 217, HC FR3 sequence SEQ ID NO: 218, HC FR4 sequence SEQ ID NO: 219, LC FR1 sequence SEQ ID NO: 220, LC FR2 sequence SEQ ID NO: 221, LC FR3 sequence SEQ ID NO: 222 and LC FR4 sequence SEQ ID NO: 223; q) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 234, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 236, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 230, LC FR2 sequence SEQ ID NO: 231, LC FR3 sequence SEQ ID NO: 232 and LC FR4 sequence SEQ ID NO: 233; r) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 241, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 243, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 237, LC FR2 sequence SEQ ID NO: 238, LC FR3 sequence SEQ ID NO: 239 and LC FR4 sequence SEQ ID NO: 240; s) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 248, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 250, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 244, LC FR2 sequence SEQ ID NO: 245, LC FR3 sequence SEQ ID NO: 246 and LC FR4 sequence SEQ ID NO: 247; t) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 255, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 257, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 251, LC FR2 sequence SEQ ID NO: 252, LC FR3 sequence SEQ ID NO: 253 and LC FR4 sequence SEQ ID NO: 254; u) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 262, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 264, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 258, LC FR2 sequence SEQ ID NO: 259, LC FR3 sequence SEQ ID NO: 260, and LC FR4 sequence SEQ ID NO: 261; v) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 269, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 271, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 265, LC FR2 sequence SEQ ID NO: 266, LC FR3 sequence SEQ ID NO: 267, and LC FR4 sequence SEQ ID NO: 268; w) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 276, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 278, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 272, LC FR2 sequence SEQ ID NO: 273, LC FR3 sequence SEQ ID NO: 274 and LC FR4 sequence SEQ ID NO: 275; or x) HC CDR1 sequence SEQ ID NO: 14, HC CDR2 sequence SEQ ID NO: 15, HC CDR3 sequence SEQ ID NO: 16, LC CDR1 sequence SEQ ID NO: 283, LC CDR2 sequence GTS, LC CDR3 sequence SEQ ID NO: 285, HC FR1 sequence SEQ ID NO: 6, HC FR2 sequence SEQ ID NO: 7, HC FR3 sequence SEQ ID NO: 8, HC FR4 sequence SEQ ID NO: 9, LC FR1 sequence SEQ ID NO: 279, LC FR2 sequence SEQ ID NO: 280, LC FR3 sequence SEQ ID NO: 281 and LC FR4 sequence SEQ ID NO:

282.

25. The isolated antibody or fragment thereof according to any one of claims 1 to 20, wherein the antibody or fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL). The VH comprises an amino acid sequence represented by any one of SEQ ID NO: 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 354, 355, 356, 357, or an amino acid sequence that is at least 80% identical to the amino acid sequence represented by any one of SEQ ID NO: 314, 316, 318, 320, 322, 324, 326, 328, 330, 332, 334, 336, 338, 340, 342, 344, 354, 355, 356, 357; and The VL contains an amino acid sequence that is at least 80% identical to the amino acid sequence shown in any one of SEQ ID NO: 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 346, 347, 348, 349, 350, 351, 352, 353, or any one of SEQ ID NO: 315, 317, 319, 321, 323, 325, 327, 329, 331, 333, 335, 337, 339, 341, 343, 345, 346, 347, 348, 349, 350, 351, 352, 353.

26. The isolated antibody or fragment thereof according to any one of claims 1 to 25, wherein the antibody or fragment thereof is a bispecific antibody comprising: a) Specifically binds to the first antigen-binding domain (ABD) of BILF-1; and b) A second ABD domain that specifically binds to a cell surface receptor, wherein the cell surface receptor is expressed on immune cells, can form a heterodimer with BILF-1, and / or is co-expressed with BILF-1.

27. The isolated antibody or fragment thereof according to claim 26, wherein the antibody or fragment thereof increases the binding of BILF-1-expressing cells to the immune cells.

28. The isolated antibody or fragment thereof according to claim 26 or claim 27, wherein the immune cell is a T cell or a natural killer (NK) cell.

29. The isolated antibody or fragment thereof according to any one of claims 26 to 28, wherein the cell surface receptor is CD3, CD16, IL-8 receptor, CD19, BCMA, CD38, vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), EBV latent membrane protein 1 (LMP1) or EBV latent membrane protein 2 (LMP2).

30. The isolated antibody or fragment thereof according to claim 29, wherein the cell surface receptor is CD3 or CD16.

31. The isolated antibody or fragment thereof according to claim 29, wherein the cell surface receptor is IL-8 receptor, CD19, BCMA, CD38, vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR), EBV latent membrane protein 1 (LMP1) or EBV latent membrane protein 2 (LMP2).

32. The isolated antibody or fragment thereof according to any one of claims 1 to 31, wherein the antibody or fragment thereof is conjugated with a cytotoxic agent.

33. The isolated antibody or fragment thereof according to claim 32, wherein the cytotoxic agent is monomethylolpropionate F (MMAF), monomethylolpropionate E (MMAE), or pyruvic DM (DMDM).

34. The isolated antibody or fragment thereof according to any one of claims 1 to 33, wherein the antibody or fragment thereof is conjugated or fused with an immune activator.

35. The isolated antibody or fragment thereof according to claim 34, wherein the immune activator is a Toll-like receptor (TLR) agonist, an interferon gene stimulating factor (STING) agonist, or a cytokine.

36. The isolated antibody or fragment thereof according to claim 35, wherein the cytokine is interleukin-2 (IL-2), interleukin-15 (IL-15), or a TNF superfamily ligand.

37. The isolated antibody or fragment thereof according to claim 36, wherein the TNF superfamily ligand is TRAIL, 4-1BBL, interleukin-21 (IL-21), IFN-α, IFN-β, CD40, GITR-L, OX40L, or CD70.

38. The isolated antibody or fragment thereof according to any one of claims 1 to 25, wherein the antibody or fragment thereof is a single-chain variable fragment (scFv), wherein the scFv is fused with a transmembrane domain and an intracellular T cell signaling domain via a spacer region (hinge region) to form a chimeric antigen receptor (CAR).

39. The isolated antibody or fragment thereof according to any one of claims 1 to 38, wherein the amino acid sequence of the antibody or fragment thereof comprises one or more mutations, wherein the one or more mutations improve the binding affinity, stability and / or pharmacokinetics of the antibody or fragment thereof.

40. The isolated antibody or fragment thereof according to claim 39, wherein the one or more mutations are located in the light chain.

41. The isolated antibody or fragment thereof according to claim 39 or claim 40, wherein the one or more mutations comprise amino acid substitutions.

42. The isolated antibody or fragment thereof according to any one of claims 39 to 41, wherein the one or more mutations are located in an amino acid selected from asparagine, cysteine ​​and leucine.

43. The isolated antibody or fragment thereof according to claim 41 or claim 42, wherein the one or more mutations comprise asparagine to histidine substitution, cysteine ​​to alanine substitution, asparagine to arginine substitution, leucine to isoleucine substitution, cysteine ​​to valine substitution, asparagine to serine substitution, and asparagine to alanine substitution.

44. The isolated antibody or fragment thereof according to any one of claims 39 to 43, wherein the unpaired cysteine ​​residues in the amino acid sequence are eliminated by the one or more mutations.

45. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding an isolated antibody or a fragment thereof according to any one of claims 1 to 44.

46. ​​A vector comprising the isolated nucleic acid molecule according to claim 45.

47. The vector according to claim 46, comprising a heterogeneous promoter.

48. The vector according to claim 47, wherein the heterogeneous promoter is an inductive promoter or a constitutive promoter.

49. The vector according to claim 47 or 48, wherein the expression of the isolated antibody or a fragment thereof is driven by the promoter.

50. An isolated cell comprising the isolated nucleic acid molecule according to claim 45 or the vector according to any one of claims 46 to 49.

51. A method for producing an antibody or a fragment thereof, the method comprising culturing cells according to claim 50 under culture conditions suitable for expression of the antibody or a fragment thereof, and isolating the antibody or a fragment thereof from the culture.

52. A pharmaceutical composition comprising an antibody or a fragment thereof according to any one of claims 1 to 44 and a physiologically acceptable carrier.

53. The pharmaceutical composition according to claim 52, comprising two or more antibodies or fragments thereof according to any one of claims 1 to 44.

54. The pharmaceutical composition according to claim 52 or claim 53, further comprising a second antibody or an antigen-binding fragment thereof that specifically binds to LMP-1 and / or LMP-2.

55. The pharmaceutical composition according to claim 52 or claim 53, further comprising a second antibody or an antigen-binding fragment thereof that specifically binds to LMP-2.

56. The pharmaceutical composition according to any one of claims 52 to 55, further comprising one or more therapeutic agents that increase the expression of EBV membrane proteins in EBV-infected cells.

57. The pharmaceutical composition of claim 56, wherein the EBV-infected cells comprise B cells.

58. The pharmaceutical composition according to claim 56 or claim 57, wherein the one or more therapeutic agents are selected from the group consisting of: valproic acid, trichostatin A (TSA), 5-azacytidine (5-AZA), romidesin, pabistal, vorinostat, decitabine, netenostat, deraxixix, rituximab, and combinations thereof.

59. A method of treating a subject who has or is at risk of having one or more of Epstein-Barr virus (EBV) infection or EBV-mediated diseases, the method comprising administering to the subject a pharmaceutical composition according to any one of claims 52 to 58.

60. The method of claim 59, wherein the subject is EBV positive and has latent EBV infection.

61. The method of claim 60, wherein the EBV infection is characterized as latent type O, latent type I, latent type II, or latent type III.

62. The method of claim 61, wherein the EBV infection is a chronic active EBV infection or an acute active EBV infection.

63. The method according to any one of claims 59 to 62, wherein the EBV-mediated disease is one or more diseases selected from the group consisting of: EBV-mediated lymphoproliferative disorders (LPD), EBV-mediated cancer, EBV-mediated autoimmune diseases, infectious mononucleosis, and combinations thereof.

64. The method of claim 63, wherein the EBV-mediated disease is hemophagocytic lymphohistiocytosis (HLH), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL).

65. The method of claim 64, wherein the NHL is Burkitt lymphoma, diffuse large B-cell lymphoma, B-cell NHL, T-cell NHL, or NK-cell NHL.

66. The method of claim 65, wherein the T-cell or NK-cell NHL comprises peripheral T-cell lymphoma (PTCL), optionally angioimmunoblastic T-cell lymphoma (AILT).

67. The method of claim 63, wherein the EBV-mediated LPD is post-transplant lymphoproliferative disorder (PTLD) or HIV-related LPD.

68. The method of claim 63, wherein the EBV-mediated cancer is a non-lymphoid malignancy selected from the group consisting of nasopharyngeal carcinoma (NPC), gastric cancer (GC), gastric adenocarcinoma, and leiomyosarcoma.

69. The method of claim 63, wherein the EBV-mediated autoimmune disease is one or more diseases selected from the group consisting of: multiple sclerosis (MS), systemic lupus erythematosus (SLE), Sjögren's syndrome, type 1 diabetes mellitus (T1D), rheumatoid arthritis (RA), dermatomyositis, and combinations thereof.

70. The method according to any one of claims 59 to 69, wherein the subject is immunocompromised.

71. The method according to any one of claims 59 to 70, wherein the subject is about to receive, is receiving, or has received an organ transplant including therapeutic immunosuppression.

72. The method according to claim 71, wherein the organ transplantation surgery is a bone marrow transplantation.

73. The method according to any one of claims 59 to 72, further comprising administering an additional therapeutic agent to the subject.

74. The method of claim 73, wherein the additional therapeutic agent increases the expression of EBV membrane proteins in EBV-infected cells.

75. The method of claim 74, wherein the EBV-infected cells comprise B cells.

76. The method of claim 74 or 75, wherein the additional therapeutic agent is selected from the group consisting of romidesin, pabistal, vorinostat, decitabine, netenostat, rituximab, and combinations thereof.

77. The method according to any one of claims 59 to 76, wherein the antibody or fragment thereof increases the killing of EBV-infected cells in the subject by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, or more relative to an untreated control.

78. The method according to any one of claims 59 to 77, wherein the antibody or a fragment thereof reduces the cell-free EBV DNA load in the subject by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, or more relative to an untreated control.

79. The method according to any one of claims 59 to 78, wherein the antibody or fragment thereof reduces the EBV-positive cell count, optionally the EBV-positive cancer cell count, by at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 100%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, 1000%, 2000%, or more relative to an untreated control.

80. The method according to any one of claims 59 to 79, wherein the antibody or fragment thereof improves the subject's overall survival, progression-free survival, time to progression, or any combination thereof.

81. The method according to any one of claims 59 to 80, wherein the antibody or a fragment thereof reduces the number and / or severity of one or more adverse events in the subject.

82. The method according to any one of claims 59 to 81, wherein the subject suffers from an EBV-mediated autoimmune disease, and wherein the antibody or a fragment thereof reduces the subject’s disability progression, optionally measured by the Kurtzke Extended Disability Status Scale (EDSS) or the SLE Disease Activity Index (SLEDAI).

83. The method according to any one of claims 59 to 82, wherein the subject suffers from EBV-mediated multiple sclerosis, and wherein the antibody or a fragment thereof reduces the relapse rate and / or central nervous system (CNS) lesion burden of the subject.

84. The method according to any one of claims 59 to 83, comprising administering the pharmaceutical composition to the subject via parenteral administration.

85. The method of claim 84, wherein the parenteral administration is intravenous administration.

86. The method according to any one of claims 59 to 85, comprising genotyping EBV in the subject and administering the pharmaceutical composition to the subject if the EBV genotype is associated with a high risk of EBV-mediated disease.

87. The method according to any one of claims 59 to 86, comprising measuring EBV protein expression in activated B cells in the subject, and administering the pharmaceutical composition to the subject if the activated B cells express one or more EBV proteins, wherein the subject suffers from an autoimmune disease.

88. The method of claim 87, wherein the one or more EBV proteins are selected from the group consisting of EBNA-1, EBNA-2, EBNA-3A, EBNA-3B, EBNA-3C, EBNA-LP, LMP-1, LMP-2A, LMP-2B, and combinations thereof.

Citation Information

Patent Citations

  • Recombinant antibody composition

    US20070148165A1

  • Recombinant monovalent antibodies and methods for production thereof

    US20090226421A1

  • Single polypeptide chain binding molecules

    US4946778A

  • Biosynthetic antibody binding sites

    US5091513A

  • Biosynthetic antibody binding sites

    US5132405A